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the repair of DNA interstrand crosslinks (ICLs). Fanconi anemia is an inherited disorder associated with
a high risk to develop cancer and is caused by mutations in sixteen FA genes. Together, the FA proteins
orchestrate ICL incision, translesion synthesis and HR. We demonstrate that chromatin association of
CtIP in response to ICL-induced damage is strictly dependent on a functional FA core complex and
FANCD2 monoubiquitination. Furthermore, we show that CtIP recruitment to ICL lesions is mediated
by its direct interaction with FANCD2 and might be further reinforced by the discovered ability of CtIP
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ZUSAMMENFASSUNG)
Die Erbinformation (DNA) in unseren Zellen wird durch eine Vielzahl von 
Umwelteinflüssen konstant beschädigt. DNA Doppelstrangbrüche (DSB) gehören zu den 
gefährlichsten aller DNA Schäden, weil sie ohne Reparatur zum Tod einer Zelle führen 
können. Zudem besteht eine direkte Verbindung zwischen falscher DSB Reparatur und 
Krebs. Zellen besitzen zwei verschiedene Systeme für die DSB Reparatur: Nicht-
homologe Enden-Verknüpfung (NHEJ) und Homologe Rekombination (HR). Im 
Unterschied zu NHEJ, müssen für HR die Enden der Brüche zuerst prozessiert werden, 
sodass einzelsträngige DNA Überhänge entstehen. An diesem Schritt, der als 'DNA-
Endresektion' bezeichnet wird, ist das CtIP Protein massgeblich beteiligt. 
Der erste Teil meiner Doktorarbeit beschäftigt sich mit der Frage ob CtIP auch in der 
Reparatur von kovalent-quervernetzten DNA Strängen, sogenannten 'interstrand 
crosslinks' (ICL), eine Rolle spielt und ob ein Zusammenspiel zwischen DNA-
Endresektion und dem Fanconi anemia (FA) Signalweg existiert. Die FA-Proteine 
steuern die komplexe Reparatur von ICLs, indem sie diese im Chromatin erkennen, 
prozessieren und, in Zusammenarbeit mit anderen Reparatursystemen inklusive der HR, 
korrigieren. Wir zeigen, dass die Bindung von CtIP an ICL-geschädigtes Chromatin von 
der Funktion des FA-Kernkomplexes und der Mono-Ubiquitinierung des FANCD2 
Proteins abhängig ist. Wir legen außerdem dar, dass die Lokalisierung von CtIP an ICLs 
durch die direkte Interaktion von CtIP mit FANCD2 vermittelt und möglicherweise durch 
die Fähigkeit von CtIP ubiquitinierte Substrate zu binden verstärkt wird. 
Bemerkenswerterweise haben Zellen in denen FANCD2 inaktiviert ist, einen ähnlichen 
Defekt in der DNA-Endresektion wie CtIP-defiziente Zellen. Zudem haben wir eine 
FANCD2-Bindestelle innerhalb des CtIP Proteins identifizieren können, welche für eine 
fehlerfreie Reparatur von ICLs erforderlich ist und somit potentielle, durch NHEJ-
verursachte, chromosomale Aberrationen verhindert. Interessant ist auch, dass 
charakteristische Phänotypen von FANCD2-defizienten Zellen, wie genomische 
Instabilität und Hypersensitivität gegenüber ICL-induzierenden Stoffen, durch eine 
zusätzlichen Verlust von CtIP verschlimmert werden. Daraus schließen wir, dass CtIP 
auch in Abwesenheit von FANCD2 eine bedeutende Funktion für die ICL Reparatur hat. 
Insgesamt zeigen unsere Ergebnisse, dass FANCD2 ein wichtiger Regulator der CtIP-
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vermittelten DNA-Endresektion darstellt und dass CtIP eine essenzielle Rolle in der 
Aufrechterhaltung der Stabilität unseres Genoms spielt. 
Im zweiten Teil meiner Doktorarbeit untersuchen wir eine spezielle Klasse von 
Mutationen des menschlichen RAD50 Proteins, genannt RAD50S, die in Hefe zu einer 
Trennung verschiedener Funktionalitäten des Proteins führt. Bei RAD50 handelt es sich 
um eine Untereinheit des MRE11-RAD50-NBS1 (MRN) Komplexes, der mit CtIP 
interagiert und mehrere Aufgaben in der DSB Reparatur spielt. Wir zeigen, dass RAD50S 
Mutationen die DNA-Endresektion  und DSB Reparatur beeinträchtigt, vor allem wenn 
Zellen mit DNA Topoisomerase-hemmenden Substanzen behandelt werden. RAD50S 
Mutationen führten jedoch weder zu einer veränderten Struktur des MRN Komplexes, 
noch zu einer Beeinträchtigung MRN-abhängiger Signalwege nach Behandlung von 
Zellen mit anderen DNA-schädigenden Substanzen. Basierend auf unseren 
biochemischen Daten kommen wir zum Schluss, dass die von uns beobachteten zellulären 
Phänotypen höchstwahrscheinlich durch eine Störung der Interaktion zwischen RAD50S 
und CtIP hervorgerufen werden, welche besonders für die Reparatur blockierter 
Topoisomerase Moleküle an DSB Enden von Bedeutung ist. 
Beide Studien eingeschlossen, belegen unsere Ergebnisse dass CtIP durch Interaktionen 
mit FANCD2 und RAD50 eine Schlüsselrolle bei der Reparatur von DNA Schäden spielt 
und somit womöglich ein wichtiger Faktor zur Verhinderung von Krebs ist. 
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SUMMARY)
Our genome is under constant threat from DNA damage that inflicts different kinds of 
lesions including DNA double-strand breaks (DSBs). Failure to correctly repair DSBs can 
cause gross chromosomal aberrations, which are a hallmark of cancer. Cells have evolved 
two major pathways to repair DSBs: non-homologous end-joining (NHEJ) and 
homologous recombination (HR). Human CtIP promotes DNA-end resection, which 
commits cells to error-free HR and prevents aberrant repair by NHEJ, hence it is a critical 
determinant of DSB repair pathway choice. However, the cellular response to DNA 
damage involves a complex interplay between different genome maintenance pathways 
and the role of CtIP in this multifaceted network is still poorly understood.   
In the first part of my PhD study, we addressed the functional interplay between CtIP-
dependent resection and the Fanconi anemia (FA) pathway during the repair of DNA 
interstrand crosslinks (ICLs). Fanconi anemia is an inherited disorder associated with a 
high risk to develop cancer and is caused by mutations in sixteen FA genes. Together, the 
FA proteins orchestrate ICL incision, translesion synthesis and HR. We demonstrate that 
chromatin association of CtIP in response to ICL-induced damage is strictly dependent on 
a functional FA core complex and FANCD2 monoubiquitination. Furthermore, we show 
that CtIP recruitment to ICL lesions is mediated by its direct interaction with FANCD2 
and might be further reinforced by the discovered ability of CtIP to recognize 
ubiquitinated substrates. Remarkably, cells lacking FANCD2 akin to CtIP-depleted cells 
are impaired in DNA-end resection. We have identified FANCD2-binding sites on CtIP 
and provide evidence that CtIP-FANCD2 complex is required for the faithful repair of 
ICLs, meanwhile counteracting mutagenic NHEJ pathway. Interestingly, the phenotypes 
of FA cells such as genome instability and ICL hypersensitivity are further aggravated by 
CtIP depletion, indicating the significance of CtIP even in the absence of proficient FA 
pathway. Taken together, our data establish FANCD2 as a critical regulator of CtIP-
mediated DNA-end resection and emphasize the essential role of CtIP in maintaining 
genome stability in response to ICL damage.  
In the second part, we examined the phenotypes of the separation-of-function (S) 
mutations in human RAD50, a subunit of the MRE11-RAD50-NBS1 (MRN) complex 
that interacts with CtIP and plays crucial roles in DSB signaling and processing. We 
demonstrate that RAD50S mutants compromise resection and repair of DSBs induced 
specifically by DNA topoisomerase poisons, but do neither alter MRN complex integrity 
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nor significantly affect MRN-dependent signaling in response to other types of DNA 
damaging agents. Based on our biochemical data we suggest that these phenotypes are 
caused by the impaired interaction between RAD50S mutants and CtIP, which is 
particularly important for the processing of topoisomerases trapped to DNA ends. 
Collectively, our results establish a key role for CtIP in the repair of ICLs and also 
highlight the significance of CtIP-MRN association for the processing of toxic protein-
DNA adducts. Work presented in my thesis thus advances the understanding of how the 
DNA-end resection activity of CtIP is regulated to preserve genome stability. 
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ABBREVIATIONS)
53BP1 p53-binding protein 1 
aa amino acid 
APLF apraxin and polynucleotide kinase-like factor 
AT ataxia telangiectasia 
ATM ataxia telangiectasia mutated 
ATR ataxia telangiectasia mutated and Rad3 related 
bp base pair 
BRCA1/2 breast cancer susceptibility gene 1/2 
BRCT BRCA1 C-terminus domain 
CHK1/2 checkpoint kinase 1/2 
CDKs cyclin-dependent kinases 
CDC cell division cycle 
CIN chromosomal instability 
CPT camptothecin 
CSR class switch recombination 
CtBP carboxy-terminal binding protein 
CtIP CtBP interacting protein  
CO crossover 
DDR DNA damage response 
DNA-PK DNA-dependent protein kinase 
DNA-PKcs DNA-PK catalytic subunit 
ssDNA single stranded DNA 
dsDNA double stranded DNA 
dHJ double Holliday junction 
DSB double strand break 
EXO1 exonuclease 1 
ETOP etoposide 
FA Fanconi anaemia 
FANCD2 Fanconi anemia complementation group D type 2 
FAN1 FANCD2-associated nuclease 1 
FHA  forkhead-associated domain 
GFP green fluorescent protein 
HR homologous recombinaton 
ICL interstrand crosslink 
IR ionizing radiation 
LigIV DNA ligase IV 
MDC1 mediator of DNA damage checkpoint 1 
MEFs mouse embryonic fibroblasts 
MMC mitomycin C 
MMS methyl methanesulfonate 
MRE11 meiotic recombination 11 homolog 1 
MRN MRE11-RAD50-NBS1 
MSI microsatellite instability 
NBS1 Nijmegen breakage syndrome 1 
NCO non-crossover 
NER nucleotide excision repair 
NHEJ non-homologous end-joining 
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alt-NHEJ alternative NHEJ 
c-NHEJ classical NHEJ 
PCNA proliferating cell nuclear antigen 
PIKK phosphatidylinositol 3-kinase-like protein kinase 
PLA proximity ligation assay 
PNKP polynucleotide kinase/phosphatase 
PTMs post-translational modifications 
pRb retinoblastoma protein 
RAD50 radiation sensitive 50 
RAD50S  RAD50 separation-of-function mutation 
RIF1 Rap-interacting factor 1 
RPA replication protein A 
RNF8 ring finger protein 8 
ROS reactive oxygen species 
Sae2 sporulation in absence of spo11 
SDSA synthesis dependent strand annealing 
SD standard deviation 
SEM standard error of the mean 
SMC structural maintenance of chromosomes 
Spo11 sporulation-specific protein 11 
SSA single-strand annealing 
TLS translesion DNA synthesis 
Top I/II topoisomerase I/II 
UBD ubiquitin-binding domain 
UBZ ubiquitin-binding zinc finger 
UV ultraviolet light 
XLF XRCC4-like factor 
XRCC4 X-ray repair cross-complementing protein 4 
Xrs2 X-ray sensitive protein 2 !
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1. INTRODUCTION 
1.1. DNA)damage)response,)genome)stability)and)cancer)
Genetic information in all known organisms is encoded in DNA that has to be faithfully 
propagated to subsequent generations. However, the integrity of DNA is under constant 
threat of DNA damage from both internal and external sources [1]. Spontaneous DNA 
alterations can be caused by inaccurate DNA replication or reactive-oxygen species 
(ROS) that arise during normal cellular metabolism [2,3]. Furthermore, DNA lesions can 
be induced by exposure to ionizing irradiation (IR), UV light or chemical compounds 
used in chemotherapy, hence representing major triggers of exogenous DNA damage [4]. 
Each cell in the human body experience about 104-106 DNA lesions per day [5]. Failure 
to correctly repair DNA lesions gives rise to mutations and genomic alterations that 
eventually can threaten cell viability [1]. Uncontrolled cell proliferation and oncogenic 
transformation are the other dangerous consequences of mutations inactivating tumor 
suppressor genes or triggering activation of oncogenes [6]. Consequently, eukaryotic cells 
have evolved different repair strategies to maintain genomic integrity. Depending on the 
type of lesion, specialized repair pathways are activated to remove the damage (Figure 1) 
[1]. Subtle modifications of DNA, including small alkylation products and oxidative 
lesions are repaired by base excision repair (BER) via incision of the damaged base [7]. 
Deletions, insertions and mismatched base pairs incorporated during DNA replication are 
corrected by the mismatch repair (MMR) pathway [8]. Nucleotide excision repair (NER) 
eliminates more complex helix-distorting DNA damage such as pyrimidine dimers and 
intrastrand crosslinks by removal of a short oligonucleotide containing the damaged base 
[9]. DNA double-strand breaks (DSBs) are the substrates of either homologous 
recombination (HR) repair or non-homologous end-joining (NHEJ) [10]. Notably, some 
DNA lesions that block replication fork progression are not repaired but instead are 
bypassed by translesion synthesis (TLS) polymerases with less stringent base-pairing 
requirements than replicative polymerases [11]. Interstrand crosslinks (ICLs) covalently 
blocking two opposite DNA strands are removed by a complex interplay between the 
Fanconi anemia (FA) repair pathway and proteins of NER, TLS and HR pathways [12]. 
The DSB and ICL repair pathways are described in detail in the following sections. 
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Figure 1. DNA damage and DNA repair mechanisms. Different DNA damaging agents 
generate various types of DNA lesions that are removed by specialized DNA repair mechanisms. 
Abbreviations: cis‐Pt, cisplatin; MMC, mitomycin C; (6-4)PP, 6-4 photoproduct; CPD, 
cyclobutane pyrimidine dimer; BER, base excision repair; NER, nucleotide excision repair; HR, 
homologous recombination; EJ, end joining. Adapted from [1].  
The repair of DNA lesions requires activation of the DNA damage response (DDR), a 
sophisticated cellular network that senses and signals the presence of DNA damage to 
effector proteins to regulate numerous biological responses, including DNA repair, 
transient cell cycle arrest, transcription and apoptosis (Figure 2) [13]. The DDR signaling 
cascade is mainly controlled by three phosphatidylinositol 3‐kinase‐like protein kinases 
(PIKKs): ataxia telangiectasia-mutated (ATM), ATM and Rad3-related kinase (ATR) and 
DNA-dependent protein kinase (DNA‐PK) [14]. Activation of ATM and DNA‐PK is 
primarily triggered by DSB formation, whereas ATR is activated by single‐stranded DNA 
(ssDNA) generated during replicative stress or DNA-end resection of DSBs [15,16]. 
PIKKs are recruited to sites of DNA lesions via conserved interactions with DNA 
damage sensor proteins [14]. ATM activation is triggered by the recruitment of the 
MRE11-RAD50-NBS1 (MRN) complex to DSBs [17]. ATM exists as an inactive dimer, 
but in response to DSB-inducing agents it undergoes MRN-mediated activation, dimer 
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dissociation and autophosphorylation [18]. Once activated, it phosphorylates various 
downstream targets including the MRN complex itself, histone variant H2AX at serine 
139 (S139) producing γH2AX, and checkpoint kinase 2 (CHK2) [19,20]. CHK2 kinase 
activated via phosphorylation at a specific threonine 68 (T68) acts on multiple substrates 
such as p53 and cell division cycle 25 (CDC25) phosphatases [21,22]. CDC25 
phosphatases control cell cycle transition by removing inhibitory phosphorylation from 
cyclin-dependent kinases (CDKs) [23]. Phosphorylation of CDC25 phosphatases leads to 
their inactivation and inhibition of CDKs that delays the progression of the cell cycle at 
the G1-S, intra-S and G2-M cell cycle checkpoints, thereby giving sufficient time for 
DNA repair before replication or entering mitosis [24]. The major sensor of DNA damage 
promoting activation of ATR kinase is a replication protein A (RPA) complex [15]. It 
consists of three subunits RPA1, RPA2 and RPA3 and binds to ssDNA regions protecting 
them from the nuclease degradation and preventing formation of secondary structures that 
may interfere with subsequent recombination events [25]. Moreover, RPA-ssDNA 
complex plays a crucial role in activation and maintenance of ATR-mediated checkpoint 
by recruiting ATR kinase via its functional partner, ATR-interacting protein (ATRIP), to 
the sites of DNA damage and to the stalled replication forks [26,27]. Following 
activation, ATR kinase acts on various substrates including checkpoint kinase 1 (CHK1) 
that gets phosphorylated on serine 317 and serine 345 [28,29]. Similar to CHK2, CHK1 
also limits the activity of CDKs, thereby triggering activation of cell cycle checkpoint 
[30]. In parallel, the DDR coordinates the action of DNA repair pathways by other 
post‐translational modifications (PTMs) such as acetylation, sumoylation and 
ubiquitylation [31]. Once DNA repair is completed, the DDR gets inactivated, allowing 
resumption of the cell cycle. However, if the damage cannot be removed, constitutive 
DDR signaling triggers cell death by apoptosis or cellular senescence, both of which 
prevent propagation of mutations and hence have critical antitumor function [14]. 
Consequently, DDR plays an essential role in maintaining genome integrity.  
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Figure 2. The DNA damage response cascade. DNA damage induced by endogenous or 
exogenous sources is recognized by sensor proteins (e.g. MRN, RPA). Through the recruitment of 
mediator proteins the presence of the lesion is signaled and the signal is amplified by transducers 
(e.g. ATM, ATR). The signal reaches the effector proteins (e.g. CHK1, CHK2) to initiate a cellular 
response, including cell cycle arrest, activation of DNA repair and transcriptional program, and, in 
case the damage is too severe, apoptosis or senescence. Adapted from [17].  
Genomic instability is a hallmark of cancer [5]. Cancer cells have also other 
characteristics such as self-sufficiency in growth signals, insensitivity to anti-growth 
signals, evasion of apoptosis, sustained angiogenesis, tissue invasion and metastasis, 
unlimited replication potential [32]. Remarkably, genomic instability is present in all 
stages of cancer, from precancerous lesions to advanced malignancies [33]. There are 
various forms of genomic instability with chromosomal instability (CIN) being the major 
one. CIN is referred to different types of chromosomal aberrations such as changes in 
chromosome structure (e.g. translocations, deletions) and in chromosome number [34]. 
Another form of genomic instability is microsatellite instability (MSI) characterized by 
the expansion or reduction of the number of oligonucleotide repeats present in 
microsatellite sequences [35]. Hereditary cancers such as non-polyposis colon cancer, 
breast and ovarian cancer, and leukemias are driven by mutations in DNA repair genes 
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and demonstrate genomic instability [5]. Importantly, inherited defects in DDR genes can 
cause tumorigenesis in precancerous lesions by enhancing the accumulation of 
spontaneous mutations [36]. Although sporadic (non-hereditary) cancers also show 
genomic instability, they rarely contain mutations in DNA repair genes [14]. Instead, they 
are often triggered by constitutive activation of proto‐oncogenes and inactivation of 
tumor suppressors that elicit a growth‐ and, associated with it, a replication‐rate increase, 
which eventually leads to the activation of the DDR [37]. Indeed, the DDR is commonly 
activated in early neoplastic lesions and presumably protects against malignancy [38]. 
However, constitutive activation of DDR also leads to elevated levels of errors during 
DNA replication and repair, favoring the transition of a precancerous lesion into cancer 
[30]. Therefore, coordination and tight regulation of DNA repair processes and DDR play 
critical role in preventing tumorigenesis.  
1.2. MRE114RAD504NBS1)(MRN))complex)
1.2.1.) Structure)and)functions)of)the)MRN)complex)
DSBs are one of the most deleterious DNA lesions that can lead to genome 
rearrangements and carcinogenesis if they are misrepaired. The MRE11-RAD50-NBS1 
(MRN) complex plays a crucial role in DSB repair due to its ability to recognize and to 
maintain the broken ends in close proximity, thereby facilitating repair [39]. It also 
promotes DNA-end resection of the breaks and activation of DSB response. In addition, 
to its function in DSB repair, the MRN complex is associated with the replication forks 
and telomeres promoting their maintenance [40]. This complex is highly conserved and 
orthologues of MRE11 and RAD50 are found in all taxonomic kingdoms [41]. Yeast 
strains bearing null mutations of Rad50, Mre11 or Xrs2, which is an orthologue of human 
NBS1 in budding yeast, are viable, but show similar phenotypes such as poor vegetative 
growth, hypersensitivity to DSB-inducing agents and defects in meiosis [39]. However, 
all three components of the mammalian MRN complex are essential for survival as 
knockout mice display early embryonic lethality [42-44]. Hypomorphic mutations in 
NBS1 in humans cause Nijmegen breakage syndrome (NBS), a rare autosomal recessive 
disorder characterized by microcephaly, immunodeficiency and cancer predisposition 
[45,46]. Hypomorphic mutations in RAD50 lead to phenotypes similar to NBS that are 
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classified as an NBS-like disorder (NBSLD), but only one patient has been reported so 
far [47]. Mutations in MRE11 gene trigger ataxia-telangiectasia-like disorder (ATLD) 
[48]. ATLD patients display ataxia and neurodegeneration and resemble the phenotypes 
of ATM deficiency [49]. Given the importance of the MRN complex in the activation of 
ATM kinase, cells from patients with hypomorphic mutations in MRE11, RAD50 or 
NBS1 genes exhibit defective ATM-mediated signaling, radiosensitivity and 
chromosomal instability [50].  
RAD50 is the largest component of the MRN complex. It has both sequence and structure 
homology to SMC family members, involved in sister-chromatid cohesion and 
chromosome condensation, and plays essential role in tethering broken DNA ends [17]. 
The N- and C-termini contain Walker A and Walker B motifs, respectively, that can 
associate forming a bipartite ATP-binding cassette (ABC)-type ATPase domain that 
possesses both ATPase and DNA-binding activity (Figure 3) [51-53]. The central part of 
RAD50 consists of two large coiled-coil structures with a zinc-hook motif (CXXC) in the 
middle that can coordinate a zinc ion to form an interaction interface between two 
RAD50 molecules [54]. Mutations targeting the invariant cysteines of the RAD50 hook 
domain globally disrupt functions of the MRN complex and phenocopy the null Rad50 
mutation in yeast, fail to support viability in mice and lead to severe defects in ATM 
activation and repair in human cells [54-57]. RAD50 also contains MRE11-binding sites 
located at the intersection of coiled-coil and ATPase domains [52,53]. 
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Figure 3. Structure of RAD50. (A) The domain structure of RAD50. RAD50 contains Walker A 
and B motifs in N- and C-terminus, respectively, that are responsible for ATPase activity of 
RAD50. The central part of RAD50 consists of two coiled-coil regions that are linked by zinc-
hook motif in the middle. MRE11 interacts with RAD50 via two regions localized at the 
intersection of coiled-coil and ATPase domains. (B) Schematic representation of RAD50 
dimerization. RAD50 molecule can fold back on itself and form a dimer with another RAD50 
molecule via zinc-hook domain in presence of a Zn2+ ion. A globular head formed by the Walker 
motifs and MRE11-interacting regions binds DNA. Adapted from [17]. 
MRE11 is composed of an N-terminal phosphoesterase domain that harbors the nuclease 
active site, dimerization motifs and an interaction region with NBS1 [52,58]. The central 
and C-terminal parts contain DNA-binding sites and RAD50 interaction domain. MRE11 
possesses intrinsic DNA-binding activity, endo- and 3'-5' exonuclease activities in vitro 
that are required for the function of the MRN complex in DNA-end resection [59-63]. 
Atomic force and electron microscopic imaging indicate that each MRE11 molecule 
binds to a single RAD50 and they form a heterotetrameric core complex consisting of 
MRE112RAD502 (M2R2) in vivo [52-54,64]. The third subunit, NBS1/Xrs2 interacts with 
the core complex through binding to MRE11 forming a functional MRN dimer [40,65]. 
Given the importance of these interactions for the MRN complex stability, depletion of 
individual subunits leads to the destabilization of the whole complex [45,47,48]. 
NBS1 contains N-terminal forkhead-associated domain (FHA) domain followed by two 
adjacent breast cancer susceptibility protein 1 C-terminus domain (BRCT) motifs [66,67]. 
Both of them can recognize and bind to phosphoproteins, therefore NBS1 acts as an 
adapter linking the MRN complex to proteins phosphorylated in response to DNA 
damage [41]. Notably, such phospho-specific interaction of NBS1 with MDC1 mediates 
stable association of the MRN complex with damaged chromatin [66,68,69]. In fission 
yeast, Nbs1 recognizes phosphorylated Ctp1 and recruits Ctp1 to DSB ends to promote 
resection [66,70-72]. Similar mechanism to regulate DNA-end resection has been 
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proposed for NBS1 and human CtIP, an orthologue of Ctp1, however the MRN complex 
is not required for CtIP recruitment to DSBs in human cells [73-75]. The C-terminus of 
NBS1 harbors MRE11 and ATM-binding sites. Interaction of NBS1 with MRE11 is 
critical for the nuclear localization of the MRN complex and may also stimulate its DNA-
binding and endonuclease activities [45,76]. NBS1 directly binds to ATM kinase that 
triggers its full activation and autophosphorylation at serine 1981 (S1981) and several 
other sites [18,77,78]. Noteworthy, the MRN complex is not absolutely required for it as 
ATM can still be activated in ATLD and NBS patient cells upon DNA damage, though at 
a much reduced efficiency [79].  
The relationships between the MRN complex conformations and their biological 
functions for a long time remained enigmatic. Recent structural analysis of the bacterial 
and archaeal Rad50 and Mre11 proteins revealed that in the absence of ATP Walker A 
and B domains of Rad50 bound to Mre11 persist in open configuration [80,81]. ATP-
binding by Rad50 dramatically alters the conformation of the complex leading to the 
closed configuration [82,83]. ATP-bound state is associated with a higher affinity of the 
MRN complex for DNA ends and with DNA tethering as well as with stimulation of 
Mre11 endonuclease activity to initiate DNA-end resection [81,84]. Following ATP 
hydrolysis, complex configuration changes back from closed to the open state that 
facilitates Mre11 exonuclease activity to continue DSB resection [84]. Therefore, Rad50-
mediated ATP hydrolysis acts as a molecular switch that regulates Mre11 nuclease 
activity and DNA-end resection. Moreover, there is a temporal sequence of DNA-end 
tethering followed by DNA-end resection that is orchestrated by the MRN complex. 
1.2.2.) Separation4of4function)RAD50)(RAD50S))mutations)
Given the critical role of the MRN complex in DSB repair, it is also required for the 
processing of DSBs formed during meiosis [85]. Meiotic DSBs are induced by 
topoisomerase-like transferase Spo11 that cuts both strands of a DNA molecule and 
remains covalently attached to 5'-ends [86]. To allow DNA-end processing and 
subsequent homologous recombination repair, Spo11 needs to be released from DNA 
ends. The MRN complex is required for the removal of Spo11 [85]. In budding yeast 
Saccharomyces cerevisiae (S. cerevisiae) it is also essential for the formation of meiotic 
DSBs together with Spo11 [87,88]. Thus, mutants lacking any subunit of the MRX 
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complex fail to generate meiotic DSBs [89]. A specific class of separation-of-function 
mutations located in the N-terminus of Rad50, named rad50S, allows Spo11-induced 
formation of the break, but is totally defective in processing of meiotic DSBs in S. 
cerevisiae [90]. Hence, rad50S mutants accumulate unprocessed DSBs with covalently 
attached Spo11 in meiosis [86]. Despite a strong defect in meiotic recombination, these 
mutations show no overt mitotic phenotype and nearly wild-type resistance to DNA-
damaging agent methyl methanesulfonate (MMS) [90]. Notably, seven out of nine 
Rad50S mutations are clustered at a surface patch forming a putative protein interaction 
site, suggesting that the cause of the rad50S phenotype can be due to an interaction defect 
with a meiosis-specific protein rather than impaired ATP-binding or hydrolysis [51].  
Removal of Spo11 from DSBs requires both the nuclease activity of the MRX complex 
and Sae2 [61,91-93]. Akin to rad50S mutations, deletion of Sae2 also leads to the 
accumulation of unprocessed DSBs during meiosis [85,94]. Remarkably, Sae2 
overexpression could partially rescue the DNA processing defects of rad50S, implying 
that rad50S mutations may impair the interaction between Rad50 and Sae2 [91]. The 
activity affected in rad50S and sae2Δ strains seems to be required for the processing of 
DNA ends blocked by covalently bound protein, such as Spo11 described above or DNA 
topoisomerase cleavage complexes [95]. DNA topoisomerases are enzymes that release 
torsional stress in the DNA or resolve DNA catenanes through a DNA breakage and 
rejoining mechanism during DNA replication and transcription [96]. In order to form a 
break, the topoisomerases get first covalently bound to the DNA and then reversibly 
released. DNA topoisomerase poisons such as camptothecin (CPT) or etoposide (ETOP) 
increase the half-life of the Top I-DNA and Top II-DNA cleavage complexes, 
respectively [97]. Due to prolonged presence of these complexes ssDNA breaks induced 
by Top I get converted into toxic DSBs in replicating cells, whereas Top II initially 
generates DSBs. To support cell viability, these toxic topoisomerase-DNA adducts have 
to be removed and the remaining DNA breaks need to be repaired. The MRN/X-mediated 
processing of blocked DNA ends seems to be one of major pathways promoting cellular 
resistance to CPT and ETOP, but the detailed molecular mechanism is still unclear [41]. 
Remarkably, reminiscent of the phenotypes observed in budding yeast, rad50S (K81I) 
mutation in fission yeast Schizosaccharomyces pombe (S. pombe) as well as deletion of 
Ctp1, an orthologue of Sae2 in fission yeast, result in hypersensitivity to DNA 
topoisomerase poisons [71,98,99].  
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Yeast rad50S mutations were also modeled in mouse [100]. However, two out of three 
tested RAD50S alleles were embryonic lethal and thus only Rad50-K22M allele, 
corresponding to yeast rad50-R20M, was analyzed [101]. Though Rad50S mice were 
fertile, they had strong spermatogenic and hematopoietic attrition resulted in severe 
anemia and shortened lifespan [101]. Apoptosis in the hematopoietic and spermatogenic 
lineages of Rad50S mice was triggered by chronic ATM activation [101-103]. A similar 
constitutive activation of Tel1, an orthologue of ATM kinase in budding yeast, was also 
observed in rad50S mutants [104]. Though the mechanisms underlying these phenotypes 
remain elusive, the increased spontaneous chromosomal instability observed in mutant 
cell indicates unprocessed DNA damage accumulating in Rad50S background [101]. 
Furthermore, mouse cells expressing a RAD50S allele conferred hypersensitivity to both 
Top I and Top II poisons, but not to other DSB-inducing agents such as ionizing 
radiation, suggesting that Rad50S mutations specifically affect the processing of DSB 
ends blocked by topoisomerase cleavage complexes by a yet unknown mechanism [100-
103].  
1.3.) CtIP)
1.3.1.) Role)in)DNA)repair)and)tumorigenesis)
Human CtIP, the CtBP (carboxi-terminal binding protein) interacting protein, was first 
described as a binding partner of the transcriptional corepressor CtBP [105]. CtIP 
contains PLDLS sequence representing a PXDLS motif for CtBP binding that is highly 
conserved among other CtBP interaction partners (Figure 4) [106,107]. Subsequently, 
CtIP was shown to associate with two bona fide tumor suppressor proteins, BRCA1 and 
retinoblastoma (pRb), thereby it also acquired another name, retinoblastoma-binding 
protein 8 or RBBP8 [108-110]. CtIP is essential for embryonic development as Ctip-/- 
mouse embryos were reported to die at a very early stage during embryogenesis [111]. 
Remarkably, the heterozygous Ctip+/− mice were viable, but their life span, compare to 
Ctip+/+, was shortened by the development of multiple types of tumors, predominantly, 
large lymphomas, indicating that CtIP haploinsufficiency promotes tumorigenesis. CtIP 
frameshift mutations caused by microsatellite instability were found in colorectal and 
endometrial cancers [112,113]. Moreover, low expression of CtIP correlates with high-
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grade breast cancer and is associated with resistance to tamoxifen treatment, further 
supporting the idea that CtIP might be a tumor suppressor gene itself [114,115].  
The CtIP in complex with pRb functions in the regulation of G1/S cell cycle progression 
[116]. The interaction between CtIP and pRb is mediated by a pRb-binding motif LECEE 
in the N-terminus of CtIP [110]. CtIP binds pRb releasing it from the E2F-responsive 
promoters in G1 phase of the cell cycle. The inactivation of pRb-mediated transcriptional 
repression leads to the expression of E2F-responsive genes such as CtIP itself and cyclin 
D1 and promotes G1/S transition [116]. Accordingly, G1 arrest observed in mouse 
embryonic fibroblasts (MEFs) lacking CtIP was circumvented by absence of pRb, 
indicating the role for CtIP in counteracting pRb-mediated G1 restraint and facilitating 
G1/S progression [111].  
At the molecular level human CtIP is a nuclear protein of 897 amino acids (aa) [105]. The 
amino acid sequence of CtIP is relatively well conserved among mammals. There are also 
conserved limited regions in human CtIP and its functional orthologues in budding and 
fission yeast, Sae2 and Ctp1, respectively, as well as in other species [117]. The C-
terminal domain (CTD) of CtIP is the most evolutionary conserved region and is required 
for its function in DNA-end resection [118-120]. The RPA-bound ssDNA generated 
during resection serves as the signal for sustained ATR-CHK1 checkpoint signaling [27]. 
Due to its crucial function in DNA-end resection, CtIP is essential for maintaining both 
the intra-S- and G2-phase checkpoints in response to DNA damage [121]. Noteworthy, 
mutations in CtIP leading to a truncated protein that lacks the whole C-terminus cause 
related disorders, Seckel and Jawad syndromes, characterized by congenital 
microcephaly, impaired DNA-end resection and ATR-mediated signaling [122].  
Little is known about the structure of CtIP. It contains two putative coiled-coil domains 
located near the N- and C-termini [110]. The N-terminus of CtIP, particularly the residues 
20-45, are required for CtIP dimer formation [123,124]. Dimerization of CtIP is essential 
for proper localization to the DSBs and its function in DNA-end resection [124]. The 
central region of CtIP contains replication foci targeting sequence (RFTS, 515-537 aa) 
that includes consensus PCNA-interacting protein (PIP) box mediating both the CtIP-
PCNA interaction and the assembly of CtIP into replication foci during S-phase [125]. 
Though the exact function of the PIP-box remains elusive, it was suggested that PCNA 
might facilitate CtIP localization to replication foci. Accumulation of CtIP at laser-
induced DNA damage sites requires a "damage recruitment (DR) motif" (509-557 aa) 
[74]. The N-terminus of DR motif contains two critical lysines K513 and K515, which 
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are conserved from chicken to humans. These residues are essential for direct DNA-
binding of CtIP, but do not overlap with the PIP-box, suggesting distinct modes of CtIP 
recruitment to the DNA lesions.  
To promote DNA-end resection CtIP directly interacts with the MRN complex 
[118,126,127]. Multiple regions of CtIP seem to be involved in binding to the MRN 
complex: both N-terminus, especially residues 22-45, and conserved C-terminus (790-
897 aa) mediate CtIP-MRN complex formation [118,126,127]. In addition, it was 
recently reported that several CDK-dependent phosphorylation sites in the central region 
of human CtIP contributes to its binding to NBS1 in response to DNA damage [73].  
 
 
Figure 4. Protein domains of human CtIP. The N-terminus of CtIP contains a dimerization 
region (20-45 aa), a coiled-coil domain (45-160 aa) and a consensus motif for Rb-binding 
(LECEE). The middle region consists of a CtBP interaction sequence (PLDLS), two conserved 
lysines (K513 and K515) important for DNA-binding and a PIP-box (515-537 aa) mediating 
interaction with PCNA. Two sites (S276 and T315) phosphorylated by proline-directed kinases are 
required for PIN1-binding and CtIP isomerization. CDK phosphorylation at S327 mediates 
interaction with BRCA1. Three lysine residues (K432, K526 and K604) are constitutively 
acetylated and undergo SIRT6-mediated deacetylation in response to DNA damage. The C-
terminal domain (CTD, 793-897 aa) is conserved from yeast to humans and contains CDK 
phosphorylation sites T847 essential for CtIP function in DNA-end resection. Three ATM 
phosphorylation sites (S664, S745 and T859) are conserved in vertebrates. MRN-binding regions 
are located in both N- (22-45 aa) and C-terminus (790-897 aa) of CtIP. Adapted from [117]. 
 
1.3.2.) Regulation)of)CtIP)
To ensure that DNA-end resection takes place only in appropriate stages of the cell cycle 
the function of CtIP is tightly regulated both at the level of protein expression and 
posttranslational modifications (PTMs) (Figure 4). Transcript levels of CtIP are relatively 
constant throughout the cell cycle, however protein levels of CtIP are remarkably lower 
in G1 compared to other cell cycle phases [128,129]. A possible E3 ubiquitin ligase 
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promoting polyubiquitination and subsequent proteasomal degradation of CtIP in G1 is 
SIAH-1 [130].  
During S and G2 phases, CtIP is phosphorylated in a CDK-dependent manner on several 
sites including serine 327 (S327) and threonine 847 (T847) [120,131]. Phosphorylation 
on S327 mediates CtIP interaction with BRCA1, whereas phosphorylation on T847 is 
required for DNA-end resection [120,131]. Although the function of BRCA1-CtIP 
complex in resection remains controversial, it plays an important role in G2/M 
checkpoint control and in suppression of NHEJ [132,133]. Mutation of T847 causes 
cellular hypersensitivity to DSB-inducing agents and chromosomal rearrangements, 
indicating the importance of CDK-dependent phosphorylation for CtIP function in repair 
and maintaining genome stability [120]. 
The cellular response to genotoxic stress is mediated via a protein phosphorylation 
cascade propagated by DNA damage-activated protein kinases such as ATM and ATR 
kinases [4]. CtIP recruitment to DSBs was shown to be dependent on ATM and partially 
on ATR kinase activities [74,134]. CtIP is phosphorylated by ATM on at least three 
residues, serine 664 (S664), serine 745 (S745) and threonine (T859) [73,74]. However, 
recruitment of CtIP mutant lacking all three phosphorylation sites (CtIP-3A) to DSBs is 
not affected [74]. Remarkably, CtIP-3A mutant cells are impaired in DNA-end resection, 
suggesting the role for ATM-mediated phosphorylation of CtIP in promoting repair [73].  
An important regulatory mechanism of CtIP stability by a phosphorylation-specific prolyl 
isomerase PIN1 was recently discovered in our lab [135]. PIN1 binds to CtIP 
phosphorylated on serine 276 (S276) and threonine 315 (T315) by a proline-directed 
kinase and CDK2, respectively, and triggers its conformational change that results in 
ubiquitination and subsequent proteasomal degradation of CtIP. Therefore, PIN1-
mediated isomerization of CtIP plays an important role in counteracting DNA-end 
resection and in the regulation of DSB repair.  
Deacetylation of CtIP represents another layer of its regulation. Human CtIP is 
constitutively acetylated at lysine 432 (K432), lysine 526 (K526) and lysine 604 (K604) 
that maintains the protein in the inactive state [136]. In response to DNA damage CtIP 
undergoes deacetylation mediated by SIRT6, a member of the sirtuin family of protein 
lysine deacetylases. Deacetylation of CtIP facilitates its ability to promote DNA-end 
resection, thus contributing to DSB processing and genome stability. 
In summary, CtIP is a multifunctional protein involved in cell cycle control, checkpoint 
signaling, transcription and DNA repair. Due to the crucial role of CtIP-dependent DNA-
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end resection in homologous recombination, CtIP appears to be one of the major 
determinants influencing DSB repair pathway choice. Therefore, proper regulation of 
CtIP is of particular importance for maintaining genome stability.  
1.4.) DNA4end)resection))
DNA-end resection is the first step of homologous recombination (HR) and plays crucial 
role in the DSB repair pathway choice [10]. Once the DSB is formed, both the MRN 
complex and Ku heterodimer can bind the DNA ends to initiate distinct modes of DSB 
repair [137]. Remarkably, cells lacking non-homologous end-joining (NHEJ) factors 
demonstrate enhanced HR frequency, suggesting that there is a competition between Ku-
mediated DNA-end protection resulting in NHEJ and DNA-end resection triggering HR 
[138,139]. The MRX complex can remove Ku from DNA ends to facilitate HR in 
budding yeast [140]. Furthermore, once the DSB ends are processed, they are no longer 
suitable substrates for Ku binding and, thus, for the repair by NHEJ [141]. However, the 
MRN/X complex alone is not sufficient to promote DNA-end resection and requires 
additional factors. The process of 5'-3' DNA-end resection is conserved in different 
organisms [141]. In budding yeast MRX complex cooperates with Sae2 endonuclease 
during DNA-end resection (Figure 5) [142]. Human CtIP and its counterpart Ctp1 in 
fission yeast physically interact with the MRN complex and promote DNA-end resection, 
though it is still unknown whether they possess endonuclease activity similar to Sae2 
[71,118]. Importantly, human CtIP can stimulate MRE11-RAD50-dependent 
endonuclease activity in vitro [118]. Whereas the MRN complex in conjunction with CtIP 
initiates and promotes short-range resection, other nucleases, such as EXO1 or DNA2 in 
complex with BLM helicase, or its orthologue in budding yeast Sgs1, are involved in the 
extensive, long-range 5'-3' resection [141]. The MRN/X complex and CtIP/Sae2 are 
required for both EXO1-dependent resection and its recruitment to DSBs [75,143,144]. 
Furthermore, they also stimulate resection mediated by DNA2-BLM/Sgs1 complex 
[144,145]. Since only simultaneous depletion of EXO1 and DNA2-BLM/Sgs1 severely 
impairs ssDNA formation, EXO1 and DNA2-BLM/Sgs1 seem to play redundant roles 
during DNA-end resection [145-147]. Though many aspects of how DNA-end resection 
is executed remain enigmatic, recent study on processing of DNA ends which are blocked 
by a protein complex such as Spo11, suggest that it can be a bidirectional process [62]. 
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As mentioned previously, upon generation of DSB in meiosis, Spo11 stays covalently 
attached to the 5'-end of DNA [86]. To remove Spo11, Mre11 endonuclease in 
conjunction with Sae2 creates a nick in DNA strand up to 300 nucleotides from the 5'-
terminus of the DSB. The subsequent repair requires Mre11 exonuclease activity in the 
3'-5' direction towards the end, meanwhile Exo1 and Dna2-Sgs1 promote DNA resection 
in the opposing 5’‐3’ direction that result in formation of long ssDNA regions. Similar 
mechanism is proposed for DNA-end resection of all DSB ends that are blocked by a 
protein complex that prevents direct exonuclease-mediated processing of the DSBs [62]. 
Given the conservation of the DNA-end resection mechanisms, human MRN complex 
and CtIP also play a critical role in the processing of DNA ends containing protein 
adducts [41,118]. Accordingly, depletion of CtIP confers cellular hypersensitivity to a 
wide range of DSB-inducing agents, and particularly to the inhibitors of DNA 
topoisomerases I and II, such as camptothecin (CPT) and etoposide (ETOP), respectively 
[118,120]. 
To ensure that HR takes place in S/G2 when a template for recombination is available, 
DNA-end resection is tightly regulated during cell cycle [141]. As we briefly discussed 
above, cyclin-dependent kinases (CDKs) are the master regulators of cell cycle 
progression [24]. Remarkably, CDK activity that increases in S/G2 is required for DNA-
end resection and HR [148,149]. Human CtIP, as well as its yeast counterpart Sae2, are 
the CDK substrates [117]. Similar to T847 in CtIP, phosphorylation on serine 267 (S267) 
in Sae2 by CDK is essential for its function in resection and HR, however molecular 
mechanism of CtIP/Sae2 activation by CDK phosphorylation still remains to be 
elucidated [119,120]. CtIP phosphorylation on S327 mediates its interaction with E3 
ubiquitin ligase BRCA1 as well as the assembly of MRN-CtIP-BRCA1 complex 
[126,150]. BRCA1-mediated ubiquitination of CtIP does not target it for degradation, but, 
instead, was reported to be important for CtIP association with chromatin following DNA 
damage [150]. Furthermore, MRE11 by direct interaction with CDK2 facilitates 
phosphorylation of CtIP at S327 and CtIP-BRCA1 complex formation [151]. CtIP-
BRCA1 complex is required for the activation of the DNA damage-induced G2/M 
checkpoint, but the role of this complex in DNA-end resection is disputable [131]. CtIP-
BRCA1 association was proposed to promote resection and efficient processing of DNA 
ends that are covalently trapped by DNA topoisomerases in chicken DT40 cells 
[129,152]. However, mouse cells, in which the formation of CtIP-BRCA1 complex is 
abrogated, did not display severe defects in HR, implicating that this interaction may not 
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be required for DNA-end resection in mammalian cells [132]. Instead, CtIP-BRCA1 
association may facilitate the suppression of aberrant NHEJ in S/G2 [133]. Other factors 
involved in DNA-end resection also undergo CDK‐mediated phosphorylation, further 
supporting the significance of this regulation in DSB repair [153].  
 
Figure 5. Mechanism of DNA-end resection. Following formation of a DSB, the MRX/N 
complex rapidly binds to the damaged DNA. In S/G2 phases of the cell cycle, DSB repair via HR 
is initiated by DNA-end resection. The MRX/N complex in conjunction with Sae2/CtIP promotes 
short-range resection by trimming DNA ends and generating short 3′-ssDNA overhangs, which are 
immediately coated by replication protein A (RPA). Subsequent long-range resection is carried out 
either!by the 5′-3′ exonuclease Exo1 or the helicase Sgs1/BLM in complex with the endonuclease 
Dna2. RPA is then replaced by RAD51 recombinase performing strand invasion of the sister 
chromatid that is required for downstream steps of HR. Adapted and modified from [153].  
1.5.) DNA)double‐strand)break)(DSB))repair)
DSBs are one of the most toxic lesions with respect to survival and maintenance of 
genomic integrity. Ionizing radiation (IR), radiomimetic drugs (e.g. bleomycin and 
neocarzinostatin) and chemical agents such as poisons of DNA topoisomerases (e.g. 
camptothecin, etoposide and their derivatives) are the major exogenous sources of DSBs 
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[97,154]. Endogenously generated reactive oxygen species, conversion of stalled 
replication forks or single-strand DNA nicks encountered by replication fork also result in 
DSB formation [155,156]. In certain contexts, DSBs are generated in a controlled 
manner. Programmed DSBs occur during meiosis to trigger strand exchange between 
homologous chromosomes or during class-switch recombination (CSR) and V(D)J 
recombination in B‐ and T‐lymphocytes to provide antibody diversity [87,157]. Failure to 
repair DSBs leads to genetic alterations including deletions, translocations, chromosome 
loss or fusion, which enhance genome instability and may trigger either apoptosis or 
carcinogenesis [14]. Therefore, the recognition and repair of DSBs is a multifaceted and 
tightly regulated process involving a multitude of proteins. Two major pathways promote 
DSB repair: non-homologous end-joining (NHEJ) and homologous recombination (HR) 
[4]. Whereas NHEJ does not require extensive resection of the break, HR depends on the 
generation of ssDNA tracts as repair intermediate [158,159]. In addition, DSBs 
containing complementary sequences flanking broken DNA ends can be repaired via 
alternative NHEJ (alt-NHEJ), in case of microhomology (5‐25 bp), or via single-strand 
annealing (SSA), in case of longer repeats [158]. Similar to HR, both of the mechanisms 
require DNA-end resection promoted by the MRN complex and CtIP that gives rise to 
DNA strands, which subsequently are annealed [129,160,161]. However, given that alt-
NHEJ and SSA are intramolecular mechanisms leading to the loss of the intervening 
sequence, in contrast to HR, they are highly mutagenic [158].  
1.5.1.) Non‐homologous)end4joining))
Non‐homologous end-joining (NHEJ), also called as classical NHEJ (c-NHEJ), is a 
prominent DSB repair pathway in mammalian cells that is active throughout the cell 
cycle [162]. NHEJ does not require extensive DNA-end processing and can perform 
direct ligation of broken DNA ends [163]. However, radiation-induced DSBs often 
contain chemically modified ends such as 5'-hydroxyl and 3'-phosphate groups that 
cannot be joined without some limited processing. Since removal of these altered 
nucleotides or joining of DSBs present in different genomic locations results in mutations 
or chromosomal aberrations, NHEJ is considered to be error-prone [159].  
Ku70 and Ku80 form the Ku heterodimer, which has high affinity for DNA ends [164]. 
Ku rapidly binds to DSBs, thus allowing NHEJ to make the first attempt in rejoining 
DSBs [63,165]. Once bound to DNA, Ku recruits the catalytic subunit of the DNA-
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dependent protein kinase (DNA-PKcs) to form the active DNA-PK holoenzyme (Figure 
6) [166]. The key role of DNA-PK is to stabilize DSB ends in close proximity and to 
promote DNA-end processing through phosphorylation and recruitment of downstream 
NHEJ factors [163]. Subsequently, DNA-PKcs autophosphorylation at six SQ/TQ sites 
within the ABCDE cluster domain destabilizes its interaction with DNA and, therefore, 
facilitates the access of DNA-end processing factors and subsequent religation steps 
[167]. In contrast, DNA-PKcs autophosphorylation at five SQ/TQ sites within the PQR 
cluster domain was reported to inhibit extensive end processing, thus protecting DNA 
ends from repair via HR. Remarkably, SQ/TQ sites within the ABCDE cluster can be also 
phosphorylated by ATM to stimulate HR in case of NHEJ failure [168]. Mutations in 
these clusters as well as chemical inhibition of DNA-PKcs increase cellular sensitivity to 
DSB-inducing agents, indicating that phosphorylation-induced alterations in DNA-PKcs 
are critical for DSB repair [169-171]. As mentioned above, DNA termini containing 
incompatible end groups require additional processing before ligation can take place. One 
of the main factors involved in DNA-end processing during NHEJ is Artemis, a member 
of the vertebrate SNM1 endonuclease family [172]. Artemis was first characterized as an 
enzyme possessing DNA hairpin-opening activity during V(D)J recombination [172,173]. 
Artemis interacts with and is phosphorylated by DNA-PKcs at its C-terminus that is 
required for its endonuclease activity [173,174]. Artemis also possesses 5'-3' exonuclease 
activity and can endonucleolytically process 3'- and 5'-overhangs during NHEJ [173]. 
Another group of proteins promoting end processing includes aprataxin, aprataxin-PNKP-
like factor (APLF) and polynucleotide kinase/phosphatase (PNKP) [159]. The latter 
exhibits both 5'-kinase and 3'-phosphatase activity and therefore generates ligatable 5'-
phosphate and 3'-hydroxyl termini [175]. Short gaps on DNA strands that can arise 
during the DSB processing steps are filled-in by X family DNA polymerases such as polµ 
and polλ, though these polymerase are only required for a subset of NHEJ-mediated 
repair events [176,177].  
After DNA-end processing, two juxtaposed ends are joined together by the coordinated 
action of DNA ligase IV (Lig IV) in complex with XRCC4 and XLF (XRCC4‐like factor) 
[163]. Hypomorphic mutations in genes encoding for NHEJ factors such as Lig IV or 
Artemis lead to immunodeficiency and radiosensitivity, indicating that despite being 
potentially error-prone, NHEJ activity in higher eukaryotes is critically important for 
V(D)J recombination and cell survival [178]. 
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Figure 6. Mechanism of c-NHEJ. Rapid binding of the Ku70/80 heterodimer to both ends of the 
DSB promotes recruitment of DNA-PKcs. The DNA-PK holoenzyme tethers the DNA ends 
together and stimulates the subsequent association of DNA-end processing factors such as Artemis 
and PNKP. Finally, LigIV/XRCC4/XLF complex repairs the break by ligating the DNA ends. 
Adapted from [178].  
1.5.2.) Homologous)recombination)(HR))
HR employs the undamaged sister chromatid as a template for error-free repair and is 
therefore restricted to S and G2 phases of the cell cycle, being most pronounced in mid-S 
phase [154,179]. HR is initiated via recognition of the DSBs by the MRN complex that 
tethers broken DNA ends together and promotes repair by performing short-range DNA-
end resection in complex with CtIP (Figure 7) [118,126]. Subsequent extensive DNA-end 
resection is mediated by BLM together with DNA2 nuclease and EXO1 exonuclease, 
resulting in formation of ssDNA up to several kilobases in length [75,145,146]. To 
promote the recombination steps, RPA is displaced from ssDNA by RAD51 recombinase 
resulting in formation of presynaptic filament. The loading of RAD51 onto ssDNA and 
stabilization of presynaptic filament requires additional factors called recombination 
mediators [180]. The key complex promoting RAD51 assembly in mammalian cells 
consists of a breast cancer 1 (BRCA1) and its partner BRCA1-associated RING domain 
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protein 1 (BARD1), BRCA2 (also known as FANCD1), and PALB2, a partner and 
localizer of BRCA2 (also known as FANCN) [181,182]. BRCA2 can directly bind to 
RAD51 and promote RAD51 loading onto ssDNA meanwhile suppressing RAD51 
assembly on dsDNA [183,184]. In absence of functional BRCA1, BRCA2 or PALB2 
alternative HR factor RAD52 was shown to support RAD51-dependent recombination in 
human cells [185]. Another group of recombination mediators includes five RAD51 
paralogues that form two distinct complexes: RAD51B-RAD51C-RAD51D-XRCC2 
(BCDX2) and RAD51C-XRCC3 (CX3) [186]. Whereas BCDX2 complex facilitates 
RAD51 assembly and stability of presynaptic filament, CX3 is implicated in HR 
downstream of RAD51 recruitment, but its exact function is unknown [187]. At this step, 
HR can still be reversed by antirecombinases such as RECQ5 helicase that dismantle 
RAD51-ssDNA filaments to prevent illegitimate recombination events [10]. 
The formed RAD51-ssDNA nucleoprotein filament invades the duplex DNA and 
searches for homology to produce a displacement loop (D-loop) intermediate. Once the 
D-loop is formed, the 3'-end of the filament primes DNA synthesis using the homologous 
partner as a template resulting in the D‐loop extension. The D-loop can be dissociated by 
the antirecombinases like RTEL1 helicase and the extended 3'-invading strand anneals to 
the processed second end of the break [188]. This pathway is called SDSA and it gives 
rise to non-crossover (NCO) products with short gene conversion tracts [189]. The D-
loop can also capture the second DNA end generating a double Holliday junction (dHJ) 
that is further processed and leads to the formation of either crossover (CO) or NCO 
products. dHJs are also able to undergo branch migration along DNA that is promoted by 
RAD54 and result in increasing or decreasing lengths of heteroduplex DNA [190]. Most 
dHJs are processed as NCOs by the BLM-TOPIII-RMI1-RMI2 (BTR) complex, the 
mechanism that is termed as dHJ dissolution [191,192]. BLM helicase promotes 
convergent branch migration of the dHJ, while TOPIII decatenates the intervening 
strands. Alternatively, dHJs can be resolved by nucleases. The majority of mitotic COs in 
mammalian cells is produced by the cooperation of SLX1-SLX4 and MUS81-EME1 
endonucleases [193-195]. Structure-specific endonuclease SLX4 (also known as 
BTBD12 or FANCP) functions as a scaffold protein for SLX1 and MUS81-EME1 and 
coordinates their activities during dHJ resolution [196-199]. Another pathway to resolve 
dHJ is mediated by endonuclease GEN1, though it was shown to play a minor role in dHJ 
processing [193,195,200]. Given that HR is the only pathway generating crossovers 
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(COs) as repair products and leading to genetic diversity by creating new allele 
combinations, it is particularly important for the repair of meiotic DSBs [201]. 
 
Figure 7. Mechanism of homologous recombination. Following DSB formation, the MRN 
complex binds to DNA ends and initiates DNA-end in conjunction with CtIP. BLM in complex 
with DNA2 and EXO1 promote extensive DNA-end processing generating long stretches of 
ssDNA. RPA protects ssDNA from degradation and is then exchanged by RAD51 with the help of 
BRCA1-BRCA2-PALB2 proteins. RAD51 nucleoprotein filament promotes search for homology 
sequence and strand invasion, forming D-loop. D-loop structure formed after strand invasion can 
be displaced by RTEL1 during SDSA generating non-crossover products. If the second DNA end 
is captured by the D-loop, it results in the dHJ formation. This intermediate can be processed 
either by dissolution involving BLM-TopIII complex or by resolution promoted by GEN1 or by 
SLX4-SLX1 and MUS81-EME1 complex to form non‐crossover and crossover products. Adapted 
and modified from [4]. 
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1.5.3.) DSB)repair)pathway)choice)
The choice of an appropriate repair pathway is required for maintaining genomic integrity 
[10]. Although the detailed molecular mechanism of DSB repair pathway choice remains 
unclear, given that DNA-end resection irreversibly commits cells to HR, the competition 
between DNA-end protection and resection seems to determine it [137]. The two tumor 
suppressors 53BP1 and BRCA1 are the critical regulators of DSB repair pathway choice 
[10]. Recruitment of both proteins to chromatin is mediated by the ubiquitin-dependent 
signaling activated in response to DNA damage [202]. Though both 53BP1 and BRCA1 
are effectors of the RNF8 E3-ligase-dependent ubiquitination pathway, they play 
antagonistic roles in DSB repair: 53BP1 promotes NHEJ, while BRCA1 channels DSB 
repair into HR (Figure 8) [10]. BRCA1 deficiency is associated with genome instability 
and predisposes carriers to breast and ovarian cancer [203-205]. Mice expressing mutant 
Brca1Δ11/Δ11 allele show increased tumorigenesis and chromosomal abnormalities due to 
impaired HR [206]. Remarkably, these phenotypes can be alleviated by 53BP1 deletion 
indicating that BRCA1 acts as a suppressor of aberrant 53BP1-mediated NHEJ [206,207]. 
However, deletion of classical NHEJ factors, for instance DNA Ligase IV, could not 
rescue HR defect of BRCA1-deficient cells, indicating that the lack of NHEJ per se is not 
responsible for the restoration of DNA-end resection in absence of 53BP1 [206]. In wild-
type cells, 53BP1 promotes NHEJ in G1, but is inhibited in S/G2, and this regulation 
seems to be altered in BRCA1-deficient cells [208]. Insights into how 53BP1 acts to 
promote NHEJ came from several recent studies characterizing RIF1, a downstream 
effector of 53BP1 [133,209-212]. RIF1, the mammalian orthologue of the yeast Rap1-
interacting factor 1, binds to 53BP1 in ATM-dependent manner inhibiting DNA-end 
resection and damage-induced BRCA1 foci formation in G1 [133,209,211,212]. On the 
other hand, BRCA1 strongly diminishes RIF1 localization at DSBs in S/G2 in a CtIP-
dependent manner [133]. Accordingly, both depletion of CtIP and abrogation of CDK-
mediated phosphorylation of CtIP on S327 or T847 lead to the increased RIF1 foci 
formation in S/G2 [133]. Given the significance of CDK-dependent phosphorylation in 
suppressing RIF1 and facilitating resection, CDK-mediated regulation is one the 
important mechanisms to insure the switch of DSB repair from NHEJ in G1 to HR in 
S/G2 phases [153,208]. In addition, CtIP protein levels are low in G1, but high during 
S/G2 phases, therefore triggering HR when sister chromatid is available [128]. Due to the 
crucial role of CtIP in conjunction with the MRN complex in promoting DNA-end 
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resection and suppression of RIF1, it is likely that DSB resection does not only produce a 
substrate for HR, but also inhibits the accumulation of pro-NHEJ factors such as RIF1 at 
the sites of damage [213]. Therefore, the formation of ssDNA regions as a result of DNA-
end resection regulates the DSB repair pathway choice: it prevents NHEJ and represents 
the commitment step for HR.  
 
Figure 8. Cell cycle dependent, antagonistic relationships of 53BP1-RIF1 and BRCA1-CtIP 
in DSB repair. During G1 phase of cell cycle RIF1, a downstream effector of 53BP1, prevents the 
accumulation of BRCA1 at DSBs, thus promoting c-NHEJ and inhibiting DNA-end resection and 
HR. As cells enter S-phase, CtIP is phosphorylated in a CDK-dependent manner. Phosphorylated 
CtIP together with BRCA1 antagonizes the accumulation of RIF1 at sites of DNA damage and in 
conjunction with the MRN complex initiates DNA-end resection, which commits cells to HR. 
Adapted from [208]. 
In contrast to 53BP1, RIF1 deficiency does not fully restore HR in BRCA1-deficient 
cells, implying the existence of additional 53BP1 effector proteins inhibiting HR [212]. 
Such 53BP1 effector, a PAX transactivation domain-interacting protein or PTIP, has been 
recently identified [214]. It interacts with phosphorylated 53BP1 via its BRCT domain 
and, similar to RIF1, is recruited to DSBs in a 53BP1- and ATM-dependent manner 
[214,215]. Both PTIP and RIF1 block DNA-end resection and promote NHEJ repair, 
however, unlike RIF1, ablation of PTIP efficiently rescues the HR defect in BRCA1-
deficient cells, indicating a more prominent role for PTIP in NHEJ [214]. On the other 
hand, whereas RIF1 is essential for 53BP1-initiated NHEJ during class switch 
recombination (CSR) in B cells, PTIP is dispensable for CSR, demonstrating two distinct 
functions of PTIP and RIF1 [216]. However, the mechanism of DNA-end resection 
inhibition by 53BP1 and its effectors still remains elusive. It is known that 53BP1 binds 
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methylated and ubiquitinated nucleosomes minimally as a dimer and thus may act in a 
wheel clamp-like manner or as a factor bridging adjacent nucleosomes, making chromatin 
refractory to the resection machinery in G1 [217]. Furthermore, PTIP and RIF may block 
the chromatin accessibility for BRCA1 or nucleases that mediate resection [213]. 
Alternatively, 53BP1 is evicted from the core of IR-induced foci in S phase in a BRCA1-
dependent manner [218]. Though the mechanism of 53BP1 inhibition by BRCA1 is not 
clear, it is plausible that BRCA1 modulates ubiquitination events at chromatin flanking 
DSBs, thereby protecting DNA ends from NHEJ factors and granting access for the end 
resection machinery [10]. While E3-ubiquitin ligase activity of BRCA1 seems to be 
dispensable for promoting HR and NHEJ suppression, BRCA1 may antagonize the 
ubiquitin-dependent recruitment of 53BP1 and its effectors to damaged chromatin via the 
interaction with deubiquitinating enzymes such as BRCC36 [133,219,220]. Multiple 
other factors including ubiquitin and SUMO E3 ligases are involved in the regulation of 
repair [202]. 
DSB repair occurs in the context of chromatin, therefore the complexity of chromatin 
structure influence pathway choice. DSBs in the heterochromatin regions that represent 
tightly packed DNA require remodeling prior to repair and mainly undergo slow repair by 
HR, whereas DSBs in more open euchromatic regions are repaired by NHEJ [221]. 
Repair of breaks in heterochromatin requires ATM-mediated phosphorylation of 
transcriptional corepressor Krüppel-associated box (KRAB)-associated protein KAP1 
[222,223]. KAP-1 forms densely packed chromatin by recruiting CHD3, HP1 and other 
remodeling factors [224,225]. Phosphorylation of KAP1 on serine 824 (S824) leads to the 
dissociation of KAP1 and CHD3, resulting in chromatin relaxation that facilitates repair 
[222,225,226]. Recruitment of another ATP-dependent chromatin remodeler 
SMARCAD1 to DSBs weakens histone-DNA interactions in nucleosomes flanking 
breaks and stimulates end resection and HR [227,228]. In summary, the balance between 
HDR and NHEJ is tightly controlled at different levels to ensure maintenance of genome 
stability since deregulation of DSB repair mechanisms may lead to apoptosis or 
tumorigenesis. 
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1.6.) DNA)interstrand)crosslink)(ICL))repair))
1.6.1.) DNA)interstrand)crosslinks)
DNA interstrand crosslinks (ICLs) are highly toxic DNA lesions generated by chemical 
compounds that covalently link two bases on the complementary DNA strands [229]. The 
mechanism of action of ICL-inducing drugs is broadly similar. The formation of a DNA 
interstrand crosslink requires an initial reaction to produce a monoadduct and subsequent 
slow conversion of monoadduct into crosslink [230]. Furthermore, ICL-inducing agents 
cause a wide variety of DNA lesions in addition to ICLs, such as monoadducts, DNA-
protein crosslinks and intrastrand crosslinks when adjacent DNA bases on the same DNA 
strand are covalently linked. However, ICLs are the most toxic lesions because they 
prevent DNA strand separation and thus block essential cellular processes such as DNA 
replication and transcription [231]. Given the detrimental effect of ICLs on rapidly 
dividing cells, ICL-inducing agents are widely used in chemotherapy. Mitomycin C 
(MMC) and psoralen combined with ultraviolet-A irradiation (PUVA) as well as nitrogen 
mustards and platinum compounds, such as cisplatin, are applied for treatment of 
different types of cancer including lymphomas, ovarian, breast and colorectal cancer 
[229,231]. Endogenous compounds arising from normal cellular metabolism such as 
malondialdehydes or acetaldehydes produced during lipid peroxidation and ethanol 
oxidation, respectively, can also induce ICLs [232,233]. A well-orchestrated 
multicomponent machinery, consisting of Fanconi Anemia (FA) proteins, aided by 
factors of nucleotide excision repair (NER), translesion DNA synthesis (TLS) and HR 
removes ICLs during DNA replication (Figure 9) [234]. ICLs in actively transcribed 
genes can be encountered by the transcription machinery and repaired via transcription-
coupled ICL repair involving NER proteins and TLS polymerases independently of FA 
pathway [231]. However, ICL repair is mainly active during S-phase, implying that ICLs 
predominantly affect DNA replication [235,236].  
1.6.2.) Fanconi'anemia)pathway)'
Fanconi anemia (FA) is a rare hereditary disorder characterized by progressive bone 
marrow failure, congenital abnormalities and susceptibility to both solid tumors and acute 
myeloid leukemia (AML) [237]. FA is genetically heterogeneous disorder. So far, sixteen 
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FA genes that constitute the FA repair pathway have been identified as mutated in 
patients (Table 1) [231]. The predisposition of FA patients to cancer is attributed to the 
essential role of FA pathway in DNA repair, particularly in the repair of ICLs. Cells 
isolated from FA patients display chromosomal instability and hypersensitivity to ICL-
inducing agents such as MMC and cisplatin that is used as a diagnostic test for FA [238]. 
The FA pathway orchestrates replication-coupled ICL repair involving nucleolytic 
incision of the crosslink, TLS and HR and therefore maintains genomic stability [12]. The 
replication fork stalling at ICLs serve as a signal to initiate the repair and currently 
different models with one or two replication forks converging on ICL are discussed [239]. 
Complex consisting of FANCM DNA translocase in conjunction with FA-associated 
protein 24 kDa (FAAP24) and two histone-fold-containing FANCM-associated proteins, 
MHF1 and MHF2, recognizes the stalled replication fork structure, initiates ATR-
mediated checkpoint signaling and promotes recruitment of the FA core complex to 
chromatin (Figure 9) [240-243]. Upon ATR activation multiple FA proteins undergo 
phosphorylation representing a close connection of the FA pathway with DDR signaling 
[244]. FA core complex consists of FANCA, FANCB, FANCC, FANCE, FANCF, 
FANCG, FANCL, FAAP20 and FANCM in subcomplex with FAAP24 and MHF1-2 
[231]. Members of the core complex stabilize the complex via protein-protein interactions 
and are essential for proper downstream signaling, particularly for monoubiquitination of 
FANCD2 and FANCI (FANCD2-I) heterodimer [245]. A FANCL subunit is an E3 
ubiquitin ligase that in concert with the UBE2T E2 enzyme conjugates a single ubiquitin 
to lysine 561 (K561) and lysine 523 (K523) of human FANCD2 and FANCI, respectively 
[246-248]. Monoubiquitination of FANCD2-I by the FA core complex is a critical 
regulatory step in ICL repair required for both stable association of FANCD2-I complex 
on damaged chromatin and coordination of crosslink repair activities together with 
downstream FA proteins (FANCD1, J, N, O, P, Q) [12]. Efficient monoubiquitination of 
FANCD2-I is independent of subsequent events such as nucleolytic processing of ICLs, 
but requires phosphorylation of FA core complex and FANCD2-I (ID) by ATR kinase 
[247,249,250]. FANCD2 is also monoubiquitinated during S-phase progression that 
might be important for the its function in protecting stalled replication forks from 
degradation [251,252].  
Remarkably, monoubiquitinated FANCD2 is considered to be a platform for recruiting 
proteins that contain ubiquitin-binding domain (UBD). One of such proteins is FA-
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associated nuclease 1 (FAN1) harboring an ubiquitin-binding zinc finger 4 (UBZ4) motif 
in the N-terminus required for specific recognition of ubiquitin moiety of FANCD2 [253-
256]. FA complementation group P (FANCP or SLX4) protein also contains a UBZ motif 
that is implicated in the binding to monoubiquitinated FANCD2 and is essential for its 
localization at sites of ICL-induced damage at least in chicken DT40 cells [257]. 
Therefore modified FANCD2 can specifically recruit UBD-containing proteins to 
damaged chromatin. Deubiquitination of FANCD2 is mediated by deubiquitinating 
(DUB) enzyme USP1 (ubiquitin-specific peptidase 1) in complex with its activating 
partner UAF1 (USP1-associated factor 1) [258,259]. Given the importance of FANCD2 
deubiquitination for the completion of repair, genetic disruption of murine Usp1 gene 
results in a phenotype similar to FA and Usp1-/- cells are hypersensitivity to ICL-inducing 
agents [260].  
Intriguingly, recent study using single-molecule technique for visualizing encounters of 
replication forks with ICLs in living cells revealed a frequent pattern consistent with 
replication traverse of the ICL without repair of the lesion [261]. It implies that DNA 
synthesis can resume past an ICL leaving behind still crosslinked parental strands. 
Replication traverse is promoted by the translocase and DNA-binding activities of 
FANCM-MHF1-2 independently of FA core complex, whereas FA proteins could 
participate in postreplication repair of the lesion. Though details of the regulation of this 
mechanism remain to be elucidated, it is a first indication that ICLs are not always 
absolute blocks to DNA replication. 
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Table 1. Fanconi anemia genes and their role in ICL repair. Adapted and modified 
from [231]. 
 
1.6.3.) Structure4specific)nucleases))
Following activation of the FA pathway, the crosslink has to be unhooked to allow 
subsequent repair to proceed. Excision of ICL requires two endonucleolytic incisions in 
one strand of the duplex on both 5'- and 3'-side of the lesion [12]. Though unhooking of a 
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crosslink is not sufficient for it complete removal, it permits DNA synthesis past the 
lesion. The FA pathway has been implicated in the recruitment and regulation of several 
nucleases such as MUS81-EME1, XPF-ERCC1, SLX4-SLX1, FAN1 and SNM1A [231]. 
However, given the variety of nucleases involved in ICL repair, the extent of the 
redundancy and their precise role in processing of the lesion still remain to be elucidated. 
MUS81-EME1 is DNA structure-specific endonuclease preferentially cleaving 3′-flap 
structures, aberrant replication fork structures and nicked HJ [262-264]. The formation of 
DSBs in response to ICL-inducing agents was shown to be dependent on MUS81-EME1, 
suggesting a critical role for this complex in promoting incision of crosslink on one side 
of the lesion [265,266]. To complete the unhooking of ICL, a second incision on the other 
side of the lesion is required. It is not clear, which endonuclease promotes this step. One 
of the candidates is XPF-ERCC1 endonuclease that functions both in NER and ICL repair 
[267]. In contrast to other factor involved in NER of bulky DNA adducts, only depletion 
of XPF-ERCC1 confers cellular hypersensitivity to ICL-inducing agents [249]. 
Moreover, mutations in XPF-ERCC1 impairing its interaction with NER proteins do not 
affect ICL repair, suggesting that specific protein-protein interactions regulate distinct 
roles of this complex in NER and ICL repair [268]. Remarkably, mutations in XPF that 
caused abnormal nuclease activity of the protein strongly disrupted the function of XPF 
in ICL, but not in NER repair, and resulted in FA phenotype, defining XPF as a novel FA 
complementation group, FANCQ [269].  
Another recently identified FA protein is SLX4 or FANCP that plays role of a scaffold 
and regulator of the three structure-specific nucleases XPF-ERCC1, MUS81-EME1 and 
SLX1 that is considered to be a key function of SLX4 in ICL repair [197-199,270]. 
Disruption of Slx4 in mice recapitulates many key features of FA [271]. SLX4 contains a 
UBZ domain that is required for its recruitment to ICLs via recognition of 
monoubiquitinated FANCD2 or other ubiquitinated substrates and ICL resistance [257]. 
Mutation analysis of SLX4 revealed that its interaction with XPF-ERCC1 is absolutely 
essential for resistance to ICL-inducing agents, whereas complex formation with MUS81-
EME1 or SLX1 is less important [194,249,272]. 
Though XPF-ERCC1 has an ability to perform both 5' and 3' incisions at the site of ICL, 
it was reported to preferentially cleave 3′-flap structures, implying additional nucleases to 
be involved in ICL incision [262,273,274]. FAN1 is a 5'-3' exonuclease and endonuclease 
with a preference for 5'-flaps [253-256]. It is recruited to ICLs through direct binding to 
monoubiquitinated FANCD2 via its UBZ4 domain and might play a role in the initial 
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incision of ICL, though it is currently unknown at which stage FAN1 acts. Furthermore, 
cells depleted of FAN1 show hypersensitivity to ICL-inducing agents and increased 
chromosomal instability, strongly suggesting a role in ICL repair [253,255]. However, 
patients with FAN1 deficiency do not display any characteristic symptoms of FA [275]. 
The 5'-3' exonuclease SNM1A is also required for ICL resistance and is implicated in the 
processing of the crosslink after the initial incision [276]. In vitro, it can digest a DNA 
substrate containing a crosslink starting from a single nick, and therefore generating a 
favorable intermediate for TLS [276].  
1.6.4.) Translesion)DNA)synthesis)
After ICL unhooking, the lesion has to be bypassed by a TLS polymerase in order to 
extend the leading strand that serves as a template for HR, whereas the unhooked ICL is 
eventually removed by nucleotide excision repair [12]. TLS is a mechanism for DNA 
damage tolerance or post-replication repair [277]. It allows replication over DNA lesion 
without initiating the repair of the lesion though predominantly in an error-prone manner. 
TLS requires replacement of the replicative polymerases by specialized translesion 
polymerases that have usually low fidelity and processivity and are characterized by a 
larger active site, which allows them to insert a base opposite the lesion [11]. The switch 
from replicative to translesion polymerases is mediated by the ubiquitination of 
proliferating cell nuclear antigen, PCNA [278]. PCNA is a polymerase processivity factor 
that functions as a moving platform along the strand to ensure DNA synthesis. Upon 
stalling of replication fork, PCNA gets monoubiquitinated on lysine 164 (K164) by the 
E2-E3 ubiquitin ligase complex RAD6-RAD18 [279,280]. Many TLS polymerases in 
addition to PIP-box also contain a UBD, such as the ubiquitin-binding motif (UBM) of 
REV1 or the UBZ3 motif of Pol η to specifically recognize monoubiquitinated form of 
PCNA [281,282].  
REV1 and Pol ζ, a heterodimer of REV3 and REV7, play critical role in TLS synthesis 
during ICL repair as cells lacking either one of these genes are hypersensitive to ICL-
inducing agents [283,284]. REV1 functions as a scaffold for recruiting and coordinating 
other TLS polymerases such as Pol ζ [285]. REV1 binds to REV7 via its C-terminus and 
mediates loading of Pol ζ to the lesion [286]. Given the critical role of this interaction, its 
disruption renders cells hypersensitive to cisplatin [287]. Furthermore, REV1 was 
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reported to stimulate Pol ζ extension in vitro, implicating a role for REV1 in regulating 
enzymatic activity of the recruited TLS polymerases [288].  
FA core complex coordinates REV1-dependent TLS pathway both by promoting 
FANCD2 monoubiquitination and ICL incision and directly by interacting with REV1 via 
FAAP20 [12]. FAAP20 is an integral subunit of FA core complex that binds to FANCA 
and also interacts with REV1 stabilizing its nuclear foci [289,290]. Remarkably, 
FAAP20-REV1 complex formation is enhanced in response to ICL damage through the 
interaction of FAAP20 UBZ4 domain with monoubiquitinated form of REV1 [290]. 
Therefore, FA core complex promotes stable association of the REV1 in conjunction with 
PCNA to replicate over a DNA lesion. Other TLS polymerases such as Pol η and Pol κ 
are also likely to play role in the repair of a subset of ICL lesions, but their significance 
for ICL repair still remains to be determined [231].  
1.6.5.) Role)of)HR)factors)in)ICL)repair)
The incision of the crosslink converts the stalled replication fork into a DSB intermediate 
that is primarily resolved by HR using the homologous strand restored by TLS as a 
template for repair [12]. The key steps of HR involve loading of RAD51 onto newly 
resected DNA and subsequent RAD51-mediated strand invasion of the restored sister 
chromatid. Downstream FA proteins such as FANCD1/BRCA2 and FANCN/PALB2 in 
complex with BRCA1 promote loading of RAD51 on RPA-coated single-stranded DNA 
[181,291,292]. FANCO/RAD51C and additional RAD51 paralogues also facilitate the 
RAD51 loading [293,294]. 5'-3' helicase FANCJ/BRIP1 (BRCA1-interacting protein C-
terminal helicase 1) acts downstream from RAD51 to complete HR by preventing 
promiscuous recombination [295,296]. Inhibition of RAD51 in Xenopus egg extracts 
blocks replication-coupled ICL repair, indicating a functional link between the FA and 
HR pathways [297]. Though recombination takes place after nucleolytic incision of ICL, 
RAD51 was shown to bind ICL-stalled replication forks even before FANCD2-I 
monoubiquitination [297]. The loading of RAD51 on ssDNA at stalled forks may 
function to prevent fork breakage or degradation in favor of proper incisions regulated by 
the FA pathway [298,299].  
Mutations in downstream FA genes frequently cause breast and ovarian cancer, 
underlining the connection between FA and breast cancer, so called FA-BRCA pathway 
associated with impaired HR [12]. Whereas FA pathway-deficient cells are compromised 
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in HR, the level of HR impairment detected by classical GFP reporter assays is relatively 
mild when compared with the severe defects observed in BRCA1- or BRCA2-mutant 
cells [247,300]. However, ICL-induced HR, measured using a modified GFP reporter that 
is able to replicate, was substantially compromised in FANCA-deficient cells, indicating 
that the FA pathway is specifically involved in replication-coupled HR repair, though its 
direct contribution to HR still remains to be elucidated [299]. Remarkably, inactivation of 
NHEJ pathway by depleting NHEJ factors such as Ku70, DNA-PKcs and Lig IV or by 
applying specific DNA-PKcs inhibitor in FA-deficient background partially rescues the 
hypersensitivity of FA cells to ICL-inducing agents [301,302]. Therefore, FA pathway 
not only promotes error-free HR, but also seems to play a critical role in inhibiting 
aberrant repair of DSB intermediates by NHEJ, thereby suppressing chromosomal 
rearrangements during ICL repair [237]. However, recent mouse knockout studies 
demonstrated that deletion of either Ku or 53BP1 aggravates genomic instability in cells 
lacking FANCD2, suggesting that FANCD2 provides a key activity in ICL repair that 
cannot be bypassed only by ablation of NHEJ [303]. One of the critical determinants of 
the DSB repair pathway choice is DNA-end resection that channels repair into HR and 
inhibits NHEJ [10]. Cells lacking DNA-end resection factors such as the MRN complex, 
CtIP, BLM or DNA2 and EXO1 are hypersensitive to ICL-inducing agents, implicating 
their role in ICL repair, however the connection between the FA pathway and resection 
machinery is poorly investigated [304-308]. Furthermore, FANCD2 was shown to 
interact with NBS1, DNA2 and BLM, indicating a putative regulation of DNA-end 
resection by FANCD2 [304-307]. 
Collectively, extensive studies of the replication-coupled ICL repair have revealed a 
complex interplay of nucleolytic incision, TLS and HR repair mechanisms regulated by 
the FA pathway. FANCD2 monoubiquitination is a prerequisite for ICL repair, 
connecting signaling with enzymatic repair steps. Deciphering further details about the 
molecular mechanism of ICL repair will provide better understanding of FA as a disease 
and a rationale for ICL-based chemotherapy in cancer treatment.  
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Figure 9. Model of replication-coupled ICL repair. Upon stalling of the replication fork, the FA 
core complex is phosphorylated by ATR kinase and is recruited to the lesion by FANCM, 
FAAP24 and MHF1-2. This complex possesses ubiquitin E3 ligase activity and monoubiquitinates 
FANCD2-FANCI heterodimer to promote its stable association with damaged chromatin. 
Monoubiquitinated FANCD2 serves as a scaffold to recruit multiple nucleases such as 
SLX4/FANCP in complex with MUS81-EME1 and XPF-ERCC1, and FAN1 that perform the 
incision of the crosslink. Translesion polymerases REV1 and Pol ζ fill in the gap opposite the 
unhooked oligonucleotide, which is then released by nucleotide excision repair. Incision creates 
DSB intermediates that are repaired via HR machinery, including FANCD1/BRCA2, 
FANCN/PALB2, FANCJ/BRIP1 and FANCO/RAD51C factors. To complete the repair, the 
USP1-UAF1 DUB complex deubiquitinates FANCD2-I heterodimer. Adapted and modified from 
[12]. 
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2. AIMS)
DSBs are the most deleterious lesions with respect to survival and preservation of 
genomic integrity. If left unrepaired, they lead to cell death and, if misrepaired, they 
trigger genomic instability, a hallmark of almost all human cancers. On the other hand, 
DSBs are induced by chemo- or radiotherapy as a means to treat cancer. Therefore, a 
detailed understanding of the molecular mechanisms promoting DSB repair is of 
particular importance. The major goal of my thesis is to further expand our knowledge on 
the role of CtIP in DNA-end resection, which initiates error-free repair of DSBs by 
homologous recombination (HR). 
2.1. Addressing) the) interplay) between) CtIP4dependent) DNA4end)
resection)and)the)Fanconi'anemia)pathway)during)DNA)interstrand)
crosslink)repair)
Distinct DNA repair activities are required for the resolution of DNA interstrand 
crosslinks (ICLs), including the recognition of the lesion by proteins of the Fanconi 
anemia (FA) pathway, nucleolytic incision of the crosslink, and HR. Remarkably, DSBs 
formed as intermediates during ICL processing are preferentially repaired via HR, 
whereas DSB repair by the more mutagenic non-homologous end-joining (NHEJ) 
pathway is suppressed. FANCD2 monoubiquitination and CtIP-mediated DNA-end 
resection represent key events in FA and HR pathway activation, respectively, but very 
little is known about their functional relationship. Therefore, the first aim of my thesis 
was to investigate the physical and functional interplay between CtIP and the FA pathway 
during ICL repair. We first analyzed the phenotypes of cells lacking CtIP and FANCD2 
in response to ICL damage and revealed that both factors are required for DNA-end 
resection and faithful ICL repair. Furthermore, we examined the interdependence of CtIP 
and FANCD2 regarding their localization to damaged chromatin and discovered that CtIP 
is recruited to ICLs in a FANCD2-dependent manner. We also addressed the physical 
interaction between CtIP and FANCD2 and identified a minimal FANCD2-binding 
region on CtIP, highlighting the functional significance of CtIP-FANCD2 interaction for 
ICL repair. Moreover, we elucidated the contribution of CtIP-mediated DNA-end 
resection to the maintenance of genome stability in FANCD2-deficient cells. The 
obtained data were compiled into manuscript that has recently been accepted for 
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publication in the peer-reviewed Cell Reports journal. The scientific manuscript is 
included in section 3.1. 
2.2. Functional)characterization)of)human)RAD50S)mutants)in)the)
DNA)damage)response)
The MRE11-RAD50-NBS1 (MRN) complex plays an essential role in the sensing and 
signaling of DSBs, as well as in HR, by promoting the resection of DSBs in collaboration 
with CtIP. However, the molecular mechanism by which MRN and CtIP cooperate in 
DNA-end resection still remains largely elusive. Thus, the second part of my thesis 
focused on the analysis of human RAD50 separation-of-function mutants (RAD50S), 
which were originally described in budding yeast to impair meiosis but to have no overt 
mitotic phenotype. Subsequently, RAD50S mutants were characterized in fission yeast 
and mice. To study the function of RAD50S mutants in human cells, we complemented a 
patient-derived RAD50 hypomorphic cell line, F239, with wild-type RAD50 or different 
RAD50S alleles and analyzed their phenotypes both in absence and presence of genotoxic 
stress. Hypothesizing that some of the RAD50S phenotypes might be attributed to 
alterations in MRN-CtIP complex formation, we also examined the impact of human 
RAD50S mutations on the interaction between MRN and CtIP. Results from these studies 
are presented in section 3.2. 
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SUMMARY
The resolution of DNA interstrand crosslinks (ICLs)
requires a complex interplay between several pro-
cesses of DNA metabolism, including the Fanconi
anemia (FA) pathway and homologous recombina-
tion (HR). FANCD2 monoubiquitination and CtIP-
dependent DNA-end resection represent key events
in FA and HR activation, respectively, but very little
is known about their functional relationship. Here,
we show that CtIP physically interacts with both
FANCD2 and ubiquitin and that monoubiquitinated
FANCD2 tethers CtIP to damaged chromatin, which
helps channel DNA double-strand breaks generated
during ICL processing into the HR pathway. Conse-
quently, CtIP mutants defective in FANCD2 binding
fail to associate with damaged chromatin, which
leads to increased levels of nonhomologous end-
joining activity and ICL hypersensitivity. Interest-
ingly, we also observe that CtIP depletion aggravates
the genomic instability in FANCD2-deficient cells.
Thus, our data indicate that FANCD2 primes CtIP-
dependent resection during HR after ICL induction
but that CtIP helps prevent illegitimate recombina-
tion in FA cells.
INTRODUCTION
Fanconi anemia (FA) is a rare hereditary disorder characterized
by bone marrow failure, developmental abnormalities, and can-
cer predisposition (Moldovan and D’Andrea, 2009). Cells iso-
lated from FA patients display chromosomal instability and
hypersensitivity to DNA interstrand crosslink (ICL)-inducing
agents such as mitomycin C (MMC) and cisplatin. The high cyto-
toxicity of MMC, a property exploited in cancer therapy, is pri-
marily based on the strong inhibitory effect of unrepaired ICLs
on DNA replication (Deans andWest, 2011). Recent studies indi-
cate that the FA pathway orchestrates replication-coupled ICL
repair—involving nucleolytic incision, translesion DNA synthesis
(TLS), and homologous recombination (HR)—to maintain
genomic stability (Knipscheer et al., 2009). In response to ICL
damage, the FA core complex, consisting of eight proteins
(FANCA, B, C, E, F, G, L, and M), promotes monoubiquitination
of FANCD2 and FANCI (Garcia-Higuera et al., 2001; Smogor-
zewska et al., 2007). The ubiquitinated FANCD2/I complex reloc-
alizes to damaged chromatin, where it coordinates downstream
repair events (Kim and D’Andrea, 2012). ICL repair is initiated by
nucleolytic incisions on either side of the crosslink and carried
out by SLX4-associated XPF-ERCC1 and MUS81-EME1 nucle-
ases and FAN1 (Kottemann and Smogorzewska, 2013). ICL inci-
sion converts the stalled replication fork into a one-ended DNA
double-strand break (DSB), which is repaired by HR. Interest-
ingly, FA phenotypes can be partially rescued by inhibition of
nonhomologous end-joining (NHEJ), suggesting that the FA
pathway not only promotes error-free HR but also actively sup-
presses inappropriate repair of DSB intermediates by NHEJ in
order to prevent chromosomal instability (Adamo et al., 2010;
Pace et al., 2010).
Although FANCD2 is critically important for ICL repair, its
contribution to HR remains largely elusive (Nakanishi et al.,
2011; Smogorzewska et al., 2007). HR is initiated by DNA-end
resection, which occurs in human cells through the combined
action of CtIP and the MRE11-RAD50-NBS1 (MRN) complex,
together with DNA2 or EXO1 nucleases (Nimonkar et al., 2011;
Sartori et al., 2007). Importantly, DNA-end resection is a key
determinant of DSB repair pathway choice, as it commits cells
to HR, while, at the same time, suppresses NHEJ (Chapman
et al., 2012). A putative connection between the resection ma-
chinery and the FA pathway was recently proposed, based on
data showing that DNA2 and EXO1 depletion leads to cisplatin
hypersensitivity (Karanja et al., 2012). Additionally, CtIP was
shown to accumulate at sites of locally induced ICLs (Duquette
et al., 2012). However, the contribution of DNA-end resection
to ICL repair and the regulation of CtIP by the FA pathway
have not yet been thoroughly investigated.
RESULTS
FANCD2 Is Required forCtIP Localization to ICLDamage
Similar to FA cells, we observed that CtIP depletion results in hy-
persensitivity and increased chromosomal aberrations following
MMC treatment, implicating a key role for CtIP in ICL repair (Fig-
ures 1A, S1A, and S1B). Because FANCD2 monoubiquitination
constitutes a key step of the FA pathway, we investigated
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whether CtIP affects FANCD2 foci formation. However, silencing
of CtIP did not significantly change the assembly of FANCD2 foci
after MMC treatment (Figure 1B). Moreover, FANCD2 monoubi-
quitination and chromatin assembly still efficiently occurred in
CtIP-depleted cells (Figures S1C and S1D). Recently, it was
shown that the knockdown of CtIP leads to a 2-fold reduction
in FANCD2 accumulation at ICLs induced by 8-methoxypsoralen
plus UVA laser microirradiation (PUVA) (Duquette et al., 2012).
Therefore, we subjected CtIP-depleted cells to PUVA treatment
and noticed partially reduced levels of monoubiquitinated
FANCD2 on chromatin (Figures S1E and S1F). Taken together,
our data indicate that CtIP is not strictly required for FANCD2
monoubiquitination in response to ICL-inducing agents but that
its lossmay lead to a negative feedback loop limiting FA pathway
activation during ICL repair.
We also noticed that CtIP was highly enriched on chromatin
upon MMC or PUVA treatment (Figures S1C and S1F). Consis-
tent with this, ICL damage caused a strong increase in CtIP
foci that colocalized with FANCD2 (Figure 1C). Remarkably,
both spontaneous and damage-induced CtIP foci were abro-
gated in FANCD2-depleted cells (Figure 1C). Accordingly,
FANCD2 depletion impaired CtIP chromatin association in
Figure 1. FANCD2 Is Required for the Accumulation of CtIP at Sites of ICL Damage
(A) Metaphase spreads fromHEK293 cells transfectedwith the indicated small interfering RNAs (siRNAs) and treated for 20 hr withMMC (25 ng/ml) were analyzed
for chromosomal aberrations. A total of 100metaphase spreads from three independent experiments were analyzed for each condition. The percentages of cells
displaying chromatid breaks or radial chromosomes are shown (see also Figure S1B).
(B) After 48 hr of transfection with indicated siRNAs, U2OS cells grown on coverslips were treated for 24 hr with MMC (120 ng/ml), pre-extracted, fixed, and
immunostained for FANCD2. Nuclei were visualized by DAPI-staining. Graph shows the percentage of cells displaying more than ten FANCD2 foci/nuclei.
(C) U2OS cells stably expressing GFP-tagged CtIP were transfected with indicated siRNAs, and 48 hr later, cells grown on coverslips were treated as in (B) and
immunostained for FANCD2. Graph shows the percentage of cells displaying more than ten GFP-CtIP foci/nuclei.
(D and E) U2OS cells were transfected with indicated siRNAs, and 48 hr later, cells were treated as in (B) and extracts were analyzed by immunoblotting.
(F) FANCD2 mutant human fibroblasts (PD20F) and PD20F stably expressing wild-type FANCD2 (WT) or K561R mutant FANCD2 were treated as in (B) and
harvested for immunoblot analysis (see also Figure S1H).
(G) U2OS cells were transfected with FAN1 siRNA and processed as in (D).
In (B) and (C), for each condition, at least 100 cells were scored and the data are presented as the mean ± SD (n = 3). The scale bar represents 5 mm.
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MMC- and PUVA-treated cells (Figures 1D and S1G). In
response to ICL damage, FANCD2 becomes monoubiquitinated
at K561 by the FA core complex (Garcia-Higuera et al., 2001;
Meetei et al., 2003). Depletion of FANCA, a subunit of the FA
core complex, abolished both FANCD2 and CtIP association
with damaged chromatin (Figure 1E). Importantly, impaired
CtIP accumulation at ICLs in FANCD2-deficient fibroblasts
(PD20F) was restored by complementation with wild-type (WT)
FANCD2, but not with the K561R mutant (Figures 1F and S1H).
In addition, CtIP failed to form MMC-induced foci in cells pre-
treated with the proteasome inhibitor MG-132, which leads to
the sequestration of ubiquitin in the cytoplasm, further indicating
that FANCD2 monoubiquitination is a prerequisite for CtIP local-
ization to ICLs (Figure S1I).
During the initial processing of DSBs, CtIP acts together
with the MRE11-RAD50-NBS1 (MRN) complex. We therefore
explored whether efficient localization of CtIP to ICLs may
require theMRNcomplex. However, while NBS1 downregulation
resulted in defective chromatin association of MRE11, the levels
of chromatin-bound FANCD2 and CtIP remained unaltered (Fig-
ure S1J). On the other hand, monoubiquitinated FANCD2 was
reported to directly interact with and recruit FAN1 and SLX4 to
coordinate ICL incision (Kottemann and Smogorzewska, 2013;
Yamamoto et al., 2011). However, depletion of FAN1 or SLX4
did not significantly affect the binding of CtIP to damaged chro-
matin (Figures 1G and S1K). Collectively, our results suggest that
proper localization of CtIP to ICLs is controlled by FANCD2 but
occurs independently of bothMRN and structure-specific nucle-
ases involved in ICL incision.
FANCD2 Facilitates CtIP-Mediated DNA-End Resection
during ICL Repair
We observed that both MMC and PUVA treatment resulted in
robust RPA2-S4/S8 phosphorylation (Figures S2A and S1E).
RPA2 phosphorylation, particularly at S4 and S8, has been
widely used as a surrogate marker for single-stranded DNA
(ssDNA) that is generated by DNA-end resection (Kousholt
et al., 2012). Remarkably, knockdown of CtIP or FANCD2
strongly impaired RPA2 hyperphosphorylation in response to
ICL-inducing agents, which was particularly evident in the chro-
matin-bound fractions (Figures 2A and S2B). Likewise, the per-
centage of cells with RPA2-pS4/S8 foci was significantly
reduced in CtIP- or FANCD2-depleted cells (Figures 2B and
S2C). Moreover, by immunostaining of cells with anti-bromo-
deoxyuridine (anti-BrdU), we found thatMMC triggered substan-
tial ssDNA formation, which was reduced upon depletion of CtIP
or FANCD2 (Figures 2C and S2D). Impaired DNA-end resection
commits cells to error-prone repair of DSBs by NHEJ. Recently,
RIF1 was characterized as a key NHEJ-promoting factor by vir-
tue of its role in counteracting resection (Chapman et al., 2013; Di
Virgilio et al., 2013; Escribano-Dı´az et al., 2013; Zimmermann
et al., 2013). Indeed, MMC-induced RIF1 foci were elevated
in CtIP- or FANCD2-depleted cells, further supporting the idea
that both factors promote DNA-end resection and, thus, sup-
press NHEJ during ICL repair (Figures 2D and S2E).
To further substantiate the role of CtIP-dependent resection in
ICL repair, we monitored RIF1 foci in cells expressing GFP-
tagged CtIP-WT, CtIP-T847A, or CtIP-S327A (Figure S2F). The
mutated residues in CtIP represent CDK phosphorylation sites
required for resection (T847A) or for interaction with BRCA1
(S327A) (Figure S2G) (Huertas and Jackson, 2009; Yu and
Figure 2. FANCD2 and CtIP Promote DNA-End Resection during ICL
Repair
(A) U2OS cells were transfected with indicated small interfering RNAs
(siRNAs), and 48 hr after siRNA transfection, cells were either mock-treated
or treated for 24 hr with MMC (120 ng/ml) and extracts were analyzed
by immunoblotting. RPA2 and P-RPA2 represent nonmodified and hyper-
phosphorylated forms of RPA2, respectively.
(B) Same cells as in (A) were grown on coverslips, pre-extracted, fixed, and
coimmunostained for RPA2-pS4/S8 (pRPA2) and RPA2 (see also Figure S2C).
Graph shows the percentage of RPA2-foci-positive cells displaying more than
ten pRPA2 foci.
(C) Same cells as in (A) were coimmunostained for gH2AX and BrdU to visu-
alize single-stranded DNA under nondenaturing conditions (see also Fig-
ure S2D). Graph shows the percentage of gH2AX-foci-positive cells displaying
more than ten BrdU foci.
(D) Same cells as in (A) were immunostained for RIF1 (see also Figure S2E).
Graph shows the percentage of nuclei displaying more than ten RIF1 foci.
(E) U2OS cells were transfected with CtIP siRNA, and 24 hr post-siRNA
transfection, cells were transfected with siRNA-resistant GFP-tagged CtIP
wild-type (WT), T847A, or S327A mutant CtIP (see also Figure S2F). After 48 hr
of siRNA transfection, cells were treated as in (A) and immunostained for RIF1.
Graph shows the percentage of GFP-foci positive cells displaying more than
10 RIF1 foci. The scale bar represents 5 mm.
In (B)–(E), for each condition, at least 100 cells were scored and data are
presented as the mean ± SEM (n = 3).
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Chen, 2004). Our analysis revealed a strong increase in RIF1 foci
in MMC-treated T847A mutant cells, whereas the S327A muta-
tion had no significant impact on RIF1 foci formation (Figure 2E).
In agreement with this result, T847Amutant cells were hypersen-
sitive to MMC, whereas the viability of cells expressing CtIP-
S327A was similar to CtIP-WT cells, further supporting the idea
that BRCA1-CtIP interaction is not required for resection during
ICL repair (Figures S2H and S2I) (Reczek et al., 2013). Thus far,
our findings suggest a pivotal regulatory role for FANCD2 in
priming CtIP-mediated DNA-end resection to prevent aberrant
NHEJ activity following ICL damage.
CtIP Physically Interacts with FANCD2 and Ubiquitin
Given that CtIP localization to sites of ICL damage is facilitated
by FANCD2, we next addressed whether they exist in a complex
and found that FLAG-CtIP efficiently coimmunoprecipitated with
GFP-FANCD2, and vice versa (Figures 3A and S3A). Moreover,
we were able to specifically detect endogenous CtIP coimmuno-
precipitating with FLAG-FANCD2 but did not observe significant
changes in complex formation uponMMC treatment, suggesting
thatmonoubiquitination of FANCD2may not be essential for CtIP
binding (Figure 3B). In order to further address this issue, we
mixed recombinant CtIP purified from insect cells with GFP-
FANCD2 immunoprecipitated from human embryonic kidney
293T (HEK293T) cells. While CtIP efficiently bound to FANCD2-
WT, it only weakly interacted with the FANCD2-K561R mutant,
indicating that FANCD2 and CtIP physically interact and that
complex formationmight be reinforced by FANCD2monoubiqui-
tination (Figures 3C and S3B).
To verify the existence of endogenous CtIP-FANCD2 com-
plexes, we performed proximity ligation assays (in situ PLA). As
shown in Figure 3D, we could readily detect nuclear PLA signals
in undamaged cells, which significantly increased in numbers
upon MMC treatment, indicating that the FANCD2-CtIP interac-
tion is enhanced following ICL damage. Moreover, we observed
a strong reduction in CtIP-FANCD2 complex formation in
FANCA-depleted, but not SLX4- or FAN1-depleted, cells (Figures
3D,S3C, andS3D). These findings further support the importance
of FANCD2 monoubiquitination for the accumulation of CtIP
at damaged chromatin, presumably by facilitating FANCD2-
CtIP interaction. Although sequence analysis revealed that CtIP
does not contain any known ubiquitin-binding motifs (Hofmann,
Figure 3. CtIP Physically Interacts with
FANCD2 and Ubiquitin
(A) HEK293T cells were cotransfected with
FLAG-CtIP along with either empty vector or
GFP-FANCD2, and 48 hr after transfection, cells
were lysed in NP-40 buffer and whole cell ex-
tracts were analyzed before (input) or after
immunoprecipitation (IP) with anti-GFP (see also
Figure S3A).
(B) HEK293T cells were transfected with either
empty vector or FLAG-FANCD2, and 48 hr post-
transfection, cells were either mock-treated or
treated for 24 hr with MMC (120 ng/ml). Cells were
lysed in Triton-X buffer, and whole-cell extracts
were analyzed before (input) or after IP using anti-
FLAG M2 affinity resin.
(C) HEK293T cells were transfected with empty
vector, GFP-FANCD2 (WT), or GFP-FANCD2
K561R (KR). Then 48 hr after transfection, cells
were lysed in NP-40 buffer and whole-cell ex-
tracts were subjected to IP with anti-GFP. After
stringent washings, immunoprecipitated GFP-
tagged proteins were incubated with 0.5 mg of
recombinant FLAG-tagged CtIP (rFLAG-CtIP;
see also Figure S3B). Inputs and recovered
protein complexes were analyzed by immuno-
blotting.
(D) U2OS cells transfected with the indicated
siRNAs were left untreated or treated as in (B).
After pre-extraction, cells were fixed on coverslips
and incubated with antibodies against CtIP and
FANCD2 before the detection of protein-protein
interactions using a fluorescently labeled probe
(PLA-613). Nuclei were visualized by DAPI stain-
ing. Graph shows the quantification of the PLA
signals/nucleus. PLA signals from at least 100 cells were analyzed (n = 3) (see also Figures S3C and S3D). The scale bar represents 5 mm.
(E) His alone (!) or recombinant His-tagged ubiquitin (rHis-Ub) coupled to nickel nitrilotriacetic acid (Ni-NTA) agarose beads were incubated with HeLa nuclear
extracts (NE). Input and precipitated bead fractions from the pull-downs were subjected to immunoblotting. Ponceau staining is shown to indicate the amounts
of rHis-Ub used in the pull-down assay.
(F) Recombinant FLAG-tagged CtIP was incubated either alone or together with recombinant hemagglutinin (HA)-tagged ubiquitin and the samples were
subjected to IP with anti-HA. Inputs and recovered protein complexes were analyzed by immunoblotting.
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2009), our results prompted us to examine whether CtIP can bind
toubiquitin. Asshown inFigure3E,wediscovered thatCtIP is able
to interact with ubiquitin, although less efficiently compared to
Polh that contains a ubiquitin-binding domain (UBD) (Bienko
et al., 2005; Plosky et al., 2006). Furthermore, we observed com-
parable ubiquitin binding abilities of GFP-CtIP and UBZ-domain
containingGFP-SLX4 (Figure S3E) (Yamamoto et al., 2011). How-
ever, while the ubiquitin I44A mutant completely abolished UBZ-
mediated interactions of SLX4 and Polh with ubiquitin, it did not
affect the binding of CtIP, implicating a distinct type of ubiquitin
recognition (Figure S3F). We were also able to detect an interac-
tion between purified, recombinant proteins, implying that CtIP
can directly recognize ubiquitin (Figure 3F). Collectively, these
data demonstrate that CtIP interacts with FANCD2 and that
FANCD2 monoubiquitination enhances FANCD2-CtIP complex
formation, perhaps owing to the ability of CtIP to bind ubiquitin.
FANCD2-CtIP Interaction Promotes Crosslink
Resistance
To establish the functional significance of the FANCD2-CtIP
interaction for ICL repair, we sought to identify the FANCD2-
binding motif in CtIP. Whereas FANCD2 did not bind to a region
of CtIP containing putative coiled-coil motifs (45–160), it bound
efficiently to fragments of CtIP comprising amino acid (aa) resi-
dues 45–298 or 45–371 (Figure 4A), highlighting the region be-
tween aa residues 160–298 of CtIP to be important for FANCD2
binding. Detailed protein sequence analysis of this region re-
vealed four motifs with high sequence conservation between
vertebrates (Figure S4A). Remarkably, cells expressing RRK/
AAA or RYIE/AAIA mutant variants of CtIP were impaired in
MMC-induced GFP-CtIP foci formation and showed increased
RIF1 foci (Figures S4B and S4C). Consistent with a defect in
CtIP foci formation, RRK/AAA and RYIE/AAIA mutants exhibited
reduced FANCD2 binding in glutathione S-transferase (GST)
pull-down experiments (Figures 4B and 4C). Moreover, PLA sig-
nals were reduced in both CtIP mutants after MMC treatment,
further supporting the role of RRK and RYIE motifs in CtIP-
FANCD2 interaction (Figures 4D and 4E). MMC-induced CtIP
foci were also abrogated in U2OS cells stably expressing GFP-
tagged CtIP-RRK/AAA and -RYIE/AAIA mutants, whereas RIF1
foci were significantly increased in those cells (Figure 4F). How-
ever, both CtIP mutants were efficiently recruited to DSB-con-
taining tracks generated by laser microirradiation (Figure S4D).
Underscoring a differential regulation of CtIP in response to
ICL damage, CtIP recruitment to laser-induced DNA lesions
was FANCD2-independent (Figure S4E). Of note, a truncated
CtIP mutant lacking residues 153–322 was still proficient in ubiq-
uitin binding, indicating that neither RRK (aa 177–179) nor RYIE
(aa 185-188) sequence motifs are required for the interaction
between CtIP and ubiquitin (Figures S4F and S4G). Finally,
both RRK/AAA and RYIE/AAIA mutant cells were hypersensitive
to MMC, further supporting the idea that FANCD2 regulates CtIP
functionality during ICL repair (Figure 4G).
CtIP Counteracts ICL-Induced DNA Damage in the
Absence of FANCD2 Activation
To genetically determine the epistatic relationship between
CtIP and FANCD2 in ICL repair, we generated an MRC5 cell
line stably expressing doxycycline (DOX)-inducible small hairpin
RNA (shRNA) against CtIP (Figure 5A). Interestingly, depletion of
FANCD2 in DOX-treated MRC5 cells led to a further increase
in MMC hypersensitivity (Figures 5A and 5B). In agreement
with this, survival of PD20 cells uponMMC treatment was further
reduced after silencing of CtIP (Figure S5A). CtIP/FANCD2-defi-
cient MRC5 cells also showed elevated levels of MMC-induced
RIF1 foci and radial chromosomes compared to cells depleted
for either factor alone, indicative of potent, illegitimate repair of
DSBs by NHEJ (Figures 5C, 5D, S5B, and S5C). Previously,
BRCA1 has been reported to regulate the accumulation of
FANCD2 into repair foci and CtIP recruitment to PUVA-induced
ICLs (Garcia-Higuera et al., 2001; Duquette et al., 2012). Further
supporting a dual, nonredundant role for CtIP in ICL repair,
knockdown of BRCA1 in DOX-treated MRC5shCtIP cells resulted
in increased MMC sensitivity (Figure S5D). Thus, our data sug-
gest that CtIP-dependent DNA-end resection is essential to
counteract the toxic effects of ICL damage when the FA/BRCA
signaling pathway is compromised.
ATR kinase is a major regulator of the FA pathway and pro-
motes FANCD2/I monoubiquitination (Andreassen et al., 2004;
Smogorzewska et al., 2007). Recently, both ATM and ATR
kinases have been implicated in DNA-damage-induced CtIP
phosphorylation (Peterson et al., 2013; Wang et al., 2013). In
order to gain further mechanistic insight into the regulation of
CtIP during ICL repair, we applied selective ATR and/or ATM
inhibitors prior to MMC treatment (Reaper et al., 2011). CtIP
and RPA2 phosphorylation was strongly elevated after ATR
inhibition; meanwhile, FANCD2 monoubiquitination and CHK1
phosphorylation were reduced as expected (Figure 5E, lane 2).
Interestingly, MMC-induced hyperphosphorylation of CtIP and,
to a lesser extent, of RPA2 was reversed when both inhibitors
were combined (Figure 5E, lane 4). These data suggest that
ATM gets hyperactivated when ATR kinase is blocked, probably
as a result of prevalent cleavage of collapsed replication forks
into DSBs. The structure-specific endonuclease MUS81-EME1
has been implicated in the conversion of stalled replication forks
into DSBs, particularly in checkpoint-deficient cells (Hanada
et al., 2006; Murfuni et al., 2013). Indeed, inhibition of ATR
combined with MUS81 depletion significantly reduced the phos-
phorylation of H2AX and KAP1, both established ATM targets,
indicating that MUS81 is at least partially required for the
processing of ICL-stalled forks into DSBs (Figure 5F). Remark-
ably, phosphorylation levels of CtIP were also decreased, further
implying CtIP in promoting DNA-end resection and HR of repli-
cation-associated DSBs in the absence of a fully functional FA
pathway. Taken together, our results demonstrate that during
conventional ICL repair, CtIP-mediated DNA-end resection is
regulated by FANCD2 but that CtIP also helps prevent illegiti-
mate repair of stalled forks in FA-pathway-defective cells.
DISCUSSION
CtIP is an essential factor required for the initiation of DNA-end
resection during HR and, thus, for the suppression of DSB repair
byNHEJ.Given that FA-pathway-deficient cells exhibit increased
chromosomal instability in response to ICL damage, FA pro-
teins have also been implicated in NHEJ inhibition. Indeed, we
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observed that depletion ofCtIP or FANCD2 leads to an increase in
radial chromosome formation andRIF1 foci afterMMC treatment,
indicative of enhanced NHEJ activity. Accordingly, DNA-end
resection, as measured by phosphorylated RPA2 and BrdU
focus formation,was reduced inCtIP- or FANCD2-depleted cells.
Several mechanisms have been proposed how FA proteins pre-
vent NHEJ, including the restriction of NHEJ factors to access
DNA termini, cryptic exonuclease, or nucleosome-assembly
activity of FANCD2 (Adamo et al., 2010; Pace et al., 2010; Sato
et al., 2012). Based on our data, we propose that FANCD2 sup-
presses error-prone NHEJ through promoting CtIP-dependent
resection (Figure S6).
We observed that monoubiquitinated FANCD2 tethers CtIP to
damaged chromatin and identified two short, highly conserved
motifs within CtIP responsible for CtIP-FANCD2 interaction.
Consequently, CtIP mutants defective in FANCD2 binding are
Figure 4. Functional Characterization of CtIP Mutants Impaired in FANCD2 Binding
(A) GST or GST-CtIP proteins were coupled to glutathione Sepharose beads and incubated with HEK293T cell lysates transiently overexpressing GFP-FANCD2.
The recovered materials were analyzed by immunoblotting.
(B) Alignment of the putative FANCD2-interacting region in CtIP orthologs. RRK and RYxE motifs are highlighted in black boxes. Other, highly conserved amino
acid residues are marked in bold typeface (see also Figure S4A).
(C) GST or indicated GST-CtIP (45–298) proteins were coupled to glutathione Sepharose beads and incubated with HEK293T cell lysates transiently over-
expressing GFP-FANCD2. The recovered materials were analyzed by immunoblotting.
(D) U2OS cells stably expressing siRNA-resistant GFP-tagged wild-type (WT) and mutant (RRK/AAA and RYIE/AAIA) CtIP were transfected with CtIP siRNA for
72 hr, and whole-cell extracts were analyzed by immunoblotting. (S) and (L) indicate short and long exposures of the same immunoblot, respectively.
(E) Same cells as in (D) were transfected with CtIP siRNA. After 48 hr of siRNA transfection, cells grown on coverslips were treated for 24 hr withMMC (120 ng/ml),
fixed, and incubated with antibodies against CtIP and FANCD2 before the detection of protein-protein interactions using a fluorescently labeled probe (PLA-613).
Graph shows the quantification of the PLA signals/nucleus in GFP-positive cells. PLA signals from at least 100 cells were analyzed (n = 2).
(F) Same cells as in (E) were fixed and immunostained for RIF1. Graphs show the percentage of GFP-positive cells displayingmore than tenGFP-CtIP foci or more
than ten RIF1 foci, respectively. For each condition, at least 100 cells were scored. Data are presented as the mean ± SEM (n = 2).
(G) Same cells as in (D) were either mock-treated or continuously treated with the indicated doses of MMC, and the survival was determined after 5 days using the
CellTiter-Blue cell viability assay. Data are presented as the mean ± SD (n = 3).
In (E) and (F), the scale bar represents 5 mm.
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impaired in the formation of MMC-induced foci. Whereas
FANCD2monoubiquitinationmaynot beessential for thephysical
interactionwithCtIP, it is required to retainCtIPondamagedchro-
matin. Remarkably,weshow thatCtIPdirectly interactswithubiq-
uitin in vitro. Although bioinformatic analysis failed to predict
any motifs resembling known UBDs in CtIP, it is plausible that
the FANCD2-CtIP interaction is reinforced by the ability of CtIP
to recognize ubiquitin. However, a CtIP mutant lacking both
FANCD2-interacting motifs was proficient in ubiquitin binding.
Furthermore, a mutant form of ubiquitin (I44A) defective in most
UBD-mediated interactions was still able to interact with CtIP.
Therefore, one could hypothesize that CtIP may employ a dual
modeof recognizingmonoubiquitinatedFANCD2,but, if so, binds
ubiquitin by a uniquemechanism that involves a new type of UBD
(Bomar et al., 2007). Clearly, further investigations are needed to
establish the role of CtIP-ubiquitin interaction in the DNA damage
response. On the other hand, it was proposed that monoubiquiti-
nation of FANCD2 could alter FANCD2 conformation (Joo et al.,
2011). Thus, it is tempting to speculate that such structural
changes in FANCD2 stimulate CtIP-FANCD2 interaction. Finally,
the FANCD2/I complex may also facilitate CtIP recruitment
to damaged chromatin via its histone chaperone activity (Sato
et al., 2012). Increased MMC-induced sensitivity and RIF1 foci
formation in cells expressing CtIP mutants (RRK/AAA and RYIE/
AAIA) further strengthen thesignificanceofCtIP-FANCD2 interac-
tion in ICL repair. Notably, R177Q and Y186C, two cancer-asso-
ciated missense mutations in human CtIP, map exactly to the
region implicated in FANCD2 interaction (Figure S4A). Given
that RRK and RYIE motifs reside in a highly conserved stretch of
12 amino acids, it is also reasonable to think that they constitute
a single FANCD2 interaction ‘‘domain.’’ These data are similar
to those described in the accompanying paper by Unno et al.
(2014) published in this issue of Cell Reports.
Depletion of CtIP in FANCD2-deficient cells aggravates the
phenotypes of cells lacking either factor alone, indicating that
CtIP contributes to genome stability in FA-pathway-defective
Figure 5. CtIP Contributes to Genome Stability in FA-Pathway-Deficient Cells
(A) MRC5 cells stably expressing doxycycline (DOX)-inducible shRNA against CtIP (MRC5shCtIP) were transfected with indicated siRNAs. Then 24 hr after siRNA
transfection, cells were cultivated in the absence or presence of DOX (1 mg/ml) for 48 hr. Cells were treated with MMC (120 ng/ml) for 24 hr and subjected to
immunoblotting.
(B) Same cells as in (A) were treated for 24 hr with indicated doses of MMC, and survival was determined after 10 days by colony-formation assay. Data are
presented as the mean ± SD (n = 3).
(C) Same cells as in (A) were immunostained for RIF1. Graph shows the percentage of RIF1-foci-positive cells displaying more than ten RIF1 foci. For each
condition, at least 100 cells were scored. Data are presented as the mean ± SD (n = 3) (see also Figure S5B).
(D) Metaphase spreads from the same cells as in (A) treated for 20 hr with MMC (20 ng/ml) were analyzed for chromosomal aberrations. A total of 45 metaphase
spreads from three independent experiments were analyzed for each condition. The percentages of cells displaying radial chromosomes are shown (see also
Figure S5C).
(E) U2OS cells were pretreated for 15 min with DMSO, ATR inhibitor (VE-821, 1 mM), ATM inhibitor (KU-55933, 10 mM), or both inhibitors together. Cells were then
treated for 20 hr with MMC (120 ng/ml), and extracts were analyzed by immunoblotting.
(F) U2OS cells were transfected with MUS81 siRNA, and 48 hr after siRNA transfection, cells were pretreated for 15 min with DMSO or ATR inhibitor (VE-821,
1 mM). Cells were then treated as in (E) and harvested for immunoblot analysis.
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cells. Likewise, inactivation of FAN1 or SLX4 enhanced crosslink
sensitivity of cells compromised in FANCD2 activation, suggest-
ing that these proteins, though being recruited to ICLs by
FANCD2, can promote MMC resistance in a FA-pathway-inde-
pendent manner (Yamamoto et al., 2011; Zhou et al., 2012).
Furthermore, only partial epistasis of FANCD2 over CtIP could
be explained by an additional role of CtIP upstream of FANCD2
or by the proposed role of FANCD2 in protecting stalled forks
from degradation (Duquette et al., 2012; Schlacher et al.,
2012). There is increasing evidence that arrested and unpro-
tected replication forks frequently collapse and give rise to
DSBs, which can then undergo resection and repair by HR
(Couch et al., 2013). Accordingly, we observed enhanced
ATM-dependent phosphorylation of CtIP and RPA2 in cells co-
treated with MMC and ATR inhibitor, indicative of ongoing DSB
resection (Fugger et al., 2013). In line with this, CtIP phosphory-
lation was reduced upon depletion of MUS81, an endonuclease
implicated in the cleavage of stalled forks and DSB formation
(Ciccia et al., 2008). Furthermore, CtIP-dependent processing
of collapsed forks upon hydroxyurea treatment was recently re-
ported to be beneficial for genome integrity in the absence of
FANCM (Blackford et al., 2012). Therefore, we conclude that
CtIP can partially suppress genomic instability in the absence
of FANCD2, whereas, in FA-pathway-proficient cells, monoubi-
quitinated FANCD2 coordinates CtIP-mediated DNA-end resec-
tion during ICL repair.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
U2OS, HEK293T, and HEK293 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS),
100 U/ml penicillin, and 100 mg/ml streptomycin. U2OS clones stably express-
ing siRNA-resistant forms of GFP-CtIP were described previously (Sartori
et al., 2007). FANCD2-deficient cells (PD20F) were obtained from Fanconi
Anemia Research Foundation (FARF) and cultured in DMEM supplemented
with 10% FCS and standard antibiotics. PD20F cells complemented with
FANCD2 wild-type (FARF) or K561R (kindly provided by Josef Jiricny) were
grown in standardmedium supplementedwith 1 mg/ml Puromycin.MRC5shCtIP
cells were grown in DMEM supplemented with 10% Tet system approved
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, Blasticidin (5 mg/ml), and
Zeocin (250 mg/ml). Plasmids were transfected either by using the standard
calcium phosphatemethod or FuGENE 6 (Roche) according to manufacturer’s
instructions. Transfection of all siRNA oligos was done with 40 nM final con-
centration using Lipofectamine RNAiMAX (Invitrogen). Data for survival curves
were generated by colony-formation assays as described previously (Sartori
et al., 2007).
Triton Extraction
Isolation of Triton-insoluble (chromatin-enriched) fractionwasperformedaspre-
viously described (Pen˜a-Diaz et al., 2012). In brief, cells were rinsed twice in cold
PBS and incubated for 5 min on ice in preextraction buffer (25 mM HEPES
[pH 7.4], 50 mMNaCl, 1 mMEDTA, 3 mMMgCl2, 300mM sucrose, 0.5% Triton
X-100, and protease inhibitors). After buffer removal, adherent cellular material
washarvestedbyscraping thecells intoLaemmlibuffer. Thechromatin-enriched
fraction was then heat denatured, sonicated, and analyzed by immunoblotting.
SUPPLEMENTAL INFORMATION
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and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.03.069.
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Supplemental Experimental Procedures  
Plasmids. 
The pcDNA3.1-based expression vectors for FLAG-FANCD2, GFP-FANCD2 and 
GFP-FANCD2 K561R were kindly provided by Minoru Takata (Kyoto University, 
Japan). Expression constructs for epitope-tagged CtIP were described previously 
(Steger et al., 2013). The pGEX-4T1 plasmids for bacterial expression of CtIP 
fragments were described previously (Sartori et al., 2007). CtIP 45-298 fragment was 
generated by introducing two stop codons in pGEX-4T1 CtIP 45-371. The pcDNA5-
based GFP-SLX4 expression vector was a kind gift from Johan P. de Winter (VU 
University Medical Center, The Netherlands) (Stoepker et al., 2011). The pET23-
based 6xHis-ubiquitin vector for bacterial expression was kindly provided by 
Matthias Peter (ETH Zurich, Switzerland). All CtIP and ubiquitin mutations were 
introduced by site-directed mutagenesis using Expand Long Template PCR System 
(Roche) and confirmed by sequencing. To generate an entry vector harboring shCtIP 
(target sequence: CGTCAGCCTTACAACGCAA (You et al., 2009)), annealed 
double-stranded DNA oligos were ligated into pENTR/HI/TO (Invitrogen). The 
lentiviral destination construct encoding shCtIP (pLenti4-shCtIP) was generated in an 
in vitro recombination reaction after transformation of bacteria with pENTR-shCtIP 
and pLenti4/DEST (Invitrogen). 
 
siRNA sequences. 
All siRNA duplexes were purchased from Microsynth AG, the sequences were as 
follows: Luciferase (CNTL; CGUACGCGGAAUACUUCGA), CtIP (CtIP-1; 
GCUAAAACAGGAACGAAUC) and CtIP-2 (UCCACAACAUAAUCCUAAU) 
(Sartori et al., 2007), FANCD2 (CAGAGUUUGCUUCACUCUCUA) (Kratz et al., 
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2010), FANCA (CAGCGTTGAGATATCAAAGAT) (Kim et al., 2008), FAN1 
(GUAAGGCUCUUUCAACGUA) (Kratz et al., 2010), NBS1 
(GGAGGAAGAUGUCAAUGUUUU) (Yoo et al., 2009), SLX4 
(AAACGUGAAUGAAGCAGAAUU) (Svendsen et al., 2009), MUS81 
(CAGCCCUGGUGGAUCGAUA) (Neelsen et al., 2013), BRCA1 
(GGAACCUGUCUCCACAAAG) (Bruun et al., 2003). 
 
Lentivirus production. 
Lentiviruses encoding either the Tet-Repressor protein (TetR) or shCtIP were 
generated in human 293FT cell line as previously described (Tiscornia et al., 2006). 
Briefly, 293FT cells were transfected with a lentiviral vector (pLenti6/TR or pLenti4- 
shCtIP) in combination with ViraPowerTM Packaging Mix using LipofectamineTM 
2000 according to the manufacturers protocol (Invitrogen). Virus-containing 
supernatant was collected 72 h post-transfection and filtered through a sterile 0.45 µm 
low protein-binding filter (Millex-HV 0.45 µm PVDF, Millipore). The filtrated viral 
supernatant was aliquoted into 1.5 ml cryovials and stored at -80°C. 
 
Generation of a stable MRC5 cell line with inducible shCtIP expression. 
SV40-immortalized MRC5 cells were first transduced with viral supernatant 
harbouring pLenti6/TR and, 24 h later, infected with viral supernatant containing 
pLenti4/shCtIP. 48 h after the second transduction, cells were split at low confluency 
and grown in selection medium containing Blasticidin (5 µg/ml) and ZeocinTM (500 
µg/ml) for 11 days. Antibiotic-resistant colonies were isolated, expanded and 
individual clones screened for doxycycline (DOX) -inducible expression of shCtIP by 
immunoblotting. 
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Generation of the stable U2OS cell lines expressing GFP-CtIP-S327A, -
RRK/AAA or -RYIE/AAIA. 
U2OS cells (40% confluent) were transfected with the pEGFP-C1 plasmid containing 
siRNA-resistant CtIP cDNA, harbouring corresponding mutations in the coding 
sequence, using FuGENE 6 (Roche). 24 h after transfection, standard medium was 
replaced with selection medium containing Genetecin® (G418, GIBCO, 500 µg/ml). 
The medium was replaced every 2-3 days and antibiotic-resistant colonies were 
isolated and screened for GFP-CtIP expression by both immunofluorescence 
microscopy and western blotting. 
 
Immunofluorescence Microscopy 
U2OS or MRC5shCtIP cells grown on coverslips were either fixed directly in 
formaldehyde and permeabilized or pre-extracted for 5 min on ice before fixation in 
4% formaldehyde (w/v) in PBS for 12 min as described previously (Sartori et al., 
2007). After incubation with indicated primary and appropriate Alexa Fluor-488, -594 
and -647 conjugated secondary antibodies (1:1'000) (Life Technologies), coverslips 
were mounted with Vectrashield® (Vector Laboratories) containing DAPI and sealed. 
Images were acquired on a Leica DMRB fluorescence microscope. Laser micro-
irradiation was performed as described previously (Eid et al., 2010). 
 
Metaphase spread analysis. 
HEK293 cells were transfected with indicated siRNAs at a final concentration of 40 
nM using Lipofectamine RNAiMax transfection reagent (Invitrogen). 48 hours later 
cells were either mock-treated or treated with MMC (25 ng/ml) for 20 hours. Prior to 
harvesting, cells were treated with Colcemid (Gibco) at a final concentration of 0.1 
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µg/ml for 1 hour. Then, cells were collected in a 15 ml Falcon tube and centrifuged at 
200 g for 5 minutes. Cells were resuspended in 5 ml of a hypotonic KCl solution 
(0.075 M) and incubated for 10 minutes at 37°C. To fix the cells, 1 ml of fixing 
solution containing Methanol:Acetic acid (3:1) was added to the suspension, mixed 
and centrifuged at 200 g for 5 minutes. Then, cells were resuspended directly in fixing 
solution containing Methanol:Acetic acid (3:1), which was added dropwise, while 
gently vortexing, and spun down. This step was repeated twice. Finally, the cell pellet 
was resuspended in 0.5-1 ml Methanol:Acetic acid fixing solution depending on the 
density of the cell suspension. 20 µl (2 drops) of the cell suspension was dropped on a 
pre-wetted glass slide (45° tilted) from 30 cm distance. Slide was air-dried and DNA 
was stained with DAPI. Immunofluorescent images were acquired in the DAPI- 
channel using the Leica DMRB microscope with Leica DFC 360 FX camera and the 
Leica objective HCX PL AP0 100x. 
To prepare metaphase spreads from MRC5shCtIP cells, they were transfected with 
nontargeting or FANCD2 siRNA. 6 h after siRNA transfection, cells were cultivated 
in absence or presence of DOX (1 µg/ml) for 48 h. Cells were treated with MMC (20 
ng/ml) for 20 h and with Colcemid at a final concentration of 0.1 µg/ml in the last 3 
hours. Cells were harvested as described above. 
 
Antibodies. 
The primary antibodies used in this study are listed in a separate table below. 
Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies were form GE- 
Healthcare and the HRP-conjugated anti-goat was from Santa Cruz Biotech. Alexa 
Fluor-488, -594, and -647-conjugated secondary antibodies were from Invitrogen. 
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Chemicals. 
Mitomycin C (MMC), 8-Methoxypsoralen (8-MOP) and MG132 were purchased 
from Sigma. ATM inhibitor (KU-55933) was purchased from Tocris Bioscience. 
ATR inhibitor (VE-821) was provided by Vertex Pharmaceuticals (Abingdon, UK). 
 
Immunoblotting, Immunoprecipitation, GST pulldown and Far-Western. 
If not specified otherwise, cell extracts were prepared in Laemmli buffer (4% SDS, 
20% glycerol, 120 mM Tris-HCl pH 6.8). Proteins were resolved by SDS–PAGE and 
transferred to nitrocellulose. Immunoblots were performed by using the appropriate 
antibodies and proteins visualized using the ECL detection system (Amersham). 
For GST pulldown assays and immunoprecipitation assays, cells were lysed in either 
NP-40 extraction buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1 mM EDTA, 15 
mM sodium pyrophosphate and 1 % NP-40 supplemented with phosphatase inhibitors 
(20 mM NaF, 1 mM sodium orthovanadate), protease inhibitors (1 mM benzamidine 
and 0.1 mM PMSF), deubiquitinase inhibitor (10 mM N-ethylmaleimide) and 10U 
Benzonase® (Roche)) or Triton X-100 buffer (50 mM Tris-HCl, pH 7.5, 200 mM 
NaCl, 1 mM EDTA, 0.2 % Triton X-100 supplemented with phosphatase, protease 
and deubiquitinase inhibitors) and clarified by centrifugation at 14000 rpm. GST pull-
downs and immunoprecipitations were performed as described previously (Sartori et 
al., 2007). Far-western blot analysis was performed as described (Wu et al., 2007). 
Anti-GFP immunoprecipitates from HEK293T cells transfected with GFP-CtIP-wt or 
GFP-CtIP-ΔN were subjected to far-western analysis using recombinant HA-
Ubiquitin (10 µg, Boston Biochem) as a probe followed by anti-HA immunoblotting.  
 
Purification of recombinant human CtIP. 
 
RESULTS!!
! 62!
Insect Sf9 cells infected with FLAG-GST-CtIP-6H recombinant baculovirus were 
harvested 50 h after infection. The cell pellet was resuspended in lysis buffer (50 mM 
Tris-HCl, pH 7.5, 0.5 M NaCl, 0.1% NP-40, 10 % glycerol, 10 mM imidazole) 
supplemented with protease inhibitors (Roche). Cells were disrupted by douncer 
homogenization and cell debris was removed by centrifugation at 45K for 45 min at 
4°C. Supernatant was filtered and loaded to Ni-NTA beads (Qiagen) overnight at 4°C. 
Beads were washed extensively with lysis buffer and lysis buffer supplemented with 
60 mM imidazole and then protein was eluted using lysis buffer supplemented with 
400 mM imidazole. Elution fractions were pooled, NaCl concentration was adjusted 
to 150 mM and loaded to heparin beads (GE Healthcare) for 90 min at 4°C. Heparin 
beads were washed with wash buffer (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.1 % 
NP-40, 10 % glycerol) and proteins were eluted with elution buffer (50 mM Tris-HCl 
pH 7.5, 1 M NaCl, 0.1% NP-40, 10% glycerol). Elution fractions were pooled and 
dialyzed against dialysis buffer (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 20% 
glycerol), aliquoted and stored at -80°C. 
 
In vitro protein interaction.  
To analyze in vitro protein interaction between CtIP and FANCD2, GFP-FANCD2 
wild-type or K561R mutant transiently expressed in HEK293T cells were 
immunoprecipitated with the anti-GFP antibody, coupled to Protein-A Sepharose 
beads (GE Healthcare) for 2 h at 4°C and immunocomplexes were stringently washed 
four times with NTEN buffer (0.5% NP- 40, 0.1 mM EDTA, 20 mM Tris-HCl, pH 
7.4, 1 M NaCl). 0.5 µg of recombinant human FLAG-GST-CtIP-6His purified from 
Sf9 insect cells were incubated either alone or with GFP-fusion FANCD2 
immunocomplexes bound to Protein-A Sepharose beads for 2 h at 4°C in 1 ml 
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TEN100 buffer (0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 200 µg/ml 
BSA). Immunocomplexes were washed four times with NTEN350 buffer (0.5% NP-
40, 0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 350 mM NaCl), boiled in SDS-sample 
buffer and analyzed by SDS-PAGE followed by immunoblotting. 
To analyze in vitro protein interaction between CtIP and ubiquitin, recombinant 
human FLAG-GST-CtIP-6His (0.2 µg) was incubated either alone or together with 
recombinant HA-Ubiquitin (5 µg, Boston Biochem) for 2 h at 4 C in the following 
buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 nM 
NaF, 1% Triton-X-100, 10% glycerol, 10 µM ZnCl2, 200 µg/ml BSA supplemented 
with EDTA-free protease inhibitor cocktail). The samples were subjected to 
immunoprecipitation using anti-HA antibody. Immunocomplexes were washed four 
times with NTEN250 buffer (0.5% NP-40, 0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 
250 mM NaCl), boiled in SDS-sample buffer and analyzed by immunoblotting. 
 
In vitro Ubiquitin-binding assay.  
pET23-6xHis-ubiquitin wt vector (His-Ub wt, kind gift from Matthias Peter), I44A 
mutant or empty vector were grown in BL21-CodonPlus(DE3)-RIL Escherichia coli 
(Invitrogen) and protein expression was induced upon addition of 1 mM IPTG for 4 h 
at 37 °C. Proteins were solubilized in the lysis buffer containing 50 mM Tris-HCl, pH 
7.5, 300 mM NaCl, 1 mM EDTA, 10 % glycerol, 1 % Triton X-100 and 20 mM 
imidazole supplemented with 1 mM DTT, 1 mM PMSF and EDTA-free protease 
inhibitor cocktail (Roche). His-Ub proteins were coupled to Ni-NTA Agarose 
(Qiagen), washed three times with lysis buffer supplemented with 500 mM NaCl and 
additional 20 mM imidazole, once with TEN100 buffer (20 mM Tris-HCl, pH 7.4, 0.1 
mM EDTA and 100 mM NaCl) and incubated in TEN100 buffer supplemented with 1 
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mg/ml BSA for 30 min at 4 °C. Next, His-Ub proteins bound to Ni-NTA Agarose 
were incubated either with 1 mg of HeLa nuclear extract or with 1 mg of HEK293T 
lysates transiently expressing GFP-CtIP or GFP-CtIP-ΔN for 2 h at 4 °C in 1 ml of 
cell lysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
25 nM NaF, 1% Triton-X-100, 10% glycerol, 10 µM ZnCl2, supplemented with 
phosphatase inhibitors (20 mM NaF) and EDTA-free protease inhibitor cocktail). 
Beads were then washed once with NTEN300 buffer (0.5% NP-40, 0.1 mM EDTA, 
20 mM Tris-HCl, pH 7.4, 300 mM NaCl), transferred to a new tube, washed another 
three times with NTEN300 and once with TEN100 buffer. Complexes were boiled in 
SDS sample buffer and analyzed by SDS–PAGE followed by immunoblotting. 
 
In Situ Proximity Ligation Assay. 
In situ proximity ligation assay (PLA) in combination with immunofluorescence 
confocal microscopy was performed using Duolink II Detection Kit with anti-Mouse 
PLUS and anti-Rabbit MINUS PLA Probes, according to the manufacturer’s 
instructions (Olink Bioscience) (Söderberg et al., 2006). 
 
CellTiter-Blue® Cell Viability assay. 
U2OS clones stably expressing siRNA-resistant forms of GFP-CtIP or MRC5shCtIP 
cells were transfected with indicated siRNA. 48 hours post-transfection cells were 
seeded in triplicates at a density of 500 cells/well in 96 well plate. 24 h later cells 
were continuously treated with indicated doses of MMC and grown for 5 days at 
37°C. To measure cell viability, CellTiter-Blue® reagent (Promega) was added on the 
last day, cells were incubated at 37°C for 4 h, and then fluorescence was measured at 
560/590 nm. 
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PUVA treatment. 
U2OS cells were incubated in PBS containing 10 µg/ml 8-MOP (Sigma) for 30 min. 
After incubation, cells were exposed to 10 kJ/m2 UV-A (365 nM, Vilber Lourmat 
Bio-Link BLX Crosslinker) in the presence of 8-MOP. Post-treatment PBS was 
removed and fresh media was added. At the indicated timepoints cells were harvested 
and proteins were analyzed by immunoblotting. 
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Supporting Table: Primary antibodies 
Antibody target Species Supplier/Reference Application* 
pATM S1981 rabbit 2152-1 (Epitomics) IB 
ATR (N-19) goat sc-1887 (Santa Cruz) IB 
BRCA1 (D-9) mouse sc-6954 (Santa Cruz) IB 
BrdU mouse RPN202 (GE Healthcare) IF 
CHK1 (G-4) mouse sc-8408 (Santa Cruz) IB 
pCHK1 S345 rabbit 2341(Cell Signaling) IB 
CtIP (14-1) mouse gift from Richard Baer IF  
CtIP rabbit A300-488A (Bethyl) IF (in situ PLA) 
CtIP (D-4) mouse sc-271339 (Santa Cruz) IB 
ERCC1 (FL-297) rabbit sc-10785 (Santa Cruz) IB 
FAN1 sheep gift from John Rouse  IB 
FANCA  rabbit A301-980A (Bethyl)  IB 
FANCD2 (FI17) mouse sc-20022 (Santa Cruz) IB and IF (in situ PLA) 
FANCD2 rabbit ab2187 (Abcam) IF 
FLAG mouse F3165 (Sigma) IB 
GFP rabbit ab290 (Abcam) IP  
GFP mouse sc-9996 (Santa Cruz) IB 
HA mouse sc-7392 (Santa Cruz) IB and IP 
γH2AX (20E3) rabbit 9718 (Cell Signaling) IB and IF 
KAP1 pS824  rabbit A300-767A (Bethyl) IB 
MRE11 (12D7) mouse GTX70212 (GeneTex) IB 
MUS81 mouse M1445 (Sigma) IB 
NBS1 (1D7) mouse GTX70224 (GeneTex) IB 
Pol η rabbit ab17725 (Abcam) IB 
RIF1 rabbit A300-569A (Bethyl) IF 
RPA2 (Ab-3) mouse NA19L (Calbiochem) IB and IF 
pRPA S4/S8 rabbit A300-245A (Bethyl) IB and IF 
SLX4 rabbit A302-270A (Bethyl) IB 
β-Tubulin (D-10) mouse sc-5274 (Santa Cruz) IB 
TFIIH p89 (S-19) rabbit  sc-293 (Santa Cruz) IB 
*IB: Immunoblot, IF: Immunofluorescence, IP: Immunoprecipitation 
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SUPPLEMENTARY FIGURE LEGENDS 
Figure S1 (related to Figure 1). CtIP localizes to ICL lesions in a FANCD2-dependent 
but NBS1- and SLX4-independent manner. 
(A) U2OS cells were transfected with non-targeting (CNTL), CtIP or FANCD2 siRNA. 48 h 
after transfection, cells were treated for 24 h with mitomycin C (MMC) and survival was 
determined after eight days by colony formation. Data are presented as the mean ± SD (N=3). 
(B) Representative images of metaphase spreads from cells described in (C) after treatment 
with MMC (25 ng/ml) for 20 h. Selected chromosomal aberrations are displayed in higher 
magnifications. (C) U2OS cells were transfected with indicated siRNAs. 48 h after 
transfection, cells were treated for 24 h with MMC (120 ng/ml) and total and chromatin-
bound proteins were analyzed by immunoblotting. (D) U2OS cells were transfected with 
different CtIP siRNAs. 48 h after transfection, cells were treated as in (C) and total proteins 
were analyzed by immunoblotting. Signal intensities of FANCD2 isoforms were quantified 
using Image J software and L/S indicates the ratio of monoubiquitinated (L) to non-
monoubiquitinated (S) FANCD2. (E) U2OS cells were grown in absence (-) or presence (+) 
of 10 µg/ml 8-MOP for 30 min prior to UVA exposure and harvested at the indicated time 
points after PUVA treatment. RPA2 and P-RPA2 represent non-modified and 
hyperphosphorylated forms of RPA2, respectively. (F,G) U2OS cells were transfected with 
the indicated siRNAs. 48 h after transfection, cells were either mock-treated (-) or treated with 
PUVA and released for 4 h. Total and chromatin-bound proteins were analyzed by 
immunoblotting using the indicated antibodies. (H) FANCD2-mutant human fibroblasts 
(PD20F) and PD20F cells stably expressing either wild-type FANCD2 (wt) or the K561R 
mutant were grown on coverslips, mock-treated or treated as in (C), pre-extracted, fixed and 
co-immunostained for CtIP and γH2AX. (I) U2OS cells grown on coverslips were pre-treated 
for 2 h with DMSO or MG-132 (20 µM) and then treated with MMC (500 ng/ml) for 4 h. 
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Cells were pre-extracted, fixed and co-immunostained for CtIP and γH2AX. (J,K) U2OS 
cells were transfected with indicated siRNAs. 48 h after transfection, cells were treated as in 
(C) and total and chromatin-bound proteins were analyzed by immunoblotting. The arrow 
indicates a non-specific band detected by the anti-SLX4 antibody. In (C, D, F, G, J and K), 
the asterisks indicate hyperphosphorylated CtIP. In (C, F, G and J), D2 and D2-Ub represent 
non-ubiquitinated and monoubiquitinated forms of FANCD2, respectively. In (C, F, G, J, and 
K), TFIIH and CHK1 were used as loading controls for chromatin-enriched and soluble 
proteins, respectively. In (H and I), graphs show the percentage of γH2AX-foci positive cells 
displaying more than 10 CtIP foci. For each condition at least 100 cells were scored. Data are 
presented as the mean ± SD (N=2). In (H and I) scale bar, 10 µm.  
 
Figure S2 (related to Figure 2). FANCD2 and CtIP promote resection during ICL 
repair. 
(A) U2OS cells were treated with MMC (120 ng/ml) for the indicated time points and whole 
cell lysates were analyzed by immunoblotting. (B) U2OS cells were transfected with the 
indicated siRNAs. 48 h after siRNA transfection, cells were either mock-treated (-) or treated 
with PUVA, released for 2 and 4 h and harvested for immunoblot analysis. (C-E) U2OS cells 
were transfected with indicated siRNAs. 48 h after siRNA transfection, cells grown on 
coverslips were treated for 24 h with MMC (120 ng/ml), pre-extracted, fixed and either co-
immunostained for RPA2 and RPA2-pS4/S8 (C), γH2AX and BrdU (D), or immunostained 
for RIF1 (E). Scale bar, 10 µm. (F) U2OS cells transfected with CtIP siRNA, were co-
transfected with siRNA-resistant GFP-tagged CtIP wild-type (wt), T847A or S327A mutant 
CtIP 24 h post-siRNA transfection. 48 h post-siRNA transfection, cells were analyzed by 
immunoblotting prior to MMC treatment. (G) HEK293T cells were transfected with the 
indicated pEGFP-C1 expression vectors. After 48 h, cells were lysed in NP-40 buffer and 
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whole cell extracts (4 mg) were analyzed by immunoblotting before (Input) and after 
immunoprecipitation (IP) using anti-GFP antibody. Ponceau staining is shown to indicate the 
amounts of immunoglobulins (IgG) used in the IPs. (H) U2OS cells stably expressing empty 
vector (e.v.) or siRNA-resistant GFP-tagged wild-type CtIP (wt), T847A, or S327A mutant 
CtIP were transfected with CtIP siRNA for 72 h and whole cell extracts were analyzed by 
western blotting. (I) Same cells as in (H) were either mock-treated or continuously treated 
with MMC and the survival was determined after 5 days using the CellTiter-Blue® Cell 
Viability assay. Data are presented as the mean ± SD (N≥3).  
 
Figure S3 (related to Figure 3). FANCD2-CtIP interaction requires FANCA but not 
SLX4 or FAN1. 
(A) HEK293T cells were co-transfected with GFP-FANCD2 together with either empty 
vector or FLAG-CtIP. 48 h after transfection, cells were lysed in NP40 buffer and whole cell 
extracts were analyzed by immunoblotting before (Input) and after immunoprecipitation (IP) 
using anti-FLAG M2 affinity resin. Ponceau staining is shown to indicate the amounts of 
immunoglobulins (IgG) used in the IPs. (B) Coomassie-stained gel of recombinant FLAG-
GST-CtIP-6His (0.5 µg) purified from Sf9 insect cells. (C) U2OS cells were transfected with 
indicated siRNAs. 48 h after siRNA transfection, cells were lysed and whole cell extracts 
were analyzed by immunoblotting. (D) Detection of endogenous CtIP-FANCD2 complexes 
by in situ PLA. Same cells as in (C) grown on coverslips were treated for 24 h with MMC 
(120 ng/ml) and pre-extracted prior to fixation. After incubation with antibodies against CtIP 
alone or against both CtIP and FANCD2, protein-protein interactions were detected using a 
fluorescently labeled probe (PLA-613). Scale bar, 20 µm. (E) Recombinant His-tagged 
ubiquitin (rHis-Ub) was immobilized on Ni-NTA agarose beads and incubated with whole 
cell extracts from HEK293T cells expressing GFP-SLX4 (left) or GFP-CtIP (right). Inputs 
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and precipitated bead fractions from the pull-downs were subjected to immunoblotting with 
anti-GFP antibody. Ponceau staining is shown to indicate the amounts of His-Ubiquitin used 
in the pull-down assays. (F) His alone (-) or recombinant wt and I44A mutant ubiquitin (rHis-
Ub) coupled to Ni-NTA agarose beads were incubated with HeLa nuclear extracts (NE). Input 
and precipitated bead fractions from the pull-downs were subjected to immunoblotting. 
Ponceau staining is shown to indicate the amounts of rHis-Ub used in the pull-down assay. 
 
Figure S4 (related to Figure 4). Identification and functional characterization of CtIP 
mutants impaired in FANCD2 interaction. 
(A) Multiple sequence alignment of the putative FANCD2-interacting region in CtIP 
orthologs (amino acids 160-298) was performed using Clustal W (www.ebi.ac.uk/Tools/msa). 
PDSP, RRK, RYxE and ILV motifs are highlighted in black boxes. Other, highly conserved 
amino acid residues are marked in bold typeface. R177Q and Y186C represent two cancer-
associated CtIP mutations recorded in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database (www.cancer.sanger.ac.uk). (B) U2OS cells were transfected with CtIP 
siRNA and after 24 h co-transfected with the indicated siRNA-resistant GFP-tagged CtIP 
constructs. 48 h post-siRNA transfection, cells grown on coverslips were treated for 24 h with 
MMC (120 ng/ml), fixed and immunostained for RIF1. Graphs show the percentage of GFP-
positive cells displaying more than 10 GFP-CtIP foci and the percentage of GFP-positive cells 
displaying more than 10 RIF1 foci, respectively. For each condition at least 100 cells were 
scored. Data are presented as the mean ± SEM (N=2). (C) Same cells as in (B) were analyzed 
by immunoblotting. (D) U2OS cells stably expressing siRNA-resistant GFP-CtIP-wt, GFP-
CtIP-RRK/AAA, or GFP-CtIP-RYIE/AAIA were transfected with CtIP siRNA and treated as 
in (D). 15 min after irradiation, cells were fixed, immunostained for γH2AX and analyzed by 
fluorescence microscopy. (E) U2OS cells stably expressing siRNA-resistant GFP-CtIP-wt 
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were transfected with indicated siRNAs. 24 h after siRNA transfection, cells grown on 
coverslips were sensitized with BrdU (10 µM) for 24 h prior to laser microirradiation. 30 min 
after irradiation, cells were fixed, co-immunostained for FANCD2 and γ-H2AX and analyzed 
by fluorescence microscopy. (F) Recombinant His-tagged ubiquitin (rHis-Ub) was 
immobilized on Ni-NTA agarose beads and incubated with whole cell extracts from 
HEK293T cells depleted of endogenous CtIP and expressing GFP-CtIP-wt or GFP-CtIP-ΔN 
(deleted of CtIP amino acids 153-322). Inputs and precipitated bead fractions from the pull-
downs were subjected to immunoblotting with anti-GFP antibody. Ponceau staining is shown 
to indicate the amounts of rHis-Ub used in the pull-down assays. (G) Anti-GFP 
immunoprecipitates from HEK293T cells transfected with GFP-CtIP-wt or GFP-CtIP-ΔN 
were subjected to far-western analysis using recombinant HA-Ubiquitin as a probe followed 
by anti-HA immunoblotting. Ponceau staining is shown to indicate the amounts of proteins 
transferred onto the nitrocellulose membrane. In (B, D and E) scale bar, 5 µm. 
 
Figure S5 (related to Figure 5). Analysis of CtIP/FANCD2 and CtIP/BRCA1 double-
deficient cells in response to MMC treatment. 
(A) FANCD2-deficient cells (PD20F) and PD20F stably expressing wild-type FANCD2 (D2) 
transfected with indicated siRNAs. 48 h post-siRNA transfection, cells were treated with the 
indicated doses of MMC for 24 h and survival was determined after eight days by colony 
formation. Data are presented as the mean ± SEM (N=3) (left). The same cells were analyzed 
by immunoblotting (right). (B) MRC5shCtIP cells were transfected with indicated siRNAs. 6 h 
post-siRNA transfection, cells were cultivated in the absence or presence of doxycycline 
(DOX, 1 µg/ml) for 48 h. Cells grown on coverslips were treated for 24 h with MMC (120 
ng/ml), pre-extracted, fixed and immunostained for RIF1. Scale bar, 10 µm. (C) 
Representative images of metaphase spreads from cells described in (B) after treatment with 
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MMC (20 ng/ml) for 20 h. Selected radial chromosomes are displayed in higher 
magnifications. (D) MRC5shCtIP cells were transfected with indicated siRNAs. 6 h post-siRNA 
transfection, cells were cultivated in the absence or presence of doxycycline (DOX, 1 µg/ml) 
for 48 h. Cells were continuously treated with the indicated doses of MMC and the survival 
was determined after 5 days using the CellTiter-Blue® Cell Viability assay. Data are 
presented as the mean ± SD (N=3) (left). The same cells were analyzed by immunoblotting 
(right). 
 
Figure S6. CtIP-mediated resection counteracts ICL-induced DNA damage in a 
FANCD2-dependent and -independent manner. 
Replication fork stalling at ICLs triggers activation of the ATR kinase resulting in 
monoubiquitination and stable association of the FANCD2-FANCI complex on chromatin. 
Monoubiquitinated FANCD2 recruits FAN1 and SLX4-associated nucleases to coordinate 
ICL incision giving rise to DSB intermediates. Translesion synthesis (TLS) polymerases 
bypass the unhooked crosslink and nucleotide excision repair (NER) removes the remaining 
adducts. Monoubiquitinated FANCD2 interacts with CtIP, thereby tethering it to damaged 
chromatin to ensure proper coordination of ICL processing and DNA-end resection. Once the 
DSB is formed, CtIP is phosphorylated by ATM kinase and promotes resection, thus initiating 
homologous recombination (HR), and, concomitantly antagonizing non-homologous end 
joining (NHEJ). In the absence of FANCD2, or in case of impaired activation of the FA-
pathway, persistent ICLs trigger the conversion of stalled replication forks into DSBs, a 
process that is at least partially dependent on the endonucleolytic activity of MUS81. Also in 
this case, CtIP-dependent resection commits cells to error-free repair of DSBs, thus 
preserving genome stability in response to ICL damage. 
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3.2. Functional)characterization)of)human)RAD50S)mutants)in)the)
DNA)damage)response)
 
Establishing)human)cell)lines)stably)expressing)RAD50'transgenes))
 
A specific class of separation-of-function RAD50 point mutations, called rad50S, that led 
to the defects in meiosis, was first isolated in budding yeast and later described in fission 
yeast and mice [90,98,101,309]. However, the mechanisms underlying RAD50S 
phenotypes are still unknown. In order to investigate the functions of human RAD50S, we 
introduced the K22M mutation, corresponding to the rad50-R20M 'S' allele in S. 
cerevisiae, into a retroviral plasmid encoding wild-type (wt) RAD50 cDNA [90]. The 
retroviral constructs containing RAD50-wt and RAD50-K22M cDNA were then used to 
complement an immortalized RAD50-deficient fibroblast cell line (F239). The F239 cell 
line was derived from a patient carrying hypomorphic mutations in both the maternal and 
the paternal RAD50 alleles resulting in low levels of unstable RAD50 protein [47]. At 
first, we verified the expression levels of the individual MRN subunits in the stable cell 
lines. As expected, analysis of patient-derived F239 cells revealed extremely low level of 
RAD50 that was detected as a weak band corresponding to a larger RAD50 variant by 
western blotting (Figure 10A, lane 1). Both RAD50-wt and RAD50-K22M-complemented 
F239 cells displayed similar expression levels of RAD50 as well as increased MRE11 
and NBS1 protein levels, indicating successful restoration of the MRN complex (Figure 
10A, lane 2 and 3). Furthermore, we observed a rescue of the impaired nuclear 
localization of MRE11 compared to the parental F239 cells (Figure 10B). 
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Figure 10. Analysis of RAD50, MRE11 and NBS1 expression levels in RAD50-wt- and -
K22M-complemented F239 cell lines. (A) RAD50-deficient cell line (F239) and F239 cells 
stably expressing RAD50-wt or -K22M mutant proteins were lysed and subjected to western blot 
analysis. (B) Same cells as in (A) were grown on coverslips, fixed and co-immunostained for 
RAD50 and MRE11. The asterisk indicates a larger RAD50 variant in patient-derived F239 cells. 
We also analyzed the potential impact of RAD50S mutation on the integrity of the MRN 
complex. Immunoprecipitation of MRE11 from F239 cells stably expressing either 
RAD50-wt or RAD50-K22M mutant demonstrated that the RAD50S mutation does not 
significantly alter the stoichiometry of the MRN complex (Figure 11).  
 
Figure 11. RAD50-K22M does not alter MRN complex formation. Normal human skin 
fibroblast cell line (HSF1), F239 and F239 cells expressing either RAD50-wt or -K22M mutant 
were lysed in RIPA buffer and whole cell extracts were subjected to immunoprecipitation using 
anti-MRE11 antibody. The asterisk indicates a larger RAD50 variant in patient-derived F239 cells 
detected in the anti-MRE11 immunoprecipitates. 
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DNA)damage)signaling)and)repair)in)cells)expressing)RAD504K22M''
 
In response to DSBs, MRN is required for the activation of ATM and downstream ATM-
dependent signaling events [77,79]. RAD50-deficient cells displayed defective 
recruitment of both MRE11 and NBS1 to sites of IR-induced DSBs, thus leading to 
impaired ATM activation, radiosensitivity and chromosomal instability [47]. Thus, we 
next investigated whether complementation of F239 cells with RAD50 would restore 
MRE11 nuclear foci formation and ATM activation after irradiation. Indeed, we observed 
IR-induced RAD50 and MRE11 foci both in cells expressing RAD50-wt and -K22M 
mutant (Figure 12A). Furthermore, stable expression of RAD50 in F239 cells restored 
ATM autophosphorylation at serine 1981, a marker for ATM activation, to a similar level 
as compared to RAD50-proficient skin fibroblasts [18] (Figure 12B). Taken together, 
these data indicate successful complementation of RAD50-deficient cells and suggest that 
RAD50S (K22M) is proficient in promoting IR-induced activation of ATM. 
 
Figure 12. RAD50-K22M does not abrogate IR-induced MRN foci and ATM activation. (A) 
Normal human skin fibroblasts (HSF1), RAD50-deficient cell line (F239) and F239 cell line 
complemented with either RAD50-wt or -K22M mutant transgenes were grown on coverslips, pre-
extracted before and 30 min after irradiation (5 Gy), fixed and co-immunostained for RAD50 and 
MRE11. (B) Same cells as in (A) were harvested for western blot analysis.  
RESULTS!!
! 84!
It was shown that mouse embryonic fibroblasts (MEFs) carrying Rad50S alleles display 
hypersensitivity to camptothecin (CPT) and etoposide (ETOP), inhibitors of 
topoisomerase I and II (Top I and Top II), respectively, indicative of defects in the repair 
of topoisomerase-mediated DNA damage [102]. To address the impact of RAD50S 
mutation on the processing of stabilized topoisomerase cleavage complexes in human 
cells, we analysed the sensitivity of complemented F239 cell lines to CPT and ETOP. 
Remarkably, while wild-type RAD50 restored the CPT and ETOP hypersensitivity of 
patient-derived F239 cells, RAD50-K22M cells exhibited increased sensitivity to both 
drugs (Figures 13A and 13B). Moreover, similar to Rad50S MEFs, human RAD50-
K22M cells were slightly more sensitive to CPT- than to ETOP-induced damage [102]. 
Importantly, cells complemented with RAD50-K22M were only mildly sensitive to 
bleomycin, a radiomimetic drug inducing DSBs that are free of protein-DNA adducts 
[310], indicating a specific defect in the repair of topoisomerase-associated DNA damage 
in RAD50S mutant cells (Figure 13C).  
We also noticed that proliferation of RAD50-deficient cells was strongly impaired 
compared to RAD50-proficient fibroblasts HSF1 (Figure 14). However, complementation 
with RAD50-wt or RAD50-K22M did not restore the reduced growth rate of F239 patient 
cells. Since RAD50 deficiency is associated with an increased spontaneous chromosomal 
instability [47], we speculated that mutations that have accumulated in cultured patient 
cells are most likely the cause of this slow growth phenotype which could not be rescued 
by re-expression of RAD50 protein. 
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Figure 13. RAD50-K22M mutation confers camptothecin and etoposide hypersensitivity but 
only mild sensitivity to bleomycin. RAD50-deficient F239 cells (F239) and F239 cells 
expressing RAD50-wt or -K22M mutant were either mock-treated or continuously treated with 
indicated doses of camptothecin (A), etoposide (B) or bleomycin (C). Sensitivity was determined 
5 days after treatment by CellTiter-Blue® Cell Viability assay. Data represent the mean ± SEM (N 
≥ 3).  
 
Figure 14. Growth curve of normal human skin fibroblasts (HSF1), F239 cells and F239 cells 
expressing either RAD50-wt or -K22M mutant. Cells were seeded in 6-well plates at a density 
of 3 × 104 cells per well and trypsinized every 48 h for cell number counting by a hemocytometer.  
To address the mechanism underlying CPT hypersensitivity of human RAD50S cells, we 
examined whether DSB signaling is altered in F239 cells expressing RAD50-K22M 
mutant by analyzing the phosphorylation status of prominent DDR factors after CPT 
treatment. Taking into account the reduced proliferation rate of F239 cells, we incubated 
them with CPT, which is an S-phase specific drug, for 24 hours in order to increase the 
amount of S-phase cells exposed to DNA damage. Interestingly, K22M cells exhibited 
diminished CHK1 phosphorylation at serine 345, implying impaired ATR activation 
(Figure 15). Collaborative action of the MRN complex and Ctp1, the fission yeast 
orthologue of human CtIP, was reported to be involved in the removal of covalently 
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bound Top I complexes that are stabilized by CPT [98]. Moreover, MRN in conjunction 
with CtIP was shown to be required for the initiation of DNA-end resection and 
subsequent HR repair events in human cells [118]. We therefore analyzed RPA2 
phosphorylation at serine 4 and serine 8, a marker for resection, in our cell lines and 
observed that resection was only partially restored in presence of the RAD50-K22M 
mutant (Figure 15). We also examined CtIP protein levels in complemented cell lines but 
did not detect any changes on western blots, thus excluding the possibility that impaired 
DNA-end resection in RAD50-K22M is related to reduced CtIP stability (Figure 15).  
To substantiate our findings regarding a potential DSB processing defect caused by 
RAD50S mutation, we monitored CPT-induced RPA and RAD51 foci formation in our 
cell lines. Although we could not detect any major changes in the localization of RPA2 at 
sites of DSBs, RAD51 foci formation was diminished in cells expressing RAD50-K22M 
compared to cells complemented with RAD50-wt, indicative of impaired DNA-end 
resection and HR (Figure 16). Collectively, our data suggest that human RAD50-K22M 
does not affect MRN-dependent signaling and repair in response to IR but elicits a 
separation-of-function phenotype, exhibiting defects in the repair of DSBs caused by 
DNA topoisomerase poisons. 
 
 
 
 
 
 
 
 
 
Figure 15. RAD50-K22M results in impaired 
ATR-mediated signaling in response to 
camptothecin. RAD50-deficient F239 cells and 
F239 cells complemented with RAD50-wt or -
K22M mutant were either mock-treated or 
treated with camptothecin (CPT, 100 nM) for 24 
h and then harvested for immunoblot analysis.  
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Figure 16. RAD51 foci formation is impaired in RAD50-K22M mutant cells. RAD50-deficient 
F239 cells and F239 cells complemented with RAD50-wt or -K22M mutant were grown on 
coverslips, treated with camptothecin (CPT, 100 nM) for 24 h, pre-extracted, fixed and co-
immunostained for γH2AX and RPA2 (A) or RAD51 (B). Graphs show the percentage of γH2AX-
foci positive cells displaying more than ten RPA2 (A) or RAD51 (B) foci. For each condition at 
least 100 cells were scored and data are presented as the mean ± SEM (N=2).  
 
Characterization)of)F239)cells)stably)expressing)RAD50/R83I,)a)second)'S')allele))
 
To determine whether impaired repair of topoisomerase-induced DNA damage is a 
general feature of cells expressing RAD50S mutants, we established an additional cell line 
stably expressing RAD50-R83I, corresponding to a second 'S' allele in S. cerevisiae, 
rad50-K81I [90]. Although RAD50-R83I expression was reduced compared to RAD50-
wt and K22M, increased stability of MRE11 confirmed successful restoration of the 
MRN complex in the R83I cell line (Figure 17A). Moreover, hypersensitivity to CPT of 
RAD50-R83I cells was comparable to that of K22M cells, indicating that defective 
processing of covalently bound Top I-DNA complexes is a general feature of cells 
expressing RAD50S alleles (Figure 17B). However, further experiments are needed to 
establish the pathological function of RAD50S in human cells. 
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Figure 17.  RAD50-R83I expression restores MRE11 levels but not camptothecin resistance. 
(A) RAD50-deficient F239 cells (F239) and F239 cells expressing RAD50-wt, -K22M or -R83I 
mutant were harvested for western blot analysis. (B) Same cells as in (A) were either mock-treated 
or continuously treated with indicated doses of camptothecin. Sensitivity was determined 5 days 
after treatment by CellTiter-Blue® Cell Viability assay. Data represent the mean ± SEM (N ≥ 3).  
 
Investigating)RAD50S)functions)at)the)molecular)level)
 
Based on the available structural and genetic data of RAD50, we speculated that RAD50S 
mutations may negatively affect the interaction between the MRN complex and CtIP, 
which would be consistent with a defect in DSB repair. We first examined the interaction 
between MRN and CtIP by co-immunoprecipitation experiments in the established cell 
lines. However, we could not detect CtIP in complex with MRN when we 
immunoprecipitated MRE11 from whole cell extracts (Figure 11). We thus used an 
alternative approach and addressed whether RAD50 directly interacts with CtIP in vitro. 
Furthermore, to test whether 'S' mutations may interfere with RAD50-CtIP association, 
we expressed GST-tagged RAD50 fragments (wt, K22M and R83I) containing the N-
terminal globular domain of RAD50 (1-172 aa) in bacteria and analyzed their ability to 
pull-down CtIP from HeLa nuclear extracts. Interestingly, we observed that the binding 
of CtIP to both RAD50S mutants was reduced compared to RAD50-wt, indicating that 
RAD50 may indeed physically interact with CtIP and that K22M and R83I mutations 
weaken the interaction (Figure 18). Structural analysis revealed that MR exists as a 
heterotetramer (M2R2) in vivo [52]. However, the absence of both RAD50 and MRE11 
in the pull-down samples suggests that the GST-RAD50 fragment does not interact with 
the MR complex and, thus, that CtIP binding is not mediated by the endogenous MRN 
complex. 
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Figure 18. RAD50S mutations impair 
RAD50-CtIP interaction. GST-fusions 
proteins were coupled to glutathione sepharose 
beads and incubated with HeLa nuclear extract 
(NE). The precipitates were thoroughly washed 
and analysed by western blotting using 
indicated antibodies. 
 
 
Impact)of)RAD50S)mutations)on)homology4directed)repair)
 
Besides analyzing cellular phenotypes of cells expressing RAD50S mutant alleles, we 
addressed the potential impact of RAD50S mutations on the efficiency of homology-
directed repair (HDR) using a HEK293-based GFP reporter assay [311]. The stably 
integrated DR-GFP reporter cassette consists of a full-length GFP gene (SceGFP) 
harboring a recognition site for the rare cutting endonuclease I-SceI and an internal GFP 
fragment (iGFP) (Figure 19A). Using the iGFP fragment as a template, repair of the I-
SceI-generated DSB by homologous recombination leads to the restoration of a functional 
GFP gene, thus resulting in GFP-positive cells that are counted by flow cytometry. To 
test the effect of RAD50S mutants on HDR, we generated FLAG-tagged RAD50-K22M 
and RAD50-R83I expression constructs by site-directed mutagenesis of the plasmid 
harboring RAD50-wt cDNA. We also made a double K22M/R83I mutant that so far has 
never been described in either yeast or mammalian systems. Expression of K22M and 
K22M/R83I mutants resulted in a significant increase in HDR compared to the RAD50-
wt protein, while expression of the R83I single mutant had no impact on the frequency of 
repair (Figure 19B). Given that I-SceI induces "clean" DSBs free of protein-DNA 
adducts, these data imply that RAD50S mutations do not impair processing of such DSBs 
and may even increase overall HDR efficiency. However, the experiments were 
performed in the presence of endogenous RAD50 protein that may attenuate the effect of 
RAD50S mutations on HDR. Therefore, alternative approaches such as the use of siRNA-
resistant RAD50 expression constructs in RAD50-depleted HEK293 DR-GFP cells or an 
integration of the DR-GFP substrate directly in the established F239 cell lines are 
required to verify the effect of RAD50S mutants on HDR.  
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Figure 19. Analysis of RAD50S mutants with respect to homology-directed repair. (A) 
Scheme of the DR-GFP reporter along with the homology-directed repair (HDR) product that 
results in GFP-positive cells. (B) HEK293 DR-GFP cells were co-transfected with the I-SceI 
expression plasmid together with indicated FLAG-RAD50 plasmids and harvested after 48 h for 
flow cytometry (left panel) and immunoblot analysis (right panel). Data is represented as mean ± 
SEM (N=3), p values were calculated using paired t-test: *p < 0.05, ns (not significant).  
 
Addressing) the) genetic) interaction) between) RAD50) and) CtIP) in)
Schizosaccharomyces)pombe)(in)collaboration)with)Dr.)Edgar)Hartsuiker)and)Dr.)
Rolf)Kraehenbuehl,)Bangor)University,)Wales,)UK))
 
Nbs1 was shown to directly bind to phosphorylated Ctp1, the fission yeast ortholog of 
human CtIP, via its FHA domain, thereby promoting the recruitment of Ctp1 to DSBs 
and HR [66,70]. Remarkably, overexpression of Ctp1 rescued the DNA damage 
sensitivity of nsb1-s10 and nbs1 (R27A) mutant strains harboring the functionally 
disruptive mutations in the FHA domain of Nbs1, but not of an nbs1 null mutant [66,72]. 
These data suggested that overexpression of Ctp1 can circumvent the repair defects of 
Nbs1 mutant impaired in Ctp1 binding. Based on these observations, we hypothesized 
that overexpression of Ctp1 might also suppress the DNA damage sensitivity of a rad50S 
mutant strain. Therefore, we established collaboration with Dr. Edgar Hartsuiker and Dr.!
Rolf Kraehenbuehl (Bangor University, Wales, UK), experts in studying the role of the 
MRN complex in S. pombe. As expected, rad50S (K81I) mutant was hypersensitive to 
CPT, though to a lesser extent than ctp1Δ, rad50Δ or ctp1Δ rad50Δ strains [98] (Figure 
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20). Ctp1 overexpression restored CPT-hypersensitivity of ctp1Δ strain confirming the 
functionality of the expressed construct. However, overexpression of Ctp1 neither 
suppressed CPT-hypersensitivity of rad50S nor of rad50Δ. Importantly, Ctp1 expression 
specifically hindered the growth of strains lacking the functional Rad50 already in 
absence of exogenous damage, thus precluding the analysis of genetic interaction 
between Rad50S and Ctp1 in response to CPT. It is plausible that highly overexpressed 
Ctp1 lacks proper regulation that might be, at least partially, MRN-dependent. To reduce 
the adverse effect of strong Ctp1 expression on the cell proliferation, Ctp1 could be 
driven by a weaker promoter or the analysis could be performed in ctp1Δ rad50S 
background to decrease the levels of Ctp1 since the growth of ctp1Δ rad50Δ strain was 
improved compared to rad50Δ upon Ctp1 overexpression. 
 
Figure 20. Analysis of RAD50S hypersensitivity to CPT upon Ctp1 overexpression in S. 
pombe. Indicated strains were transformed with a multicopy plasmid, pREP1, expressing Ctp1, or 
with an empty control plasmid. Replicates of serial dilutions of the indicated strains were spotted 
on control medium (left panel) or medium supplemented with 2.5 µM CPT (right panel) and 
grown at 30°C. 
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4. DISCUSSION)
4.1. FANCD2) and) CtIP) cooperate) to) repair) DNA) interstrand)
crosslinks)
Faithful repair of DNA interstrand crosslinks (ICLs) requires a complex cascade of 
signalling and repair events. Upon replication fork stalling in the vicinity of the ICL, 
ATR activation facilitates monoubiquitination of the FANCD2-FANCI (FANCD2-I) 
heterodimer by the FA core complex, a multi-subunit E3 ubiquitin ligase [12]. 
Monoubiquitinated FANCD2-I is targeted to damaged chromatin to coordinate 
subsequent ICL repair events, including incision of the crosslink and translesion synthesis 
[312]. Once a DSB intermediate is formed, FANCD2 is thought to regulate replication-
coupled HR through its association with downstream FA proteins such as 
BRCA2/FANCD1 and PALB2/FANCN [12]. One of the critical steps of HR is DNA-end 
resection, however, its role in the context of ICL repair has been poorly characterized. 
Therefore, in the first part of my thesis, we investigated the functional interplay between 
DNA-end resection and the FA pathway in ICL repair by focusing on CtIP, a key factor 
of the resection and HR machinery. 
We show that upon treatment of cells with ICL-inducing agents, monoubiquitinated 
FANCD2 tethers CtIP to damaged chromatin through a physical interaction with CtIP. 
This situation is reminiscent of the FAN1 nuclease, which is also recruited to ICL lesions 
by a direct interaction with monoubiquitinated FANCD2 [253,255,256]. However, in 
contrast to FAN1 implicated in ICL incision, our data strongly supports a key role for 
CtIP in the resection of DSBs generated during ICL repair. Indeed, we observed that ICL-
induced RPA2 hyperphosphorylation and BrdU focus formation, both markers for single-
stranded DNA regions, were reduced in CtIP-depleted cells. Furthermore, cells lacking 
FANCD2 displayed very similar phenotypes, indicating an unanticipated role for 
FANCD2 in promoting DNA-end resection. DSB intermediates are formed following the 
incision of the crosslink by SLX4-associated endonucleases and FAN1 [231]. 
Remarkably, depletion of SLX4 or FAN1 did not interfere with CtIP localization to 
damaged chromatin, suggesting that CtIP is recruited to ICLs before they get processed. 
However, as the precise mechanism of ICL incision has not yet been elucidated in detail 
and, potentially, there is a lot of redundancy between ICL processing enzymes, we cannot 
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completely exclude the possibility that CtIP is only recruited after DSB intermediates 
have been generated [237]. Of note, chronic MMC treatment that we applied has some 
limitations regarding the analysis of protein recruitment to ICL damage and is more 
conclusive with regards to the stable association or retention of proteins at the damage 
sites. One of the methods to address the sequential recruitment of the proteins to ICLs 
include generation of local damage by treatment of cells with psoralen followed by 
photoactivation with UVA laser (PUVA) and subsequent single cell analysis by 
immunofluorescence microscopy [313]. Alternatively, cells can be irradiated with UVA 
in the presence of psoralen and harvested at different time points for the analysis of 
protein recruitment to damaged chromatin [243]. We analyzed CtIP chromatin 
association in PUVA-treated cells and observed a time-dependent increase in levels of 
chromatin-bound CtIP. Furthermore, depletion of FANCD2 impaired CtIP localization to 
PUVA-induced lesions, thus confirming that FANCD2 anchors CtIP to the sites of ICL 
damage.  
FANCD2 monoubiquitination is commonly used as readout to define which FA proteins 
act upstream of FANCD2 and hence participate in damage signaling, or are downstream 
and therefore are more likely to directly contribute to ICL repair [314]. Though FANCD2 
monoubiquitination still efficiently occurred in cells lacking CtIP, we noticed slightly 
reduced levels of monoubiquitinated FANCD2 on damaged chromatin. CtIP has been 
recently implicated in the initiation of ICL repair at stalled forks prior to 
monoubiquitination of FANCD2 and ICL incision [308]. However, the effect of CtIP 
depletion on monoubiquitination of FANCD2 was only partial and not comparable to the 
reduction observed in absence of FA core complex or ATR kinase activity [247,250]. We 
thus suggest that CtIP is not required for FANCD2 monoubiquitination during ICL repair, 
but its lack leads to a negative feedback loop reducing FA pathway activation, which is 
similar to the effect observed in cells lacking XPF-ERCC1 complex [249]. 
FANCD2 as well as FA core proteins have been reported to directly regulate nucleases 
involved in ICL incision and TLS polymerases [231]. We therefore proposed that 
FANCD2 may tether CtIP to damaged chromatin to ensure that DNA-end resection and 
HR takes place at the right place and at the right time. Consistent with this idea, and 
together with the fact that DNA-end resection prevents NHEJ, the FA pathway has 
already been implicated in NHEJ inhibition [301,302,315]. For instance, FANCD2/I has 
been reported to possess nucleosome-assembly in vitro, which may sterically impede the 
access of the NHEJ machinery to DNA termini [315]. We observed that cells lacking 
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either CtIP or FANCD2 exhibited increased radial chromosome formation and RIF1 foci 
following MMC treatment, indicative of enhanced NHEJ activity. Remarkably, CtIP 
mutants impaired in FANCD2-binding also demonstrated elevated RIF1 foci, implicating 
a critical function of the CtIP-FANCD2 complex in resection and, thus, suppression of 
NHEJ. In analogy of the MRN-CtIP partnership involved in the processing of CPT-
induced DSBs, the FANCD2-CtIP complex may cooperate in ICL processing. 
Interestingly, few reports have indicated that both Sae2, the yeast homologue of CtIP, and 
FANCD2 possess intrinsic endo- and exonuclease activities, respectively [142,302].  
To restrict DNA-end resection to S/G2 phases, CtIP is 'activated' by CDK-mediated 
phosphorylation on several residues including S327 and T847 [120,131]. Remarkably, 
phosphorylation of CtIP on T847 appears to be a universal mechanism regulating CtIP 
function in resection, since ICL repair was impaired in CtIP-T847A mutant cells, 
displaying increased MMC-induced RIF1 foci and MMC hypersensitivity. On the other 
hand, phosphorylation of CtIP on S327, a prerequisite for CtIP-BRCA1 complex 
formation, turned out to be dispensable for the repair of ICLs. Consistent with our 
findings, isogenic mouse embryonic fibroblast cell lines expressing either Ctip-S326A 
mutant or Ctip wild-type displayed comparable levels of MMC hypersensitivity and 
chromosomal stability [132]. In contrast, however, it was shown that CtIP-BRCA1 
interaction is required to suppress IR-induced RIF1 foci and plays an important role in the 
repair of topoisomerase-mediated DNA damage, indicating that further investigations are 
needed to clarify the significance of the CtIP-BRCA1 complex in DNA repair 
[132,133,152].  
While CtIP acts with the MRN complex in the initial short-range resection of DSBs, 
subsequent long-range resection requires additional helicases and nucleases such as 
BLM, DNA2, or EXO1 [141,145]. FANCD2 was reported to interact with DNA2 and 
BLM, however the functional significance of these interactions has not been investigated 
[304,307]. To further define the role of FANCD2 in the regulation of DNA-end resection 
further, it would be important to address the relative contribution of these factors during 
ICL repair. The MRN complex is also required for the full activation of ATM kinase that 
in turn phosphorylates various target proteins including CtIP [73,74,78]. Remarkably, we 
noticed that CtIP is phosphorylated upon ICL-induced damage in an ATM-dependent 
manner. Interestingly, the efficient recruitment of CtIP to laser-induced DSBs was 
reported to require ATM kinase activity and a "damage recruitment (DR) motif" in the 
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middle part of CtIP [74] (see Figure 4). The authors proposed that ATM-dependent 
phosphorylation of CtIP unmasks the DR motif, which then mediates CtIP damage 
recruitment through its direct binding to the DSBs [74]. Based on our data, recruitment of 
CtIP to ICLs requires FANCD2, but still takes place upon ATM inhibition, implying that 
the DR motif of CtIP might play a minor role for its recruitment to crosslinks. 
Furthermore, the two short FANCD2-binding motifs that we identified within CtIP are 
located outside the DR region, indicating that DR motif is not sufficient for tethering CtIP 
to ICL-damaged chromatin. Emphasizing the potential differential regulation of CtIP 
following induction of ICLs compared to laser-induced DSBs, we show that FANCD2 is 
dispensable for CtIP localization at damage sites generated by laser micro-irradiation. 
Thus, the role of ATM-mediated phosphorylation of CtIP in the context of ICL repair still 
remains to be elucidated, but it may be required to facilitate resection function of CtIP 
after ICLs have been processed into DSBs similar to the classical HR pathway [73,74]. 
Notably, CtIP was also reported to undergo phosphorylation by ATR kinase in response 
to DSBs [134]. Given the major role of ATR-mediated signaling in processing of ICL-
induced damage, it will be worth investigating the impact of ATR-dependent 
phosphorylation on CtIP in ICL repair. 
Using a combined bioinformatics and experimental approach, we discovered two motifs 
in the N-terminus of CtIP (RRK (177-179 aa) and RYIE (185-188 aa)) required for 
FANCD2 binding, localization to MMC-induced foci and crosslink resistance. As these 
motifs reside in a highly conserved stretch of twelve amino acids, it is reasonable to think 
that they constitute a single interaction domain. However, the disruption of these motifs 
reduces CtIP-FANCD2 interaction without abolishing it, suggesting the involvement of 
additional regions in CtIP positioned outside the 177-188 aa stretch that can mediate the 
interaction. Interestingly, although CtIP and FANCD2 form a complex in unperturbed 
conditions, MMC treatment dramatically increase the interaction of CtIP with FANCD2 
(in situ PLA), indicating that FANCD2 monoubiquitination may facilitate complex 
formation. The latter is akin to the situation with the FAN1 nuclease which binds 
monoubiquitinated FANCD2 through its ubiquitin-binding zinc finger (UBZ) domain 
[253-256]. Although bioinformatics analysis failed to predict any motifs resembling 
known UBDs in CtIP, we observed that CtIP directly interacts with ubiquitin in vitro. 
Moreover, CtIP was still able to recognize a mutant form of ubiquitin (I44A) that impairs 
most of the known UBD-mediated interactions [282,316]. Due to the structural and 
functional diversity of already characterized UBDs and the continuously increasing 
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number of newly identified ubiquitin-binding motifs, it is plausible that CtIP recognize 
ubiquitin by a unique novel mechanism [317,318]. Remarkably, a CtIP mutant lacking 
both FANCD2-interacting motifs was still proficient in ubiquitin binding. We thus 
speculate that CtIP may employ a dual mode of recognizing monoubiquitinated 
FANCD2, mediated by the RRK-RYIE motifs and a 'cryptic' ubiquitin-binding domain. 
Consequently, FANCD2-CtIP interaction may be reinforced by the ability of CtIP to 
recognize ubiquitin. Similar mechanism has been described for the recognition of 
monoubiquitinated PCNA by TLS polymerases such as Pol η or Pol ι that bind modified 
PCNA via both PIP-box and UBDs to provide a more specific interaction [282,316]. 
Alternatively, CtIP may recognize ubiquitin-moiety of other ubiquitinated DDR proteins 
localized on chromatin, and hence enhance its chromatin association [319]. Clearly, 
further investigations are needed to determine the role of CtIP-ubiquitin interaction in the 
DDR. 
FANCD2 conformation is dynamic and can undergo changes upon DNA binding or 
monoubiquitination [320-322]. Thus, it is also reasonable to think that such structural 
changes in FANCD2 might expose the CtIP-binding surface on FANCD2 and thus 
stimulate CtIP-FANCD2 complex formation. According to our data, CtIP was still able to 
interact with a FANCD2-K561R mutant, albeit with lower efficiency compare to wild-
type FANCD2, implying that CtIP may bind to a region other than the stretch containing 
monoubiquitinated lysine on FANCD2. Interestingly, FANCD2 contains a conserved 
acidic EDGE motif in its C-terminus which may be involved in protein-protein 
interactions [323]. Similar to cells lacking CtIP, cells expressing an EDGE mutant of 
FANCD2 are proficient in FANCD2 monoubiquitination and foci formation, but are 
hypersensitive to MMC, suggesting that this region is involved in the repair process 
downstream and independent of FANCD2 monoubiquitination [323]. It would be 
interesting to test whether the observed phenotype is caused by the impaired interaction 
between CtIP and FANCD2-EDGE mutant. 
We noticed that CtIP mutants impaired in FANCD2-binding failed to form MMC-
induced foci, but were still recruited to DNA damage sites generated by laser 
microirradiation, implying that FANCD2 promotes CtIP localization only to a subset of 
DNA lesions. Very recently, it has been reported that FANCD2 is required for the 
recruitment of CtIP to stalled and collapsed replication forks as well as to IR-induced 
lesions [324]. These data suggest that CtIP is recruited to chromatin in a FANCD2-
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dependent manner both during DNA replication and DSB repair. However, given that the 
overall HR defect of cells lacking FANCD2 is milder that the one of CtIP-depleted cells, 
it is likely that FANCD2 specifically regulates CtIP-mediated DNA-end resection during 
HR repair of replication-associated DSBs, but plays a less significant role in the repair of 
other types of DSBs [118,247]. To address this question, it would be beneficial to analyze 
the recruitment of our CtIP mutants compromised in FANCD2-binding in response to 
different kinds of DNA damage and examine their ability to promote DNA-end resection 
and HR using reporter assays.  
CtIP has been shown to interact with two tumor suppressor proteins: retinoblastoma and 
BRCA1 [108-110]. FANCD2 is also a tumor suppressor and besides cancer susceptibility 
of FA patients caused by mutations in FANCD2, loss or decrease in FANCD2 protein 
levels is associated with the development of sporadic cancers in non-FA patients 
[229,325]. Thus, based on our data, FANCD2 is the third tumor suppressor protein 
interacting with CtIP. Remarkably, R177Q and Y186C are two cancer-associated 
missense mutations in human CtIP recorded in the COSMIC database that map exactly to 
the region responsible for FANCD2 interaction, suggesting that CtIP-FANCD2 complex 
formation may be directly implicated in tumor suppression. Generation of mice 
expressing mutant CtIP and monitoring them for tumor development may be a valuable 
approach to assess the role of the CtIP-FANCD2 interaction in tumor suppression.  
Interestingly, we repeatedly observed residual CtIP levels on chromatin in FANCD2-
depleted and PD20F FANCD2-deficient cells, implying that small amounts of CtIP bind 
to chromatin independently of FANCD2 and thus may promote DNA-end resection in 
absence of FANCD2. Indeed, depletion of CtIP in cells lacking FANCD2 aggravates the 
phenotypes such as MMC hypersensitivity and aberrant NHEJ activity of cells lacking 
either factor alone, indicating that CtIP supports genome integrity in a FA-deficient 
background. Consistent with our findings, there is increasing evidence for FA-pathway 
independent functions of proteins that are otherwise recruited to ICLs by FANCD2. 
Increased crosslink sensitivity has been shown for FAN1-deficient patient cells depleted 
of FANCD2, indicating that FAN1, despite its direct association with monoubiquitinated 
FANCD2, can participate in the processing of ICLs in the absence of the FA pathway 
[326]. Likewise, enhanced MMC and cisplatin sensitivity was reported for chicken DT40 
cells lacking both FA pathway and FAN1 or another FANCD2-interacting protein SLX4 
[257,327]. Alternatively, only partial epistasis of CtIP and FANCD2 can result from 
additional role of FANCD2 in protecting stalled forks from degradation or, conversely, 
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by the recently proposed role of CtIP in resection upstream of FANCD2 [251,308]. 
Similarly, we observed non-epistatic relationships between CtIP and BRCA1 in the repair 
of ICL damage. BRCA1 is a multifunctional DDR protein that participates in various 
cellular processes, including HR and checkpoint control [205]. Furthermore, BRCA1 was 
reported to function independently of HR in crosslink repair by promoting optimal 
FANCD2 accumulation at the sites of ICL-induced damage [303]. Thus, we conclude that 
enhanced MMC sensitivity of CtIP/BRCA1-double depleted is probably caused by non-
overlapping functions of two proteins in ICL repair, supporting the idea that CtIP-
mediated DNA-end resection is important to alleviate the toxic effects of ICL damage in 
the absence of proficient FA/BRCA signaling pathway.  
ICL-stalled replication forks frequently collapse into DSBs that can undergo resection 
and repair by HR or get misrepaired by NHEJ giving rise to chromosomal aberrations 
[234,265,328]. Accordingly, we observed that co-treatment of cells with MMC and a 
small molecule ATR inhibitor triggered increased formation of DSBs and enhanced 
ATM-dependent phosphorylation of CtIP and RPA2, indicative of elevated DNA-end 
resection [329]. Consequently, depletion of MUS81, an endonuclease implicated in the 
cleavage of stalled forks and DSB formation, significantly reduced CtIP phosphorylation, 
further supporting the role of CtIP in the resection of aberrant replication-associated 
DSBs [262,265]. Notably, it has been shown that HU-stalled forks collapse into DSBs 
upon ATR inhibition via SLX4-dependent endonuclease cleavage [330]. Given that 
SLX4 is a scaffold protein for several endonucleases such as XPF, MUS81 and SLX1, it 
would be interesting to test whether SLX4 depletion gives a stronger defect than 
depletion of MUS81 alone in cleavage of ICL-stalled forks in ATR-inhibited cells, and 
whether it further reduces CtIP phosphorylation. Remarkably, and in line with our data, 
CtIP-dependent processing of collapsed forks upon HU treatment was demonstrated to be 
beneficial for genome integrity and cellular survival in the absence of the FANCM 
translocase [331].  
In summary, our findings highlight the complex interplay between CtIP-mediated DNA-
end resection and the FA pathway and demonstrate that monoubiquitinated FANCD2 
coordinates CtIP-dependent resection during ICL repair. Furthermore, they reveal the 
crucial role of CtIP in preserving genome integrity in response to ICL damage. 
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4.2. Characterization) of) human) RAD50S) mutants) in) the) DNA)
damage)response)
In the second part of my thesis, we investigated molecular aspects of DNA-end resection 
in human cells by examining the phenotypes of separation-of-function (S) mutations in 
RAD50, a subunit of the MRN complex. Several studies highlighted the critical role of 
the MRN complex both in the removal of covalently attached proteins from DNA termini 
and in promoting DNA-end resection [41]. The most detailed evidence for the function of 
the MRN complex in this process came from analysis of meiosis in yeast [332]. The 
MRX complex is required for the clearance of meiosis-specific topoisomerase-like 
transferase Spo11 that remains covalently attached to 5'-ends after induction of the break 
[61,87]. Certain Rad50 mutations that blocked Spo11 cleavage, but did not show any 
strong mitotic repair defects, were isolated more than 20 years ago and named "S" 
mutations for the separation of meiotic and mitotic functions [90]. The existence of such 
"S" mutations indicated the requirement of some specific functions of the MRN complex 
in meiosis. However, these mutations were not extensively characterized in budding 
yeast. Instead RAD50S mutations were modelled and analysed in fission yeast and 
mouse, but the molecular mechanisms underlying RAD50S phenotypes are still unclear 
[100]. Here, we provide the first phenotypic characterization of RAD50S mutations in 
human cells. Most of our analysis has been performed for human RAD50-K22M 
mutation since it is the only "S" mutation examined in mice [101]. Similar to the RAD50S 
alleles in S. pombe and mice, human RAD50S alleles caused cellular hypersensitivity to 
topoisomerase I and II inhibitors, CPT and ETOP [98,101-103]. These inhibitors stabilize 
topoisomerase I and II cleavage complexes leading to blocked DNA ends [97]. 
Consequently, these complexes have to be released from DNA to allow further DNA-end 
processing and repair. We observed a slight reduction in phosphorylated form of RPA2 in 
RAD50-K22M cells in response to CPT indicative of a DNA-end resection defect. The 
impairment of resection can be caused by the delay in the initial removal of Top I 
cleavage complexes from DNA or in the progression of DNA-end resection per se. 
Analysis of Rad50S alleles in fission yeast suggested that they might be defective in both 
Top I and Top II removal [98,99]. It will be interesting to check whether human RAD50S 
mutations demonstrate a similar defect. One of the approaches to address this question is 
to use DNA-linked protein detection (DLPD) assay that analyzes the presence of 
topoisomerases covalently bound to the DNA [333]. If this is the case, then the molecular 
mechanism of the removal of covalently attached protein complexes from DNA impaired 
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by RAD50S appears to be universal between different organisms. Notably, our 
preliminary data demonstrate reduced RAD51 foci formation in RAD50-K22M cells 
upon CPT treatment, suggesting a defect in HR. It is plausible that due to faulty DNA-
end resection formation of RAD51 nucleoprotein filament is also compromised or 
delayed in these cells. Time course experiments will help to answer whether the 
appearance of CPT-induced RAD51 foci is delayed in RAD50S background.  
The RPA-coated ssDNA arising from 5’-3’ end resection of DSBs triggers activation of 
ATR-CHK1-mediated signaling, thus the MRN complex has been implicated in the ATR 
activation due to its role in resection [41]. We also noticed impaired CHK1 
phosphorylation on S345 in RAD50S cells, indicative of attenuated ATR activation. 
Since the decrease in CHK1 phosphorylation is more profound in RAD50-K22M mutant 
cells than in RAD50-deficient parental cell line, it is tempting to speculate that RAD50S 
might impair some specific functions of the MRN complex required for ATR activation. 
Recently, several groups reported a direct contribution of the MRN complex to ATR-
CHK1 activation via recruitment of TopBP1 in response to replication stress [334-336]. 
Further studies are required to establish if human RAD50S mutations indeed lead to a 
dominant negative phenotype in regards of ATR activation. Whereas there is no strong 
evidence for the impact of RAD50S mutations on ATR activation in other species, 
constitutive ATM-dependent signaling was reported for RAD50S alleles in mice and 
budding yeast [103,104]. However, we did not observe any significant changes in 
activation of ATM kinase as measured by autophosphorylation on S1981 in human 
RAD50-K22M cells. The unprocessed DNA damage accumulating in Rad50S 
background as evident from increased spontaneous chromosomal instability was 
proposed to be a trigger of chronic ATM activation and was further exacerbated by CPT 
treatment [101]. Thus, the analysis of chromosomal aberrations in human RAD50S cells 
in both unperturbed and CPT-treated cells can be useful to address the potential defects of 
RAD50S mutations in repair.  
The integrity of the MRN complex is essential for the proper DNA-end resection and 
DDR [88]. However, RAD50-K22M mutation did not significantly alter the stability of 
the MRN complex. Moreover, RAD50S cells were proficient in MRN foci formation and 
activation of ATM kinase in response to IR, further confirming the functionality of the 
MRN complex. Remarkably, RAD50S mutations did not show any defect in the repair of 
I-SceI-induced "clean" DSBs that are free of protein-DNA adducts as measured by the 
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DR-GFP reporter assay. In addition, RAD50-K22M cells were only mildly sensitivity to 
bleomycin that induces DSBs, which also do not contain any proteins trapped to DNA 
ends. Therefore, these data suggest that RAD50-K22M mutation does not impede the 
ability of the MRN complex to repair DSBs per se, but specifically impairs processing of 
toxic protein-DNA adducts, implying the separation-of-function phenotype of human 
RAD50S mutation. In line with our observations, RAD50S alleles in fission yeast and 
mice did not show any profound sensitivity to the DSB-inducing agents except of Top I 
and Top II poisons [98,101-103].  
It is still unclear why RAD50S mutant cells are predominantly hypersensitive to DNA 
topoisomerase poisons. Intriguingly, cells lacking CtIP, a partner of the MRN complex 
required for DNA-end resection, also demonstrate hypersensitivity to CPT and ETOP, but 
only mild sensitivity to IR [118,120]. Given that RAD50S mutations cluster on a surface 
patch predicted to form a conserved protein-protein interaction site and that cells lacking 
CtIP are phenotypically similar to cells expressing RAD50S mutant allele, we 
hypothesized that the MRN-CtIP interaction might be impaired by RAD50S mutations 
[52,118]. CtIP has been already reported to interact with individual subunits of the MRN 
complex [118,127]. However, we could not co-immunoprecipitate CtIP together with the 
MRE11 from whole cell lysates, probably due to the low abundance of CtIP protein. 
Indeed, when we used HeLa nuclear extracts that are enriched for nuclear proteins, we 
succeeded in detection of CtIP interaction with recombinantly expressed N-terminal part 
of RAD50. Remarkably, the presence of either RAD50S mutations, K22M or R83I, 
reduced this interaction. Though the interaction between CtIP and RAD50 was expected, 
the binding region on RAD50 has not been mapped so far [127]. We provide evidence 
that CtIP can interact with N-terminus of RAD50 and that RAD50S mutations impair 
CtIP-RAD50 association. Nevertheless, it still remains to be tested whether additional 
regions on RAD50 can mediate its binding to CtIP.  
The collaborative action of the MRN complex and CtIP is required for DNA-end 
resection in different eukaryotes, however the molecular basis of DNA-end resection 
seems to be slightly distinct [141]. In budding yeast, resection is carried out by the MRX 
complex together with Sae2, which possesses intrinsic endonuclease activity [142]. 
However, no similar activity has been yet reported for any Sae2/CtIP orthologues from 
different species. On the other hand, Sae2 does not physically interact with the MRX 
complex, whereas human CtIP directly associates with MRN and stimulates its 
endonuclease activity [118,143]. Endonuclease activity of the MRN-CtIP (i.e. MRX-Sae2 
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in S. cerevisiae) complex is particularly important for the repair of the DSBs blocked by a 
protein adduct. In this case, endonuclease activity is required to create nicks in DNA 
flanking the DSB ends that allows subsequent resection by exonucleases [62]. Given that 
impairment of MRN-CtIP association by RAD50S mutations may interfere with the 
endonuclease activity of the complex, it is likely to impede the processing of toxic 
protein-DNA adducts. However, further biochemical analysis of RAD50S mutations is 
required to substantiate this hypothesis.  
Fission yeast Ctp1 is more similar to CtIP than Sae2 in terms of its function in DNA-end 
resection [71,98]. Although biochemical data of Ctp1 interaction with RAD50 in S. 
pombe is missing, Ctp1 was shown to directly bind to Nbs1 in a 
phosphorylation‐dependent manner [66,70]. Based on our preliminary in vitro data 
showing that RAD50S weakens CtIP binding, it is possible that a comparable interaction 
defect can be observed for Rad50S mutations in fission yeast. Besides pull-down 
experiments, a valuable approach to address the interaction between two proteins is to 
analyze the suppression of repair defects of the mutant protein by overexpression of its 
interaction partner [66,72]. However, we did not observe a rescue of CPT sensitivity in 
rad50S mutant strains by Ctp1 overexpression. Moreover, Ctp1 overexpression in fission 
yeast turned out to be detrimental for cell viability. Therefore, additional analysis is 
needed to address the interaction between CtIP/Ctp1 and RAD50 as well as the effect of 
RAD50S mutations on the CtIP-RAD50 complex formation. Importantly, retention of 
proteins at DSBs can influence subsequent repair steps [62,137]. Since the MRN complex 
and CtIP most likely act together on damaged chromatin, it will also be informative to 
explore the chromatin association of these factor in RAD50 wild-type and RAD50S 
background both in unperturbed and damaged cells. 
Collectively, our data indicate that RAD50S mutations in human cells cause a defect in 
the repair of DSBs induced by DNA topoisomerase poisons and suggest that the 
underlying molecular mechanisms is associated with impaired interaction between 
RAD50 and CtIP.  
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5. CONCLUSIONS)AND)PROSPECTIVES)
DNA repair mechanisms are essential for any organism to maintain the genome integrity 
and guarantee survival. DNA-end resection represents a major restriction point during 
DSB repair because it irreversibly commits cells to HR and counteracts NHEJ, thereby 
controlling the balance between the two pathways. Inappropriate repair of DSBs is a 
major source of gross chromosomal aberrations that can trigger carcinogenesis. 
Therefore, a detailed mechanistic understanding of how DNA-end resection is executed 
and how it is interconnected with other DNA repair mechanisms is of unquestioned 
relevance for cancer biology. Although a substantial progress has been made in the last 
decades in identifying new players of DNA-end resection, the functional significance of 
their genetic and biochemical interactions is still largely elusive.  
The main focus of this thesis was on the human CtIP protein, an evolutionarily conserved 
DNA-end resection factor. We establish that CtIP is essential for the faithful repair of 
ICLs and that its DNA-end resection function is orchestrated by FANCD2, which tethers 
CtIP to damaged chromatin. Remarkably, this coordination is mainly achieved by a direct 
physical interaction between CtIP and FANCD2. Thus, our study is the first to 
demonstrate a critical role of a CtIP-FANCD2 complex during ICL repair. Given that 
FANCD2-deficient cells are impaired not only in ICL repair but also in HR, further 
analysis has to reveal whether the coordination of CtIP functions by FANCD2 represents 
a more general regulatory mechanism for DNA-end resection. We also provide evidence 
that CtIP binds to ubiquitin, indicating that CtIP may specifically interact with 
ubiquitinated substrates. However, based on our data, CtIP seems to employ a rather 
unique mode of ubiquitin recognition that does not involve any of the known ubiquitin-
binding domains. Given the importance of ubiquitination in various DNA damage 
signaling and repair pathways, further work to establish the mechanism and the role of 
CtIP-ubiquitin interaction appears to be rewarding.  
To date, 16 Fanconi Anemia (FA) complementation groups have been identified, but the 
molecular basis in some FA individuals is still unresolved. We find that depletion of CtIP 
leads to increased sensitivity to ICL-inducing agents and elevated chromosomal 
rearrangements, two key hallmarks of FA cells. However, no mutations in CtIP have so 
far been reported in unclassified FA patients and it still remains to be elucidated whether 
CtIP is a FA gene.  
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New insights into the functional interplay between FA and HR repair pathways are also 
of considerable medical relevance. Epigenetic silencing and somatic mutations with 
subsequent loss of heterozygosity of FA genes in non-FA patients are reported to be one 
of the frequent triggers of tumorigenesis [229,337]. Referring to the concept of synthetic 
lethality, inactivation of compensatory pathways such as intact cell cycle checkpoints and 
HR was shown to be particularly deleterious for these cells, and hence may significantly 
broaden the therapeutic strategies to selectively target FA-deficient tumors [338-340]. We 
observe that CtIP depletion enhances the cytotoxicity of MMC in FA-pathway deficient 
cells. Thus, one could foresee that targeted inhibition of CtIP function or possibly its 
interaction with FANCD2 might potentiate chemotherapy that is based on ICL-inducing 
agents. However, due to the current lack of structural and biochemical data of CtIP, the 
generation of potent small molecule inhibitors will take some time. Thorough 
investigation of the DNA-end resection machinery, its interactome and regulation are 
areas of future interest that will extend our understanding of the DNA damage response 
mechanisms and their clinical applications. 
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6. MATERIALS)AND)METHODS)
 
FANCD2)and)CtIP)cooperate)to)repair)DNA)interstrand)crosslinks*
Please find Materials and Methods in the manuscript (section 3.1.). 
 
Functional) characterization)of)human)RAD50S)mutants) in) the)DNA)
damage)response*
Cell)lines)and)tissue)culture)
RAD50-deficient (F239) cells immortalized with human telomerase reverse transcriptase 
(hTERT) were grown in DMEM supplemented with 15% fetal calf serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin as described previously [47]. F239 cells expressing 
RAD50 transgenes were maintained in the above medium supplemented with 500 µg/ml 
of Geneticin (G418, GIBCO). The amphotropic Phoenix packaging cells, DR-GFP 
HEK293 cells and hTERT-immortalized human skin fibroblasts (HSF1) were grown in 
DMEM medium, 10% fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin. 
All cells were maintained at 37°C with 6% CO2. 
 
Plasmids*
The pCLNXS retroviral expression vector containing full-length, wild-type human 
RAD50 cDNA was kindly provided by Yaniv Lerenthal (Tel Aviv University, Israel) and 
described previously [47]. The pcDNA3.1-based expression vector harboring FLAG-
tagged RAD50 cDNA was a kind gift from Martin F. Lavin (University of Queensland, 
Australia) [341]. The pGEX-4T1-RAD50 plasmid containing N-terminal domain of 
RAD50 (1-172 amino acids) was constructed by cloning polymerase chain reaction 
(PCR) product into pGEX-4T1 vector (Amersham) using EcoRI and XhoI restriction 
enzymes (New England Biolabs). RAD50S mutations were introduced by site-directed 
mutagenesis using Expand Long Template PCR System (Roche) and the following 
primers: RAD50-K22M forward 5'-
GACAAAGATATGCAAATTATCACTTTCTTCAGC-3', RAD50-K22M reverse 5'-
GTGATAATTTGCATATCTTTGTCCTCTATTCCA-3'; RAD50-R83I forward 5'-
AGCCCAGATTATTCTGCAATTTCGTGATGTCAAT-3', RAD50-R83I reverse 5'-
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CGAAATTGCAGAATAATCTGGGCTCTCACATCTGT-3'. All constructs were 
verified by DNA sequencing. 
 
Retroviral)production)*
Retroviruses encoding RAD50 transgenes were generated in amphotropic Phoenix 
packaging cell line as described previously [342]. Briefly, Phoenix cells plated in 100 
mm tissue culture dishes and grown for 24 h were transfected with 10 µg of retroviral 
pCLNXS plasmids bearing RAD50 transgenes using standard calcium phosphate method. 
10 h later medium was replaced. Virus-containing supernatant was collected 48 h post-
transfection and filtered through a sterile 0.45 µm low protein-binding filter (Millex-HV 
0.45 µm PVDF, Millipore). The filtrated viral supernatant was immediately used for 
infection or aliquoted into 1.5 ml cryovials and stored at -80°C.  
*
Generation)of)stable)F239)cell)lines)expressing)RAD50)transgenes)
The parental RAD50-deficient F239 fibroblasts were transduced with viral supernatant 
that harbored pCLNXS vectors containing RAD50 transgenes. Polybrene was added to a 
final concentration of 8 µg/ml and cells were incubated at 37°C. 24 h later medium was 
replaced. 48 h after transduction F239 cells were split and grown in selection medium 
containing 500 µg/ml of Geneticin (G418, GIBCO). Antibiotic-resistant bulk cell lines 
were established within 6 weeks. The expression levels of RAD50 transgenes were 
analyzed by immunobloting. 
 
Immunofluorescence)microscopy)
F239 parental cells and F239 cells expressing RAD50 transgenes grown on coverslips 
were either fixed directly in formaldehyde and permeabilized or pre-extracted to remove 
non-chromatin bound proteins for 5 min on ice before fixation in 4% formaldehyde (w/v) 
in PBS for 12 min as described previously [118]. After washing with PBS, coverslips 
were blocked in PBS with 3% fetal calf serum for 1 h. Following incubation with 
indicated primary and appropriate Alexa Fluor-488 and -594 conjugated secondary 
antibodies (1:1'000), coverslips were mounted with Vectrashield® (Vector Laboratories) 
containing DAPI and sealed. Images were acquired on a Leica DMRB fluorescence 
microscope. 
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Immunoblotting)and)Immunoprecipitation*
If not specified otherwise, cell extracts were prepared in Laemmli buffer (4% SDS, 20% 
glycerol, 120 mM Tris-HCl pH 6.8). Proteins were resolved by SDS–PAGE and 
transferred to nitrocellulose (GE Healthcare). Immunoblots were performed by using the 
appropriate primary and secondary antibodies. Proteins were visualized using the ECL 
detection system (Amersham). 
For immunoprecipitation assays, cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 
7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA and 0.1% SDS) 
supplemented with phosphatase inhibitors (20 mM NaF, 1 mM sodium orthovanadate) 
and protease inhibitors (1 mM benzamidine and 0.1 mM PMSF). Extracts were clarified 
by centrifugation at 14'000 rpm. Immunoprecipitating anti-MRE11 antibodies were added 
to the supernatant and incubated at 4°C overnight (O/N). After additional 2 h incubation 
with Protein A Sepharose beads (GE Healthcare), precipitated immunocomplexes were 
washed four times in lysis buffer (containing 0.5% NP-40, without SDS), boiled in SDS 
sample buffer and loaded on an SDS-polyacrylamide gel. Proteins were analyzed by 
immunoblotting, as described above. 
 
GST)pull4down)assay))
GST-RAD50 fusion constructs were grown in BL21 (DE3) Escherichia coli (Invitrogen) 
and proteins were expressed by incubation at 16°C for 20 h after the addition of 100 mM 
IPTG (AppliChem). Proteins were purified from soluble extracts with glutathione 
Sepharose 4 fast flow beads (GE Healthcare). GST fusion proteins bound to glutathione 
beads were mixed with 1 mg of HeLa nuclear extract pretreated with 1 mM ATP at 30°C 
for 30 min and incubated for 2 h at 4°C in 1 ml of IP buffer (20 mM HEPES-KOH, pH 
7.5, 0.2 mM EDTA, 100 mM KCl, 0.5 mM PMSF, 0.5 mM DTT). Beads were then 
washed four times with NTEN150 buffer (0.05% NP-40, 0.1 mM EDTA, 20 mM Tris-
HCl, pH 7.4, 150 mM NaCl) and twice with TEN100 (20 mM Tris-HCl, pH 7.4, 0.1 mM 
EDTA and 100 mM NaCl). Samples were boiled in SDS sample buffer and analyzed by 
SDS-PAGE followed by immunoblotting.  
 
Antibodies*
The primary antibodies are indicated in Table 2. Secondary HRP-conjugated anti-mouse 
and anti-rabbit antibodies were form GE-Healthcare. Alexa Fluor-488 and -594-
conjugated secondary antibodies were from Invitrogen. 
MATERIALS!AND!METHODS!!
! 108!
 Table 2. Primary antibodies. 
Antibody target Species Supplier/Reference Application* 
ATM (2C1) mouse GTX70103 (GeneTex) IB 
pATM S1981 rabbit 2152-1 (Epitomics) IB 
CHK1 (G-4) mouse sc-8408 (Santa Cruz) IB 
pCHK1 S345 rabbit 2341(Cell Signaling) IB 
CtIP (D-4) mouse sc-271339 (Santa Cruz) IB 
FLAG mouse F3165 (Sigma) IB 
γH2AX (JBW301) mouse 05-636 (Millipore) IF 
γH2AX (20E3) rabbit 9718 (Cell Signaling) IF 
MRE11 (12D7) mouse GTX70212 (GeneTex) IB and IF 
MRE11 rabbit NB100-142 (Novus) IP 
NBS1 (1D7) mouse GTX70224 (GeneTex) IB 
RAD50 (13B3) mouse GTX70228 (GeneTex) IB and IF 
RAD51 (H-92) rabbit sc-8349 (Santa Cruz) IF 
RPA2 (Ab-3) mouse NA19L (Calbiochem) IB and IF 
pRPA S4/S8 rabbit A300-245A (Bethyl) IB 
β-Tubulin (D-10) mouse sc-5274 (Santa Cruz) IB 
TFIIH p89 (S-19) rabbit sc-293 (Santa Cruz) IB 
*IB: Immunoblot, IF: Immunofluorescence, IP: Immunoprecipitation 
 
Chemicals)
Camptothecin (CPT), etoposide (ETOP) and bleomycin were purchased from Sigma.  
 
Ionizing)radiation)
Exposure to ionizing radiation was carried out with a Faxitron X-ray machine (Faxitron 
X-ray). 
 
Proliferation)assay)
HSF1, F239 and F239 cells expressing RAD50 transgenes were seeded in duplicates at a 
density of 3 × 104 cells per well in 6-well plates and grown under standard conditions. 
Cells were trypsinized every 48 h for cell number counting by a hemocytometer under 
microscope during 12 days. 
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CellTiter4Blue®)Cell)Viability)assay)
F239 parental cells and F239 cells expressing RAD50 transgenes were seeded in 
triplicates at a density of 1'500 and 3’000 cells/well in 96 well plate. 24 h later cells were 
continuously treated with the indicated doses of camptothecin, etoposide or bleomycin 
and grown for 5 days at 37°C. CellTiter-Blue® reagent (Promega, 20 µl/well) was added 
on the last day, cells were incubated at 37°C for 4 h, and then ﬂuorescence was measured 
at 560/590 nm.  
)
Homology4directed)repair)(HDR))reporter)assay*
HDR repair efficiency was measured in DR-GFP HEK293 cell line as described 
previously [311]. In brief, cells were co-transfected with 0.6 µg of pcDNA3.1 vector or 
0.6 µg of I-SceI expression plasmid (pCBASce) together with 0.6 µg of indicated FLAG-
tagged RAD50 constructs using 2.4 µl of JetPrime (Polyplus). 4 h after I-SceI 
transfection, the media was replaced. 48 h later cells were analyzed for GFP expression 
by flow cytometry on a CyAn ADP 9 (Dako). 
 
Yeast)Strains)and)Techniques)
Standard procedures, media for propagation and genetic manipulations and S. pombe 
strains used for sensitivity assays were described previously [98,343]. Briefly, indicated 
strains transformed with a multicopy expression vector pREP1 either empty or carrying 
Ctp1+ were spotted as serial dilutions on control medium or medium containing 2.5 µM 
CPT and grown for 4 days at 30°C. 
 
Statistics*
Statistical analyses were carried out using unpaired, two-tailed t tests. p values expressed 
as *p < 0.05 were considered significant. ns indicates that the difference between the two 
groups is not significant. 
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SUMMARY
The regulation of DNA double-strand break (DSB)
repair by phosphorylation-dependent signaling
pathways is crucial for the maintenance of genome
stability; however, remarkably little is known about
the molecular mechanisms by which phosphoryla-
tion controls DSB repair. Here, we show that PIN1,
a phosphorylation-specific prolyl isomerase, inter-
acts with key DSB repair factors and affects the rela-
tive contributions of homologous recombination (HR)
and nonhomologous end-joining (NHEJ) to DSB
repair. We find that PIN1-deficient cells display
reduced NHEJ due to increased DNA end resection,
whereas resection and HR are compromised in
PIN1-overexpressing cells. Moreover, we identify
CtIP as a substrate of PIN1 and show that DSBs
become hyperresected in cells expressing a CtIP
mutant refractory to PIN1 recognition. Mechanisti-
cally, we provide evidence that PIN1 impinges on
CtIP stability by promoting its ubiquitylation and sub-
sequent proteasomal degradation. Collectively,
these data uncover PIN1-mediated isomerization as
a regulatory mechanism coordinating DSB repair.
INTRODUCTION
In response toDNAdouble-strand breaks (DSBs), cells initiate an
elaborate signaling cascade known as the DNA damage
response (DDR) to maintain genomic integrity (Jackson and Bar-
tek, 2009). The DDR coordinates cell-cycle checkpoints and
DNA repair or—if the damage cannot be repaired—triggers
specialized programs such as apoptosis and senescence (Ciccia
and Elledge, 2010). DSBs are the most cytotoxic lesions that are
induced by ionizing radiation (IR) and DNA topoisomerase II poi-
sons, such as etoposide (ETOP) and doxorubicin (Jackson and
Bartek, 2009). They also frequently arise during S phase when
replication forks encounter persistent single-strand breaks that
are caused by camptothecin (CPT), a DNA topoisomerase I poi-
son, or poly(ADP-ribose) polymerase (PARP) inhibitors (Pom-
mier, 2006; Rouleau et al., 2010). Although DSBs are suitable
substrates for both homologous recombination (HR) and nonho-
mologous end-joining (NHEJ), DSBs resulting from replication
fork collapse are preferentially repaired by HR, whereas those
induced by IR and ETOP are mostly addressed by NHEJ (Helle-
day, 2010; Shibata et al., 2011). It has been shown that NHEJ
largely contributes to genomic instability and cytotoxicity in
HR-defective cells treated with CPT or PARP inhibitors (Adachi
et al., 2004; Eid et al., 2010; Patel et al., 2011). In contrast, HR
is able to compensate to some degree for the repair of IR-in-
duced DSBs in NHEJ mutant cells during late S/G2 phase
(Beucher et al., 2009; Shibata et al., 2011).
HR is a rather slow,multistep repair process restricted to S/G2
phase when the intact sister chromatid is available to allow error-
free repair (Heyer et al., 2010). Briefly, HR requires 50 to 30 nucle-
olytic degradation of DSB ends to generate long stretches of sin-
gle-stranded DNA (ssDNA) - a mechanism generally described
as DNA end resection. In vertebrates, DNA end resection is initi-
ated by the collaborative action of the MRE11-RAD50-NBS1
(MRN) complex together with CtIP (Sartori et al., 2007). Subse-
quently, EXO1 and BLM are involved in long-range resection
exposing long 30 ssDNA tails that are immediately coated with
RPA (Gravel et al., 2008). Finally, BRCA2 promotes the exchange
of RPA with RAD51, allowing ssDNA-RAD51 nucleoprotein fila-
ments to carry out homology search and DNA strand invasion
(Heyer et al., 2010). In contrast, NHEJ occurs with faster kinetics
and functions throughout the cell cycle (Shibata et al., 2011).
Besides cell-cycle stage and DSB complexity, the division of la-
bor between the twoDSB repair pathways was shown to depend
on the chromatin state around the lesion (Goodarzi et al., 2010).
Mechanistically, however, DNA end resection is the key determi-
nant of DSB repair pathway choice, because it prevents repair
by NHEJ and commits cells to HR (Chapman et al., 2012).
Besides ATM-mediated phosphorylation of substrates at
S/T-Q motifs in response to DSBs, phosphorylation at S/T-P
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motifs is another major signaling mechanism in the regulation of
cell-cycle progression and various stress responses (Matsuoka
et al., 2007; Bennetzen et al., 2010). Enzymes responsible for
S/T-P phosphorylation belong to a large family of proline-
directed protein kinases, including cyclin-dependent kinases
(CDKs) and mitogen-activated protein kinases (MAPKs) (Uber-
sax and Ferrell, 2007). Strikingly, CDK activity is required for
DNA end resection and HR (Aylon et al., 2004; Ira et al., 2004;
Huertas et al., 2008). However, it is currently unclear how, mech-
anistically, phosphorylation affects DSB repair pathway choice.
Interestingly, a subset of proteins phosphorylated at S/T-P mo-
tifs exist in two different configurations, namely as cis and trans
isoforms. The intrinsically slow interconversion between these
two forms can be catalyzed by PIN1, which specifically binds
phosphorylated S/T-P motifs through its WW domain and cata-
lyzes cis/trans isomerization through its peptidylprolyl isomerase
(PPIase) domain (Yaffe et al., 1997). In this way, PIN1 acts as a
molecular switch to control the function of several proteins,
including cell-cycle regulators and transcription factors, but so
far has not been linked to DNA repair processes (Liou et al.,
2011).
Here, we report that PIN1 interacts with prominent DSB repair
factors including 53BP1, BRCA1-BARD1, and CtIP. Using
immortalized and cancer cell lines, we find that PIN1 overexpres-
sion attenuates HR, while PIN1 depletion reduces NHEJ as a
result of increased DNA end resection. We further demonstrate
that PIN1-mediated isomerization of CtIP requires CtIP phos-
phorylation at two conserved S/T-P motifs (S276 and T315)
and show that CDK2 activity is required for PIN1-CtIP interac-
tion. We report that cells expressing a phosphomutant form of
CtIP (CtIP-2A) deficient in PIN1 interaction exhibit hyperre-
section phenotypes similar to PIN1-deficient cells. Finally, we
provide evidence that PIN1 negatively regulates CtIP protein sta-
bility by promoting CtIP polyubiquitylation and subsequent pro-
teasomal degradation. Altogether, our findings uncover a key
role for the prolyl isomerase PIN1 in controlling CtIP-dependent
DNA end resection and, consequently, DSB repair.
RESULTS
PIN1 Isomerase Is Involved in the Regulation of DSB
Repair
The importance of S/T-P phosphorylation in the regulation of
DSB repair and the fact that PIN1 modulates the function of pro-
teins phosphorylated at S/T-P motifs through proline isomeriza-
tion prompted us to examine whether PIN1 interacts with DSB
repair proteins. To this end, we performed pull-down experi-
ments with recombinant GST-tagged PIN1, followed by mass
spectrometry (MS) analysis. Besides known PIN1 substrates
and many potentially novel PIN1 interaction partners, we identi-
fied several prominent DDR factors implicated in DSB repair,
including BRCA1, 53BP1, and CtIP (see Figure S1 and Table
S1 available online). Since all these factors were shown to be
involved in DSB repair pathway choice, we examined whether
PIN1 affects the repair of DSB by NHEJ or HR using cell lines
bearing EJ5-GFP or DR-GFP reporter cassettes, respectively
(Bennardo et al., 2008). Depletion of PIN1 decreased NHEJ fre-
quencies to levels similar to those achieved by depleting key
NHEJ factors such as XRCC4 and 53BP1 (Figure 1A) (Bunting
et al., 2010). Conversely, we observed a slight but statistically
significant increase in HR efficiency upon PIN1 depletion in
both HEK293 and U2OS DR-GFP cells, while CtIP depletion
resulted in a strong reduction in HR, as expected (Figure 1B
and Figure S2A) (Sartori et al., 2007; Bennardo et al., 2008).
Based on these observations, we speculated that high levels of
PIN1 could interfere with HR. Indeed, transient overexpression
of PIN1 caused a significant decrease in the HR reporter signal,
without affecting the cell-cycle distribution (Figure 1C and Fig-
ure S2B). Importantly, the negative effect of PIN1 on HR was
dependent on both substrate recognition and isomerization, as
overexpression of a phospho-binding mutant (W34A) or a cata-
lytic mutant (C113A) diminished HR to a lesser extent (1.4- and
2.0-fold, respectively) compared to wild-type (WT) (3.1-fold)
(Figure 1C).
Next, we examined whether DSB signaling is altered in U2OS
cells depleted for PIN1 by analyzing the phosphorylation status
of prominent DDR factors after ETOP treatment. Interestingly,
knockdown of PIN1 caused a marked increase in RPA2 hyper-
phosphorylation, indicative of increased ssDNA formation, but
did not alter cell-cycle distribution profiles (Figure 1D, Figures
S2C and S2D) (Sartori et al., 2007; Kousholt et al., 2012). More-
over, in agreement with increased rates of DNA end resection,
we found that PIN1-depleted cells were more resistant to CPT
than control-depleted cells, a phenotype which is reminiscent
of NHEJ-deficient cells (Figure S2E) (Adachi et al., 2004; Eid
et al., 2010; Shibata et al., 2011).
To further investigate whether loss of PIN1 indeed compro-
mises NHEJ, we used pulsed-field gel electrophoresis (PFGE)
to monitor the efficiency of Pin1 knockout mouse embryonic
fibroblasts (MEFs) in repairing ETOP-induced DSBs. Pin1!/!
MEFs displayed both increased RPA2 phosphorylation and
slower repair kinetics compared to PIN1-complemented cells,
indicative of a defect in NHEJ caused by increased DNA resec-
tion (Figure 1E and Figure S2F). Consistent with impaired DNA
end resection, we detected a clear reduction in IR-induced
phosphorylation of RPA2 at S4/S8 after transient overexpres-
sion of PIN1-wt compared to mock-transfected cells or to cells
overexpressing PIN1-W34A (Figure 1F and Figure S2G). Since
we have identified the DNA end resection factor CtIP in our
screen for PIN1 interactors (Figure S1), we addressed whether
CtIP could be responsible for the observed hyperresection
phenotype of PIN1-deficient cells. To this end, we depleted
PIN1, CtIP, or both factors together from U2OS cells and moni-
tored RPA foci formation in response to ETOP treatment as
readout for DSB resection (Figure 1G and Figure S2H). As
expected, approximately 25% of control-depleted cells
exhibited RPA foci, and their formation was strictly CtIP depen-
dent (Helleday, 2010; Shibata et al., 2011). Furthermore, and
consistent with increased RPA2 phosphorylation, depletion
of PIN1 led to an almost 2-fold increase in RPA-foci-positive
cells. Remarkably, this increase was entirely dependent on
CtIP, suggesting that PIN1 limits the resection activity of
CtIP. Similarly, codepletion of CtIP partially rescued the NHEJ
defect in PIN1-depleted HEK293 EJ5-GFP reporter cells,
further demonstrating that PIN1 promotes NHEJ by counteract-
ing CtIP-dependent DNA resection (Figure 1H). The fact that
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CtIP depletion did not fully restore NHEJ could be explained by
the possibility that, besides restricting the function of CtIP in
DNA end resection, PIN1 may facilitate NHEJ through alterna-
tive mechanisms. For instance, we have identified 53BP1 and
BRCA1 as putative PIN1 substrates (Figure S1), both playing
key roles in the regulation of DSB repair pathway choice (Bun-
ting et al., 2010).
PIN1 Interacts with CtIP Phosphorylated at Two S/T-P
Motifs
To confirm the result of our MS analysis, suggesting that PIN1
and CtIP form a complex, we subjected whole-cell extracts
from U2OS cells or from U2OS cells stably expressing GFP-
tagged CtIP to GST-PIN1 pull-down assays. We found that
both endogenous CtIP and GFP-CtIP interact with PIN1-wt but
not with the PIN1-W34A mutant, indicating that the interaction
is mediated by phosphorylation (Figure 2A). Consistently, treat-
ment of extracts with l-phosphatase prior to GST-PIN1 pull-
down completely abolished the interaction with CtIP (Figures
S3A and S3B). Next, we verified whether endogenous PIN1-
CtIP complexes exist in cells by performing proximity ligation as-
says (in situ PLA), an elegant method to detect protein-protein
interactions in situ (So¨derberg et al., 2006). As shown in Fig-
ure 2B, we detected robust PLA signals in most of the cells,
demonstrating interaction between PIN1 and CtIP. Moreover,
we repeatedly observed more PLA signals per nucleus in EdU-
positive cells than in EdU-negative cells, indicative of an
increased PIN1-CtIP interaction during S phase (Figure 2B and
Figure S3C).
Human CtIP contains in total 12 S/T-P motifs that could be
targeted by proline-directed kinases (Figure S3D). To identify
which of these motifs are recognized by PIN1, we tested the
binding of PIN1 to a panel of serine/threonine to alanine point
mutants of CtIP in a series of GST pull-down experiments
Figure 1. PIN1 Regulates DSB Repair
(A) HEK293 EJ5-GFP cells were transfected with the indicated siRNAs. Two days later, cells were transfected with the I-SceI expression plasmid and harvested
after 48 hr for flow cytometry and immunoblot analysis.
(B) HEK293 DR-GFP cells were transfected with the indicated siRNAs and further processed as in (A).
(C) HEK293 DR-GFP cells were cotransfected with the indicated HA-PIN1 variants together with the I-SceI plasmid and further processed as in (A).
(D) Control- or PIN1-depleted U2OS cells were treatedwith etoposide (ETOP, 20 mM) for 6 hr, andwhole-cell extracts were analyzed by immunoblotting. Asterisks
indicate hyperphosphorylated forms of CtIP and RPA2, respectively.
(E) Pin1!/! MEFs complemented with empty vector (EV, pLPC) or PIN1 were treated with ETOP (10 mM) for 2 hr and lysed at the indicated times after ETOP
removal. Whole-cell extracts were analyzed by immunoblotting, and the amount of broken DNA was assessed by PFGE followed by ethidium bromide (EtBr)
staining (see also Figure S2F for quantification of the PFGE signals).
(F) HEK293T cells were transfected with empty vector (EV, pcDNA3.1) or HA-PIN1-wt for 72 hr. Cells were irradiated (30 Gy) and whole-cell extracts were
prepared at indicated times and analyzed by immunoblotting. Asterisk indicates hyperphosphorylated form of RPA2.
(G) Forty-eight hours after transfection with the indicated siRNAs, U2OS cells grown on coverslips were treated with ETOP (5 mM) for 1 hr, fixed, and coim-
munostained for g-H2AX and RPA2 (see also Figure S2H). In each sample at least 50 cells were scored. Graph shows the percentage of cells exhibiting more than
10 RPA foci/nuclei. Immunoblot analysis of the same samples is shown below.
(H) Shown is NHEJ assay and immunoblot analysis after transfection with the indicated siRNAs as in (A). In (A), (B), (C), (G), and (H), data are represented as
mean ± SEM (nR 3). See also Figure S2.
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(Figures S3E–S3G). Our analysis revealed that PIN1-CtIP inter-
action is mainly mediated by T315 and is almost completely
abolished in cells expressing a CtIP-S276A/T315A double
mutant (CtIP-2A; Figure 2C). To corroborate these findings, we
performed anti-HA immunoprecipitation experiments in
HEK293T cells cotransfected with FLAG-CtIP and HA-PIN1
expression constructs. As expected, CtIP-wt did not interact
with PIN1-W34A but was efficiently coprecipitated with PIN1-
wt and PIN1-C113A (Figure S3H). Moreover, we were able to
confirm that mutating either S276 or T315 to nonphosphorylat-
able alanine reduced the binding to PIN1, while PIN1-CtIP inter-
action is almost completely abolished in the CtIP-2A mutant
(Figure 2D). In addition, far-western blot analysis indicated that
this interaction is direct and that CtIP-T315 is more crucial for
PIN1 binding than CtIP-S276 (Figure 2E and Figure S3I). Finally,
we addressed whether PIN1-CtIP interaction is influenced by
DNA damage and observed a slight increase in complex forma-
tion upon ETOP treatment, suggesting that CtIP phosphoryla-
tion at S276 and/or T315 may be induced upon DNA damage
(Figure 2F).
CtIP-T315 Phosphorylation Promotes PIN1-CtIP
Interaction
By examining the amino acid sequences surrounding S276 and
T315, we noticed that both residues are highly conserved in
mammals, suggesting that they are possibly targeted by pro-
line-directed kinases in vivo (Figure S4A). In order to address
whether T315 and S276 are indeed phosphorylated in vivo, we
raised individual phospho-specific antibodies. As a first line of
evidence, both phospho-antibodies recognized wt CtIP tran-
siently overexpressed in cells, but not the corresponding alanine
substitution mutants (Figure 3A). Second, we specifically
detected CtIP-T315 after immunoprecipitating endogenous
CtIP from HEK293T cells followed by immunoblotting with the
anti-pT315 antibody, whereas the signal completely disap-
peared upon pretreatment of the extracts with l-phosphatase
(Figure 3B).
We next investigated whether CtIP-T315 phosphorylation
increased after ETOP treatment but did not observe any signifi-
cant changes in pT315 levels, suggesting that the enhanced
binding of PIN1 to CtIP in presence of DNA damage (Figure 2F)
Figure 2. PIN1 Interacts with CtIP through Phosphorylated S/T-P Motifs
(A) GST-PIN1-wt or -W34A fusion proteins were immobilized on glutathione-Sepharose beads and incubated with whole-cell extracts from either U2OS cells
(lanes 1–3) or U2OS cells stably expressing GFP-CtIP (lanes 4–6). Inputs and precipitated bead fractions from the pull-downs were subjected to immunoblotting
with anti-CtIP antibodies.
(B) (Left) Detection of endogenous PIN1-CtIP complexes by in situ proximity ligation assay (PLA). U2OS cells were pulse labeled with 50-ethynyl-20-deoxyuridine
(EdU, 10 mM) for 15 min, fixed, and incubated with antibodies against PIN1 and CtIP prior to detection of protein-protein interactions using a fluorescently labeled
probe (PLA-613). Nuclei were visualized by DAPI staining, and EdU incorporation was detected according to the manufacturer’s instructions (see also Fig-
ure S3C). (Right) Quantification of the PLA signals/cell. For both conditions, PLA signals from at least 50 cells were enumerated. Scale bar, 5 mm.
(C) (Left) GST-PIN1 pull-down assay using extracts of HEK293T cells expressing indicated FLAG-tagged versions of CtIP. The band intensities were quantified
using ImageJ and represented as input/pull-down (I/P) ratios. (Right) Data are represented as mean values of densitometric quantification ± SEM (nR 5).
(D) HEK293T cells were cotransfected with HA-PIN1 and the indicated FLAG-CtIP plasmids. HA-PIN1 was immunoprecipitated from whole-cell extracts using
anti-HA antibody, and immunocomplexes were analyzed by western blotting.
(E) Anti-FLAG immunoprecipitates from empty vector- or FLAG-CtIP-transfected HEK293T cells were subjected to far-western blotting using purified GST-PIN1
as a probe, followed by immunodetection with anti-GST antibody. After stripping, the same membrane was reprobed using anti-FLAG antibody.
(F) HEK293T cells were cotransfected with GFP-CtIP (wt and 2A) and HA-PIN1 for 48 hr before treatment with ETOP (10 mM) for 2 hr. Whole-cell extracts were
analyzed by western blotting before (input) and after immunoprecipitation (IP) using anti-GFP antibody. See also Figure S3.
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is mediated more by CtIP-S276 phosphorylation (Figure S4B).
Finally, we were able to confirm the phosphorylation on T315
in vivo by MS analysis of CtIP immunoprecipitated from
HEK293T cells (Figure S4C). To further substantiate our previous
findings that pT315 is more crucial for PIN1 binding compared
to pS276 (Figures 2C and 2D), we used synthetic CtIP phospho-
peptides and examined their ability to compete for PIN1 binding
in GST-PIN1 pull-down experiments. Remarkably, we found that
increasing amounts of pT315 peptides completely abolished
PIN1-CtIP interaction, whereas pS276 peptides and the non-
phosphopeptides failed to do so, strongly suggesting that
CtIP-pT315 is the preferred PIN1 binding site (Figure 3C and
Figure S5A).
CtIP-S276 Phosphorylation Promotes CtIP
Isomerization by PIN1
To determine whether PIN1 catalyzes cis/trans isomerization of
the phosphorylated S/T-P motifs in CtIP, we applied nuclear
magnetic resonance (NMR) spectroscopy to monitor exchange
processes in the aforementioned CtIP phosphopeptides in the
presence of recombinant PIN1 proteins (Wang et al., 2010).
ROESY spectra of both phosphopeptides recorded in the
absence of PIN1 were devoid of any crosspeaks that are indica-
tive of an exchange process between the cis and trans species
(data not shown). Importantly, upon addition of PIN1, we
detected exchange crosspeaks in the spectrum of the CtIP-
pS276 peptide, which were absent in the presence of a catalyti-
cally inactive mutant of PIN1 (C113A) and in the nonphosphory-
lated peptide (Figure 3D and Figures S5B–S5E). However, we
could not detect any cis/trans isomerization signals in the CtIP-
pT315 peptide (Figure S5F). Based on previously published
data, we speculated that the presence of two consecutive proline
residues in this peptide (pT-P-P) may hinder PIN1 isomerization
(Lippens et al., 2007). Interestingly, we observed exchange
crosspeaks in the ROESY spectrum of a modified CtIP-pT315
peptide in which the second proline was replaced with leucine
(P317L; Figure S5G). In order to addresswhether PIN1 also isom-
erizes CtIP-pS276 in the setting of an intact CtIP protein, we per-
formed limited proteolysis experiments using FLAG-CtIP purified
from HEK293T cells (Stukenberg and Kirschner, 2001). In large
agreement with our NMR data, V8 protease cleavage pattern
of CtIP-S276A was clearly different compared to CtIP-wt and
CtIP-T315A, indicating that pS276-P277 rather than pT315-
P317 is isomerized in vivo (Figure 3E). Collectively, our findings
support a model in which CtIP-pT315 is the major PIN1 docking
site, whereas CtIP-pS276 serves as a PIN1 isomerization site.
CDK2 Activity Is Required for CtIP-T315
Phosphorylation
Next, we aimed at identifying the protein kinase(s) responsible
for CtIP phosphorylation at S276 and T315 and, thus, for CtIP
recognition by PIN1. Considering recent data showing that
CtIP is targeted by CDKs, we examined whether CDK activity
is required for CtIP-PIN1 interaction (Chapman et al., 2012).
Interestingly, we found that a short treatment of cells with Rosco-
vitine (a general CDK inhibitor), but not with RO-3306 (a selective
CDK1 inhibitor), strongly reduced the binding of PIN1 to CtIP
(Figure 4A and Figure S6A). Moreover, consistent with CtIP-
T315 being the major PIN1 interaction site, cells treated with
Roscovitine also displayed reduced phosphorylation of T315,
while phosphorylation of S276 was not affected by CDK inhibi-
tion (Figures 4B and 4C). To further substantiate the role of
CDKs in promoting CtIP-PIN1 interaction, we transiently
expressed dominant-negative (dn) forms of CDK1, CDK2, and
CDK4 in HEK293T cells and examined their effect on PIN1 bind-
ing to CtIP. As shown in Figure 4D, we observed the strongest
reduction in CtIP-PIN1 complex formation in the absence of
CDK2 activity, which did not affect cell-cycle distribution (Fig-
ure S6B). Furthermore, we found that overexpression of wt
CDK2 resulted in a considerable increase in CtIP-PIN1 interac-
tion (Figure S6C). Consistent with a role for CDK2 in the phos-
phorylation of T315, CtIP-pT315 levels steadily increased during
S phase, peaked at late S/G2 phase, and were lowest in G1
(Figure S6D). From this data, we conclude that CDK2, by phos-
phorylating CtIP at T315, is predominantly responsible for the
interaction between CtIP and PIN1.
CtIP-2A Phosphomutant Promotes Hyperresection of
DSBs
To investigate the potential functions of CtIP isomerization at the
cellular and molecular level, we generated stable U2OS cell
Figure 3. CtIP-T315 and CtIP-S276 Are Phosphorylated to Promote
PIN1 Binding and cis/trans Isomerization
(A) Extracts from HEK293T cells transfected for 48 hr with the indicated FLAG-
CtIP constructs were immunoblotted with either rabbit polyclonal antibodies
raised against CtIP phosphopeptides or with anti-FLAG antibody.
(B) Extracts from HEK293T cells were treated with l-PPase, immunoprecipi-
tated using anti-CtIP antibody, and immunoblotted with the indicated anti-
bodies.
(C) GST-PIN1 pull-down assays were performed using U2OS whole-cell
extracts (0.5 mg) supplemented with the indicated CtIP peptides (80 mg).
(D) Shown is selected region of the two-dimensional ROESY spectra of the
CtIP-pS276 peptide after incubation with purified, recombinant GST-PIN1.
(E) HEK293T cells were transfected with the indicated FLAG-CtIP constructs
for 72 hr. CtIP proteins were purified using M2 magnetic beads, eluted with
3xFLAG peptides, digested with V8 protease, and analyzed by western blot-
ting using anti-CtIP antibody. See also Figure S4 and Figure S5.
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clones that expressed siRNA-resistant GFP-tagged wt (GFP-
CtIP-wt) or mutant CtIP in which both S276 and T315 were
changed to nonphosphorylatable alanine (GFP-CtIP-2A) (Figures
5A and 5B). Importantly, the GFP-CtIP-2A mutant protein was
still able to interact with BRCA1 and MRE11 (Figure S7A) and
to localize to DSB-containing tracks generated by laser microir-
radiation (Figure 5C and Figure S7B). From this we concluded
that PIN1 is required neither for CtIP complex formation with
BRCA1 andMRN nor for CtIP recruitment to damaged chromatin
that occurs exclusively in S/G2 cells (Sartori et al., 2007; Chen
et al., 2008). Moreover, similar to PIN1 depletion, cells express-
ing CtIP-2A were slightly more CPT resistant than cells express-
ing CtIP-wt (Figure 5D and Figure S7C). However, the observed
increase in CPT resistance could be, at least in part, due to
higher expression levels of GFP-CtIP-2A compared to GFP-
CtIP-wt (Figure 5A and Figure S7C). Strikingly, like PIN1-
depleted cells, CtIP-2A mutant cells treated with ETOP
displayed both increased RPA2 hyperphosphorylation and
RPA foci formation, indicating higher rates of DSB resection (Fig-
ures 5E and 5F and Figure S7D). Since ETOP-induced DSBs are
usually repaired with fast kinetics by classical NHEJ, and DNA
end resection is known to counteract NHEJ, we speculated
that NHEJ is compromised in CtIP-2A mutant cells (Shibata
et al., 2011). To this end, we monitored the amount of broken
DNA after ETOP treatment in both cell lines in the presence
and absence of a DNA-PKcs inhibitor. Indeed, in both NHEJ-pro-
ficient and -deficient backgrounds, we found that CtIP-2A cells
exhibited more DSBs than did CtIP-wt cells (Figure 5G and Fig-
ure S7E). This suggested that the DSB repair defect in CtIP-2A
mutant cells is caused by hyperresection, thereby channeling
repair into HR, which operates at slower kinetics compared to
NHEJ. To further substantiate these findings, we measured the
frequencies of HR and NHEJ in HEK293 GFP-reporter cells after
transient transfection of CtIP-wt, CtIP-T847A, and CtIP-2A (Fig-
ures S7F–S7H). At first, overexpression of the CtIP-2A mutant
coincided with a decrease in NHEJ, reflecting the fact that end
resection precludes NHEJ usage. In contrast, however, CtIP-
2A-expressing cells were as efficient in HR as cells expressing
CtIP-wt, indicating that hyperresection may also negatively
affect HR by promoting mutagenic types of homology-directed
repair such as single-strand annealing (Bennardo et al., 2008).
In fact, it was recently reported that depletion of DNA2, which
promotes ‘‘long-range’’ resection, leads to increased HR using
the same reporter cells (Karanja et al., 2012). Accordingly, the
anticipated increase in HR due to hyperresection (e.g., in CtIP-
2A cells) could be potentially outweighed by the fact that long-
range resection hinders the restoration of a functional DR-GFP
reporter gene.
Finally, we addressed whether PIN1 restricts CtIP-dependent
DNA end resection particularly in late S/G2 phase when both HR
andNHEJ are operable butmost DSBs preferably undergoNHEJ
(Shibata et al., 2011; Karanam et al., 2012). To this end, we
exposed late S/G2 cells stably expressing either CtIP-wt or
CtIP-2A to IR and measured the extent of DSB resection by
monitoring the levels of hyperphosphorylated RPA2. Consistent
with our previous results, we noted a significant increase in phos-
phorylated RPA2 in CtIP-2Amutant cells, indicative of enhanced
resection (Figure 5H). Taken together, these results suggest that
CtIP isomerization serves as a key regulatory mechanism re-
stricting DSB resection in late S/G2 phase of the cell cycle.
PIN1 Controls CtIP Stability and Promotes Its
Ubiquitylation
Prolyl isomerization by PIN1 was shown to play a crucial role in
regulating the stability of many proteins (Liou et al., 2011). Inter-
estingly, in many of our PIN1 depletion experiments, we have
noticed increased CtIP protein levels (e.g., Figures 1B and 1D).
Moreover, we repeatedly observed a reduction in the amount
of CtIP after transient transfection of cells with PIN1-wt, but
not with PIN1 mutants, particularly in the presence of DSBs (Fig-
ures 1C and 1F and Figure 6A). Thus, we speculated that PIN1
might indeed promote CtIP degradation. To address this idea,
we treated cells expressing either CtIP-wt or CtIP-2A for 8 hr
with MG132. Interestingly, by blocking the ubiquitin-proteasome
pathway, we observed a more substantial increase in the levels
of CtIP-wt (4.7-fold) compared to those of CtIP-2A (1.7-fold),
indicating that PIN1 is at least partially responsible for CtIP
degradation under these conditions (Figure 6B). Next, we
exposed CtIP-wt- and CtIP-2A-expressing cells to ETOP and,
at different time points after the removal of the drug, analyzed
CtIP protein turnover by blocking de novo biosynthesis. Strik-
ingly, CtIP-wt levels rapidly dropped after the recovery from
ETOP, whereas CtIP-2A levels remained stable (Figure 6C and
Figure 4. CtIP-PIN1 Interaction and CtIP-T315 Phosphorylation
Require CDK2 Activity
(A) Extracts from U2OS cells treated for 2 hr with DMSO, R-Roscovitine
(25 mM), or RO-3306 (25 mM) were subjected to GST-PIN1 pull-down assays.
(B) HEK293T cells were treated for 2 hr with DMSO or ROSC, and extracts
were immunoblotted for CtIP before (input) and after immunoprecipitation (IP)
using the anti-CtIP-pT315 antibody.
(C) HEK293 cells expressing GFP-CtIP (wt and 2A) were treated for 3 hr
with either DMSO or ROSC (25 mM). After lysis, whole-cell extracts were
immunoblotted for GFP either directly (input) or after immunoprecipitation (IP)
with anti-pT315 or anti-pS276 antibodies.
(D) Extracts from HEK293T cells transfected with either pcDNA3.1 (!) or
plasmids expressing HA-tagged dominant-negative (dn) mutants of CDK1,
CDK2, and CDK4 for 48 hr were subjected to GST-PIN1 pull-down assays. The
ratios of input versus pull-down (I/P; in A and D) and input versus IP (I/IP; in B
and C) were quantified by densitometry using ImageJ. See also Figure S6.
Molecular Cell
PIN1 Isomerase Regulates DSB Repair
338 Molecular Cell 50, 333–343, May 9, 2013 ª2013 Elsevier Inc.
Figure S8), further supporting the role of PIN1 in negatively regu-
lating CtIP stability. Since polyubiquitylation is a requirement for
proteasome-mediated protein degradation, we next addressed
whether PIN1 may indeed facilitate CtIP ubiquitylation. To this
end, we transfected His-Ubiquitin into HEK293 cell lines induci-
bly expressing GFP-CtIP and analyzed the level of CtIP poly-
ubiquitylation after Ni-NTA pull-down (Figures 6D and 6E).
Strikingly, CtIP ubiquitylation was largely abolished when PIN1
was efficiently depleted (Figure 6F). Moreover, the CtIP-2A
mutant was less ubiquitylated compared to CtIP-wt (Figure 6G).
Collectively, these results suggest that CtIP isomerization by
PIN1 is a prerequisite for CtIP ubiquitylation and subsequent
proteasomal degradation.
DISCUSSION
The PIN1 isomerase regulates a number of cellular processes
but has so far not been connected to DNA repair (Liou et al.,
2011). Here we report that human PIN1 interacts with key DSB
repair factors and demonstrate that PIN1 is involved in the
regulation of DSB repair. Our results point to a model in which
PIN1 affects DSB repair by restricting DNA end resection
through phosphorylation-dependent CtIP isomerization, which
in turn controls CtIP stability (Figure 7). As a consequence of de-
regulated DNA end resection, we find that cells lacking PIN1
display reduced levels of NHEJ and potentially increased levels
of mutagenic forms of homology-directed repair (e.g., single-
strand annealing), while cells overexpressing PIN1 are compro-
mised in error-free HR and repair DSBs more frequently by
NHEJ. Since PIN1-mediated isomerization of p53 was shown
to potentiate its activity in response to genotoxic stress, and
based on the fact that p53 is a regulator of HR, our findings
that PIN1 controls DSB repair pathway choice may specifically
apply to cancer or immortalized cells that have lost p53 function
(Zacchi et al., 2002; Zheng et al., 2002; Bertrand et al., 2004;
Liou et al., 2011).
Figure 5. CtIP-2A Mutant Promotes Hyperresection of DSBs
(A) U2OS cells stably expressing siRNA-resistant GFP-tagged CtIP-wt and CtIP-2A or the empty vector (!) were transfected with CNTL or CtIP siRNA for 72 hr,
and whole-cell extracts were analyzed by western blotting.
(B) The same cells as in (A) were analyzed by flow cytometry.
(C) The same cells as in (A) were sensitized with BrdU followed by laser microirradiation. After 30min, cells were fixed, coimmunostained for g-H2AX and cyclin A,
and analyzed by fluorescence microscopy (see also Figure S7B).
(D) The same cells as in (A), including the resection-defective CtIP-T847Amutant, were transfected with CtIP siRNA for 72 hr and treated for 1 hr with either DMSO
or low doses of CPT (see also Figure S7C). Survival was determined by colony formation. Data are represented as mean ± SEM (n = 3).
(E) The same cells as in (A) were treated with ETOP (5 mM) for 1 hr, released into drug-free medium for the indicated times, and analyzed by immunoblotting.
(F) The same cells as in (A) were treated with ETOP (5 mM) for 1 hr andwere either immediately fixed or released into drug-freemedium for 2 hr before fixation. After
pre-extraction, cells were coimmunostained for RPA2 and g-H2AX and analyzed by fluorescencemicroscopy (see also Figure S7D). For each condition at least 50
cells were scored. Graph shows the percentage of cells exhibiting more than 10 RPA foci per nuclei. Data are represented as mean ± SEM (nR 2).
(G) The same cells as in (A) were treated with ETOP (10 mM) for 2 hr in the absence or presence of a DNA-PKcs inhibitor (NU7441, 10 mM). Cells were harvested
either directly or at 30 min after the release into drug-free medium. Whole-cell extracts were analyzed by immunoblotting, and genomic DNA was analyzed by
PFGE. DNA breakage in each lanewas quantified using ImageJ and normalized against intact DNA. Relative amount of broken DNA in cells expressingGFP-CtIP-
wt treated with ETOP was set to 100%.
(H) Same cells as in (A) were synchronized by a single thymidine block. Eight hours after the release from thymidine, cells enriched in S/G2were irradiated at 30Gy
and, 2 hr later lysates were analyzed by immunoblotting. In (E), (G), and (H), the asterisk indicates the hyperphosphorylated form of RPA2. See also Figure S7.
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Besides restricting CtIP activity in DNA end resection, it is very
tempting to speculate that PIN1 modulates DSB repair pathway
choice through regulating the fate of other phosphoproteins. For
example, based on our results and previously published data, it
is very likely that PIN1 controls the function of 53BP1 and/or
BRCA1: (1) we have identified both proteins in a proteomic
screen for PIN1 interactors, (2) we find that depleting CtIP
does not completely rescue the NHEJ defect in PIN1-deficient
cells, (3) BRCA1 was shown to displace 53BP1 from DSBs to
enable DNA resection by CtIP (Bunting et al., 2010), (4) PIN1
was very recently identified in a SILAC-based screen for
53BP1 interactors (Di Virgilio et al., 2013), and (5) both proteins
are known to be phosphorylated at multiple S/T-P motifs, mak-
ing them attractive targets for PIN1 (Jowsey et al., 2007; Johnson
et al., 2009).
Regarding the mechanism of CtIP regulation by PIN1, we
identify S276 and T315 as the two crucial S/T-P motifs medi-
ating PIN1-CtIP interaction. Phosphorylated T315 emerges as
the main docking site for PIN1, whereas pS276 is required
for cis/trans isomerization. Furthermore, we find CDK2 to be
the responsible kinase for the phosphorylation of T315. In
contrast, phosphorylation of S276 turns out to be independent
of CDK activity. In addition, we find that DNA damage stabilizes
PIN1-CtIP interaction, but without upregulating T315 phosphor-
ylation, suggesting that it is rather S276 phosphorylation that
is induced by genotoxic stress. Interestingly, the amino acid
sequence surrounding S276 matches the consensus motif
for p38MAPK, a stress kinase reported to be activated by
ATM and ATR in response to various DNA-damaging agents
including DNA topoisomerase inhibitors (Manke et al., 2005;
Reinhardt et al., 2007). Clearly, further investigations are needed
to establish both the role of DNA damage in PIN1-mediated
CtIP isomerization and the kinase responsible for S276
phosphorylation.
Figure 6. PIN1 Destabilizes CtIP by Promoting Its Ubiquitylation
(A) Two days after transfection with the indicated plasmids, HEK293 cells were treated with CPT (1 mM) for 2 hr and whole-cell extracts were analyzed by
immunoblotting. Asterisk indicates hyperphosphorylated form of CtIP.
(B) HEK293T cells were transfectedwith either FLAG-CtIP-wt or FLAG-CtIP-2A. Eight hours after transfection, cells were splitted into two newplates. Twenty-four
hours after plasmid transfection, cells were treated with MG132 (10 mM) for 8 hr and lysed for immunoblot analysis using the indicated antibodies. The signal
intensities of CtIP bands were quantified by densitometric analysis using the ImageJ software and normalized to those of Actin. The values represent the relative
increase in CtIP-wt and CtIP-2A levels upon MG132 treatment.
(C) Three days after transfection with CtIP siRNA, U2OS cells stably expressing siRNA-resistant GFP-CtIP (wt and 2A) were treated with DMSO or ETOP (10 mM).
After 1 hr, cells were released into fresh medium supplemented with 200 mg/ml cycloheximide (CHX) or not for the indicated times, and lysates were analyzed by
immunoblotting (see also Figure S8).
(D) HEK293/Flp-In/T-REx cells containing stably integrated GFP-CtIP constructs (wt and 2A) were cultivated in the absence or presence of doxycycline (Dox;
1 mg/ml) for 24 hr, and lysates were analyzed by immunoblotting.
(E) The same cells as in (D) were treated with Dox for 24 hr. After lysis, whole-cell extracts were analyzed by western blotting either directly (input) or after
immunoprecipitation (IP) with the indicated anti-CtIP phospho-specific antibodies.
(F) Forty-eight hours after transfection with the indicated siRNAs, HEK293/Flp-In/T-REx cells were transfected with His-Ub, and the expression of GFP-CtIP-wt
was simultaneously induced with Dox (except in lane 1). Eight hours after induction, cells were transfected with siRNA for a second time. Seventy-two hours after
the first siRNA transfection, cells were treated with MG132 (20 mM) for 6 hr, followed by lysis in buffer containing guanidium-HCl. Ubiquitin conjugates were
purified using Ni-NTA-agarose beads, eluted, and analyzed by western blotting using anti-GFP antibody.
(G) Thirty hours after transfection with His-Ub, Dox-induced HEK293/Flp-In/T-REx cells expressing either GFP-CtIP-wt or GFP-CtIP-2A were lysed in buffer
containing guanidium-HCl and processed as in (F).
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It also remains to be determined how,mechanistically, isomer-
ization by PIN1 primes CtIP for polyubiquitylation and subse-
quent degradation. Interestingly, a similar regulatory mechanism
involving CDK and PIN1 has recently been reported for hypoxia-
induced PML degradation by a Cullin-3 (CUL3) E3 ubiquitin
ligase. The authors of this study showed that phosphorylation
of PML by CDK1/2 and PIN1-mediated isomerization promotes
the recruitment of a CUL3-KLHL20 ubiquitin ligase to polyubiqui-
tylate PML and trigger its degradation (Yuan et al., 2011). Alterna-
tively, a SKP1-CUL1-F box protein (SCF)-type E3 ligase may be
involved in CtIP ubiquitylation, since most F box proteins bind to
a distinct sequence in their substrates, which typically needs to
be phosphorylated (‘‘phospho-degron’’) (Silverman et al., 2012).
Ultimately, our findings that overexpression of PIN1 sup-
presses HR may have important therapeutic implications. For
example, PIN1 overexpression, which is frequently found in can-
cers, may render those cells hypersensitive to PARP inhibition
based on the concept of synthetic lethality, analogous to the sit-
uation described for BRCA mutant cancers (Bao et al., 2004;
Rouleau et al., 2010; Bouwman and Jonkers, 2012). We antici-
pate that future studies investigating the role of PIN1 in the regu-
lation of other DNA repair factors will provide further important
clues to understand how PIN1 contributes to the maintenance
of genome stability.
EXPERIMENTAL PROCEDURES
Cell Culture, siRNAs, and Plasmids
U2OS, HEK293T, Pin1!/! MEFs, and HEK293T retroviral packaging cells
were grown in DMEM supplemented with 10% FCS, 100 U/ml penicillin, and
100 mg/ml streptomycin. The Flp-In T-REx HEK293 host cell line (Invitrogen)
was maintained in medium supplemented with 10 mg/ml blasticidin and
300 mg/ml zeocin. Maintenance of the DR-GFP and EJ5-GFP HEK293 cell lines
was done as described previously (Bennardo et al., 2008). U2OS clones stably
expressing siRNA-resistant formsGFP-CtIP were generated as described pre-
viously and were cultured in DMEM supplemented with 10% FCS, standard
antibiotics and 500 mg/ml G-418 (Sartori et al., 2007). Retroviral infection of
Pin1!/! MEFs was carried out as described previously (Zacchi et al., 2002).
IR was given using a Faxitron X-ray machine. Laser microirradiation was per-
formed as described previously (Eid et al., 2010). Data for survival curves were
generated by colony formation assays as described previously (Sartori et al.,
2007). Transfection of siRNA oligos was done using Lipofectamine RNAiMAX
(Invitrogen). All siRNA duplexes were purchased from Microsynth except the
ON-TARGETplus SMARTpool for PIN1 (PIN1-SP [L-003291-00-0005] [Mar-
cucci et al., 2011; Krishnan et al., 2012] Dharmacon), and the sequences
(50 to 30) were as follows: luciferase (CNTL; CGUACGCGGAAUACUUCGA)
(Sartori et al., 2007), CtIP (GCUAAAACAGGAACGAAUC) (Sartori et al.,
2007), XRCC4 (AUAUGUUGGUGAACUGAGA) (Sartori et al., 2007), 53BP1
(CAGGACAGTCTTTCCACGAAT) (Meerang et al., 2011), PIN1-30UTR (CCGU
CACACAGUAUUUAUU), and PIN1-2 (GCUACAUCCAGAAGAUCAA) (Phan
et al., 2007). All siRNA transfections were done with 40 nM final concentration
of oligos. Plasmids were transfected by using either the standard calcium
phosphate method or FuGene 6 (Roche) according to manufacturer’s instruc-
tions. The pGEX-4T3 plasmid for bacterial expression of recombinant GST-
tagged PIN1 was a gift from Christopher Nelson (University of Victoria,
Canada). The epitope-tagged expression vectors for human CtIP have been
described previously (Yu et al., 2006; Sartori et al., 2007). The HA-tagged
expression vectors for human PIN1 were described previously (Rustighi
et al., 2009). The HA-tagged expression vectors for HA-CDK1-dn,
HA-CDK4-dn, and HA-CDK2 (wt and dn) were purchased from Addgene
(van den Heuvel and Harlow, 1993). The pcDNA3.1-6xHis-Ubiquitin plasmid
was a gift from Matthias Peter (ETH Zurich, Switzerland). All PIN1 and CtIP
point mutants were introduced by site-directed mutagenesis using Expand
Long Template PCR System (Roche) and confirmed by sequencing.
Statistics
Statistical analyseswere carried out using unpaired, two-tailed t tests. p values
expressed as *p < 0.05, **p < 0.005, and ***p < 0.0005 were considered signif-
icant. ns indicates that the difference between the two groups is not
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article at http://dx.doi.org/10.1016/j.molcel.2013.03.023.
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Figure 7. Hypothetical Model: How PIN1-Mediated CtIP Isomeriza-
tion Controls DNA End Resection
During S/G2, CtIP together with other nucleases promotes the resection of
DSBs. Following resection initiation, proline-directed kinases including CDK2
phosphorylate CtIP on T315 and S276, resulting in the binding of PIN1 to CtIP.
PIN1-mediated isomerization of CtIP leads to CtIP ubiquitylation through an
as-yet-unknown E3 ubiquitin ligase and subsequent CtIP degradation by the
proteasome. This mechanism ensures an appropriate usage of DSB end
resection. Consequently, cells with abrogated PIN1 function or inherently low
PIN1 levels display reduced NHEJ and aberrant (error-prone) forms of
homology-directed repair due to enhanced CtIP resection activity (hyper-
resection). In contrast, cells overexpressing PIN1 display reduced HR and
increased NHEJ due to decreased CtIP resection activity (hyporesection).
Therefore, we propose that PIN1 plays an important role in the regulation of
DSB repair, particularly in late S and G2 phases of the cell cycle.
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Figure S2 (related to Figure 1). PIN1 negatively regulates DNA end resection 
(A) U2OS DR-GFP cells were transfected with the indicated siRNAs. At 48 h post-
transfection, cells were transfected with the I-SceI expression plasmid and the GFP+ 
population was analyzed 72 h post-plasmid transfection. The percentage of GFP+ cells was 
determined for each condition and was normalized with the non-targeting (siCNTL) condition. 
Data are presented as the mean ± SEM (N=3). (B) HEK293 (DR-GFP) cells were transfected 
with the indicated plasmids for 96 h and analyzed by flow cytometry. (C) U2OS cells were 
transfected with the indicated siRNA oligos for 48 h and analyzed by flow cytometry prior to 
treatment. (D) Same cells as in (C) wer treated with DMSO (-) or etoposide (ETOP, 20 µM) 
for the indicated times. Whole cell extracts were subjected to SDS-PAGE followed by western 
blotting using the indicated antibodies (*hyperphosphorylated forms of CtIP and RPA2). (E) 
48 h after transfection with the indicated siRNA oligonucleotides, U2OS cells were treated for 
1 h with either DMSO or camptothecin (CPT) and survival was determined by colony 
formation. Data are presented as the mean ± SD (N=3). (F) Quantification of the PFGE 
signals shown in Figure 1E. DNA  breakage in each lane was normalized against intact DNA. 
Relative amount of broken DNA in Pin1-/- MEFs complemented with PIN1 was set to 100%. 
Data are presented as the mean ± SEM (N=3). (G) HEK293T cells were transfected with the 
indicated plasmids (EV, pcDNA3.1) for 72 h and treated with 30 Gy of IR. Whole cell extracts 
were prepared after 3 h and analyzed by immunoblotting. (H) 48 h after transfection with the 
indicated siRNA oligos, U2OS cells grown on coverslips were treated for 1 h with 5 µM ETOP, 
fixed and co-immunostained for Ȗ-H2AX and RPA2; nuclei were stained with DAPI (blue). 
Scale bar, 10 µm. 
 
 
Figure S3 (related to Figure 2). Molecular characterization of the PIN1-CtIP interaction 
(A) Lysates from HEK293T cells expressing FLAG-CtIP were mock-treated, treated with Ȝ-
PPase or treated with a combination of Ȝ-PPase and phosphatase inhibitors (50 mM EDTA 
and 1 mM sodium orthovanadate) prior to GST-PIN1 pulldown. (B) U2OS whole cell extracts 
were treated with increasing concentrations of Ȝ-PPase prior to GST-PIN1 pulldown. (C) 
Detection of endogenous PIN1-CtIP complexes by in situ PLA. Non-transfected or PIN1-
depleted U2OS cells were pulse-labeled with EdU (10 µM) for 15 min prior to fixation. After 
incubation with antibodies against CtIP alone (upper panel) or against both CtIP and PIN1 
(middle and lower panels), protein-protein interactions were detected using fluorescence 
labeled probes (PLA-613). EdU detection was carried out according to manufacturer’s 
instructions and nuclei were stained with DAPI. Scale bars, 10 µm. (D) Schematic 
representation of human CtIP with conserved domains and putative S/T-P phosphorylation 
motifs. Coiled-coil domain and the conserved C-terminal domain (CTD) are indicated. S327 
and T847, the two known S/T-P phosphorylation sites, are illustrated in bold. (E-G) GST-PIN1 
pulldowns using whole cell extracts of HEK293T cells expressing wt or mutant versions of 
FLAG-CtIP. Ponceau staining is shown to illustrate that equal amounts of GST-PIN1-wt or -
W34A were used. ǻC refers to a mutant of CtIP (aa 1-789) lacking the entire C-terminus. (H) 
HEK293T cells were transfected with either FLAG-CtIP alone (-) or together with different HA-
PIN1 plasmids (wt, W34A or C113A). Whole cell extracts were subjected to co-
immunoprecipitations using anti-HA antibodies before analysis by immunoblotting. (I) Anti-
FLAG immunoprecipitates from HEK293T cells transfected with the indicated plasmids were 
subjected to far-western analysis using purified GST-PIN1 as a probe followed by anti-GST 
immunoblotting. After stripping the same membrane was reprobed using anti-FLAG antibody. 
 
 
Figure S4 (related to Figure 3). CtIP-T315 is phosphorylated in cells 
(A) Multiple sequence alignment of the CtIP region containing S276 and T315. (B) Extracts 
from HEK293T cells (5 mg) treated with either DMSO or ETOP (10 µM) for 2 h were 
immunoprecipitated using either a non-specific, rabbit  antiserum or anti-CtIP antibodies and 
immunoblotted with the indicated antibodies. Asterisk indicates hyperphosphorylated form of 
CtIP. (C) CtIP immunoprecipitated from HEK293T cells was subjected to mass spectrometry 
(MS) analysis to map phosphorylation sites. In brief, CtIP tryptic peptides indicated by black 
boxes (covering 23 % of the CtIP sequence) were analyzed by by LC-MS-MS using a Thermo 
LTQ linear ion trap mass spectrometer. MS/MS spectra of the peptide containing T315 
(highlighted in red) is shown below with the corresponding B and Y ions. T315 and S313 were 
identified as the two likeliest phosphorylation sites using the Mascot-Delta Score (MD-score) 
phospho-localization algorithm. Note that no peptides containing S276 (highlighted in blue) 
were covered by the analysis. 
 
 
Figure S5 (related to Figure 3). Analysis of CtIP-PIN1 interaction and CtIP cis/trans 
isomerization using synthetic CtIP phosphopeptides 
(A) GST-PIN1 pull-down assays were performed in HEK293T whole cell extracts (0.5 mg) 
supplemented with either increasing amounts of the CtIP-pT315 phosphopeptide or with the 
CtIP-T315 peptide (lane 7). (B) Purification of GST-PIN1-wt and -C113A (data not shown) 
from bacterial lysates using a GSTrap FF™ column connected to a FPLC™ System. 
Fractions eluted from the column by 10 mM glutathione were separated by SDS-PAGE and 
stained with Commassie Blue. (C) 31P{1H} spectra obtained from pS276 and pT315 peptides 
(2.4 mM) in 20 mM sodium phosphate (pH 6.8) at 25 °C. The ratios of trans to cis are 4 and 
approximately 16 for pS276 and pT315, respectively, as judged by the integrals under the 
peaks. Note the presence of two weak cis peaks in pT315 peptide due to the presence of two 
consecutive proline residues in +1 and +2 after the phospho-threonine. The strong, capped 
peak at 0.55 ppm in both spectra results from the phosphate buffer. (D-G) Selected region of 
the two-dimensional ROESY spectra of the indicated synthetic CtIP peptides in presence of 
recombinant GST-PIN1. 
 
 
Figure S6 (related to Figure 4). CDK2 activity is required for CtIP-PIN1 interaction and 
CtIP-T315 phosphorylation 
(A) Extracts from U2OS cells treated with increasing amounts of R-Roscovitine for 2 h were 
subjected to GST-PIN1 pull-down assays. The ratios of input versus pull-down (I/P) were 
quantified by densitometry using Image J. (B) HEK293T cells were transfected with either 
pcDNA3.1 or plasmids expressing HA-tagged dominant-negative (dn) mutant version of 
CDK1 and CDK2, respectively, and 48 h later analyzed by flow cytometry. (C) Extracts from 
HEK293T cells, transfected with pcDNA3.1 (-) or plasmids expressing HA-CDK2 (wt and dn) 
for 48 h, were subjected to GST-PIN1 pulldown assays. The ratios of input versus pull-down 
(I/P) were quantified by densitometry using Image J. (D) U2OS cells were synchronized by a 
double thymidine (dT) block. At the indicated time points after the release from thymidine, 
cells were either subjected to flow cytometry or lysed. Whole cell extracts were analyzed by 
western blotting either directly (input) or after immunoprecipitation (IP) with anti-CtIP 
antibodies. 
 
 
Figure S7 (related to Figure 5). Increased DSB resection in cells expressing CtIP-2A 
(A) Extracts from HEK293T cells transfected with the indicated plasmids for 48 h were 
subjected to immunoprecipitation (IP) using anti-GFP antibody and analyzed by 
immunoblotting. (B) U2OS cells stably expressing siRNA-resistant GFP-CtIP constructs were 
transfected with CtIP siRNA and sensitized with BrdU. 30 minutes after laser microirradiation, 
cells were fixed, co-immunostained for Ȗ-H2AX and cyclin A and analyzed by fluorescence 
microscopy. Note that only S/G2-phase cells have pan-nuclear cyclin A staining. Scale bars, 
10 µm. (C) 72 h after siRNA transfection, U2OS cells stably expressing different GFP-tagged 
CtIP versions were treated with CPT (1 µM) for 2 h and lysates were analyzed by 
immunoblotting. Arrowhead indicates a nonspecific band; asterisk indicates 
hyperphosphorylated RPA2. (D) Same cells as in (B) were treated with ETOP (5 µM) for 1 h 
and released into drug-free medium for 2 h. Left, After pre-extraction, cells were fixed, co-
immunostained for RPA2 and Ȗ-H2AX and analyzed by fluorescence microscopy. Scale bars, 
20 µm. Right, For each condition at least 50 cells were scored. Graph shows the percentage 
of nuclei exhibiting more than 10 Ȗ-H2AX-foci. (E) U2OS cells were mock-treated (lane 1) or 
treated with ETOP (10 µM) for 2 h in the absence (lane 2) or presence (lane 3) of NU7441 (10 
µM). Additionally, cells were released into drug-free medium for 6 h after ETOP treatment 
(lane 4). Lysates were analyzed by immunoblotting and genomic DNA was analysed by 
PFGE. Asterisks indicate hyperphosphorylated forms of CtIP and RPA2. (F,G) HEK293 DR-
GFP cells were transfected with the indicated siRNAs for 48 h. Cells were then co-transfected 
with the I-SceI expression plasmid together with the indicated siRNA-resistant FLAG-CtIP 
constructs. After a second transfection with CtIP siRNA, CtIP expression and GFP+ 
population were analyzed 48 h post-I-SceI transfection by immunoblotting (F) and flow 
cytometry (G), respectively. The percentage of GFP+ cells was determined for each condition 
and was normalized with the CtIP-wt condition. (H) HEK293 EJ5-GFP cells were analyzed as 
in (G). Data in (D, G and H) are represented as mean ± SEM (N=3). 
 
 
Figure S8 (related to Figure 6C). Increased half-life of the CtIP-2A mutant protein in 
presence of DNA damage 
The signal intensities of CtIP bands from Figure 6C were quantified by densitometric analysis 
using the ImageJ software and normalized to those of Actin. The values represent the relative 
decrease in both GFP-CtIP-wt and GFP-CtIP-2A protein levels at different time points after 
CHX treatment in presence or absence of etoposide (ETOP). 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
HR and NHEJ reporter assays. 
DSB repair efficiency by HR and NHEJ was measured in DR-GFP and EJ5-GFP HEK293 cell 
lines as described previously (Bennardo et al., 2008; Meerang et al., 2011). In brief, 48 h after 
siRNA transfection, cells were either mock-transfected or transfected with 0.6 ȝg of an I-SceI 
expression plasmid (pCBASce) using 1.2 µl of JetPrime (Polyplus). 4 h after I-SceI 
transfection, the media was replaced, followed by a second transfection with siRNA oligos (15 
nM). To measure the effect of PIN1 overexpression, cells were co-transfected with 0.6 µg of 
pCBASce together with 0.6 µg of pcDNA3-PIN1 using 2.4 µl of JetPrime (Polyplus). To 
measure the effect of CtIP overexpression, 48 h after siCtIP transfection, cells were co-
transfected with 0.6 µg of pCBASce together with 0.2 µg of various FLAG-tagged CtIP 
constructs using 1.6 µl of JetPrime (Polyplus). 4 h after I-SceI transfection, the media was 
replaced, followed by a second transfection with siCtIP (15 nM). 48 h after after I-SceI 
transfection, cells were analyzed for GFP expression by flow cytometry on a CyAn ADP 9 
(Dako). HR efficiency in U2OS DR-GFP cells was measured exactly as described previously 
(Muñoz et al., 2012). 
 
Generation of stable HEK293/Flp-In/GFP-CtIP cell lines. 
To generate cell lines able to express GFP-CtIP-wt and GFP-CtIP-2A in an inducible manner, 
Flp-In T-REx-293 cells (60% confluence) were transfected with a mixture containing the GFP-
CtIP receptor cDNA in the pcDNA5/FRT/TO vector and the Flp recombinase cDNA in the 
pOG44 vector (ratio 1:9) using FuGene 6 transfection reagent (Roche) according to the 
manufacturer's instructions. Two days after transfection, cells were diluted 1:5 in 10-cm plates 
and the medium was supplemented with 100 µg/ml hygromycin. The medium was replaced 
every 2-3 days and cells were selected for approximately 2 weeks. Resistant colonies were 
pooled and cells were screened for GFP-CtIP expression by both immunofluorescence 
microscopy and western blotting. To induce expression of GFP-CtIP, cells were treated with 1 
µg/ml doxycycline (Dox) for 24 h (see Figure 6D). 
 
 
Antibodies. 
The primary antibodies used in this study are listed in a separate table below. Rabbit 
polyclonal phospho-specific antibodies against CtIP-pS276 and CtIP-pT315 were produced 
by Eurogentec with synthetic phosphopeptides (KLH-coupled) corresponding to residues 
surrounding S276 (ETQGPMpSPLGDEL) and T315 (SDSTSKpTPPQEE) of human CtIP. 
Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies were form GE-Healthcare 
and the HRP-conjugated anti-goat was from Santa Cruz Biotech. Alexa Fluor-488, -594, and -
647-conjugated secondary antibodies were from Invitrogen. 
 
Chemicals. 
R-Roscovitine and RO-3306 were purchased from Calbiochem. Etoposide and camptothecin 
were purchased from SIGMA. DNA-PKcs inhibitor (NU7441) was purchased from Tocris 
Bioscience. EdU (5-ethynyl-2'-deoxyuridine) was from Invitrogen. MG132 was purchased 
from Sigma. 
 
Immunoblotting, GST pulldown, Immunoprecipitation and Far-Western. 
If not specified otherwise, cell extracts were prepared in Laemmli buffer (4% SDS, 20% 
glycerol, 120 mM Tris-HCl pH 6.8). Proteins were resolved by SDS–PAGE, transferred to 
nitrocellulose. Immunoblots were performed by using the appropriate antibodies and proteins 
visualised using the ECL detection system (Amersham). 
For GST pulldown assays and immunoprecipitation assays, cells were lysed in either NP-40 
extraction buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1 mM EDTA, 6 mM EGTA, 15 mM 
sodium pyrophosphate and 1 % NP-40 supplemented with phosphatase inhibitors (20 mM 
NaF, 1 mM sodium orthovanadate) and protease inhibitors (1 mM benzamidine and 0.1 mM 
PMSF)) or RIPA buffer (50 mM Tris-HCl, pH 7.4, 1 % NP-40, 0.25 % sodium deoxycholate, 
150 mM NaCl, 1 mM EDTA and 0.1% SDS supplemented with phosphatase and protease 
inhibitors)) and clarified by centrifugation at 14000 rpm. For HA-PIN1 immunoprecipitations 
using anti-HA antibody, cells were lysed in modified NP-40 buffer (10 mM HEPES, pH 7.5, 
250 mM NaCl, 0.1 % NP-40, 5 mM EDTA, 0.5 mM DTT and 0.05 % SDS supplemented with 
protease and phosphatase inhibitors). GST pull-downs and immunoprecipitations were 
performed as described previously (Sartori et al., 2007). Far-western blot analysis was 
performed as described previously (Wu et al., 2007). Densitometric analysis of protein bands 
were performed using ImageJ. 
 
In Situ Proximity Ligation Assay. 
In situ proximity ligation assay (PLA) in combination with immunofluorescence confocal 
microscopy was performed using Duolink II Detection Kit with anti-Mouse PLUS and anti-
Rabbit MINUS PLA Probes, according to the manufacturer’s instructions (Olink Bioscience). 
 
Pulsed field gel electrophoresis (PFGE). 
A modified protocol for PFGE was carried out as described previously (Meerang et al., 2011). 
The gels were stained with ethidium bromide and analyzed using a CCD camera (BioRad). 
 
Liquid chromatography-MS/MS analysis. 
MS analysis was carried out as described previously (Zheng et al., 2009). In brief, Following 
GST-PIN1 pulldowns or CtIP immunoprecipitation using anti-CtIP antibody, proteins were 
separated by SDS-PAGE and stained with silver or colloidal commassie, respectively. Protein 
bands were in-gel digested with Trypsin Gold (Promega) according to standard procedures. 
The resulting peptides were further purified using C18-resin containing ZipTips according to 
manufacturer's instructions (Millipore) prior to LC-MS-MS analysis using a Thermo LTQ linear 
ion trap mass spectrometer. The precursor and fragment ion tolerances were set to 10 ppm 
and 0.8 Da, respectively.  Iodoacetamide derivative of cysteine was specified in Mascot as a 
fixed modification. Oxidation of methionine and phosphorylation of serine, threonine and 
tyrosine were specified in Mascot as variable modifications. Scaffold (version Scaffold 3.3.1, 
Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and 
protein identifications. Peptide identifications were accepted if they could be established at 
greater than 95.0% probability as specified by the Peptide Prophet algorithm (Nesvizhskii et 
al., 2003). Protein identifications were accepted if they could be established at greater than 
99.0% probability and contained at least one identified peptide. Proteins that contained similar 
peptides and could not be differentiated based on MS/MS analysis alone were grouped to 
satisfy the principles of parsimony. 
 
Immunofluorescence Microscopy. 
U2OS cells grown on cover slips were either fixed directly in formaldehyde and permeabilized 
or pre-extracted for 10 min on before fixation in 4% formaldehyde (w/v) in PBS for 12 min as 
described previously (Eid et al., 2010). After incubation with indicated primary and appropriate 
secondary antibodies, cover slips were mounted with Vectrashield® (Vector Laboratories) 
containing DAPI and sealed. Images were acquired on a Leica confocal SP2 fluorescence 
microscope. 
 
Purification of GST-PIN1. 
GST-fusion proteins of PIN1 were expressed in bacteria after induction by IPTG for 20 h at 
16°C. After centrifugation, the bacterial pellet was resuspended in cold PBS supplemented 
with 0.2 % Triton X-100 and protease inhibitors (1 mM PMSF, 1 mM benzamidine and Roche 
protease inhibitor cocktail). After sonication and centrifugation, GST-PIN1 proteins were 
purified using a GSTrap fast-flow column according to manufacturer's instructions (GE 
Healthcare). 
 
NMR spectroscopy analysis of CtIP peptides. 
Phospho- and non-phospho-peptides corresponding to residues surrounding S276 
(ETQGPM(p)SPLGDELY) and T315 (FSDSTSK(p)TPPQEEY and FSDSTSKpTPLQEEY, 
where proline 317 was replaced by leucine) of human CtIP were purchased from Bachem. 
Unless stated otherwise all NMR samples contained 2.4 mM solutions of the respective CtIP 
peptide in 20 mM sodium phosphate buffer at pH 6.5. To these solutions PIN1-wt or PIN1-
C113A were added at a concentration of 30 ȝM. All 1H-detected spectra were acquired on a 
Bruker AV-600 or AV-700 spectrometer equipped with triple-resonance cryoprobes. The 31P 
spectra were recorded on a Bruker AV2-500 spectrometer equipped with a QNP cryoprobe. 
All NMR experiments were conducted at 298K, except when stated otherwise, and water 
suppression was achieved by presaturation. Resonance assignment was achieved based on 
75 ms TOCSY, DQF-COSY and 110 ms ROESY spectra. All spectra were acquired with 2048 
x 256 complex points, using a spectral width of 5400 Hz in both dimensions, 16 to 32 scans 
per increment and a 2 s interscan delay. 31P-spectra were acquired with 1H-decoupling, 512 
scans per experiment and an interscan delay of 3 s. 
 
V8 Protease Digestion of FLAG-CtIP 
HEK293T cells were transfected with FLAG-CtIP plasmids for 72 h prior to lysis in NP-40 
extraction buffer. FLAG-CtIP was immunoprecipitated from five milligrams of total protein 
lysates using FLAG-M2 magnetic beads. The beads were washed five times with TBS. FLAG-
CtIP was eluted with 85 µl of TBS supplemented with 3xFLAG peptides for 1 h according to 
manufacturer's instructions (Sigma). The eluates (20 µl) were either mock-treated or 
incubated with 0.5 µg/ml of V8 protease (Sigma) for 30 min at 20qC. Samples were separated 
on SDS-PAGE, transferred to nitrocellulose membranes, and probed with anti-CtIP (Bethyl) 
and with anti-FLAG antibodies. 
 
In vivo ubiquitylation assay 
Stable HEK293/Flp-In/GFP-CtIP cells were induced with Dox (1 µg/ml), simultaneously 
transfected with His-ubiquitin and were cultured for 24 h followed by MG132 treatment (20 
µM) for 6 h. Cells were washed and scraped in 0.5 ml of ice-cold PBS. Five percent (5 %) of 
the cell suspension was used for direct Western blot analysis. The remaining cells (95 %) 
were lysed in buffer A (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, pH 8.0, 10 mM 
imidazole and 10 mM NEM). Lysates were incubated with Ni2+-NTA agarose for 3 h at room 
temperature. The beads were washed three times with buffer A, twice with buffer A/TI (1 vol 
buffer A: 3 vol buffer TI [25 mM Tris-HCl, pH 6.8, and 20 mM imidazole]), and three times in 
buffer TI. Purified proteins were eluted by boiling the beads in 2 x sample buffer 
supplemented with 250 mM imidazole and then analyzed by western blotting. 
 
 
Antibody target Species Supplier/Reference Application* 
ATM (2C1) mouse GTX70103 (GeneTex) IB 
pATM S1981 rabbit 2152-1 (Epitomics) IB 
Į-Actin (I-19) rabbit sc-1616 (Santa Cruz) IB 
53BP1 (H-300) rabbit sc-22760 (Santa Cruz) IB 
CtIP (14-1) mouse gift from Richard Baer IB 
CtIP rabbit A300-488A (Bethyl) IP 
CtIP (D-4) mouse sc-271339 (Santa Cruz) IB 
CtIP (T-16) goat sc-5970 (Santa Cruz) IP and IB 
CHK1 (G4) mouse sc-8408 (Santa Cruz) IB 
pCHK1 S345 rabbit 2341(Cell Signaling) IB 
CHK2 rabbit gift from Grant Stewart IB 
pCHK2 T68 (C13C1) rabbit 2197P (Cell Signaling) IB 
Cyclin A (C-19) rabbit sc-596 (Santa Cruz) IF 
Cyclin D1 rabbit RB-010 (NeoMarkers) IB 
pDNA-PKcs S2056 rabbit ab18192 (Abcam) IB 
FLAG mouse F3165 (Sigma) IP and IB 
GAPDH mouse MAB374 (Millipore) IB 
GFP rabbit ab290 (Abcam) IP and IB 
GFP mouse sc-9996 (Santa Cruz) IB 
GST mouse A00865 (GenScript) IB 
HA mouse sc-7392 (Santa Cruz) IP and IB 
ȖH2AX (JBW301) mouse 05-636 (Millipore) IF 
ȖH2AX (20E3) rabbit 9718 (Cell Signaling) IB and IF 
MRE11 mouse GTX70212 (GeneTex) IB 
MRE11 rabbit NB100-142 (Novus) IB 
PIN1 rabbit 2136-1 (Epitomics) IB and IF 
PIN1 rabbit 600-401-A20 (Rockland) IP 
p53 (DO-1) mouse sc-126 (Santa Cruz) IB 
RAD51 (H-92) rabbit sc-8349 (Santa Cruz) IB 
RPA2 (Ab-3) mouse NA19L (Calbiochem) IF and IB 
RPA2 (9H8) mouse ab2175 (Abcam) IB 
pRPA S4/S8 (BL647) rabbit A300-245A (Bethyl) IB 
ȕ-Tubulin (D-10) mouse sc-5274 (Santa Cruz) IB 
TFIIH p89 (S-19) rabbit sc-293 (Santa Cruz) IB 
XRCC4 rabbit ab145 (Abcam) IB 
*IB: Immunoblot, IF: Immunofluorescence, IP: Immunoprecipitation 
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HELQ promotes RAD51 paralogue-dependent repair
to avert germ cell loss and tumorigenesis
Carrie A. Adelman1, Rafal L. Lolo1, Nicolai J. Birkbak2, Olga Murina3, Kenichiro Matsuzaki1, Zuzana Horejsi1, Kalindi Parmar4,
Vale´rie Borel1, J. Mark Skehel5{, Gordon Stamp6, Alan D’Andrea4, Alessandro A. Sartori3, Charles Swanton7,8 & Simon J. Boulton1
Repair of interstrand crosslinks (ICLs) requires the coordinated
action of the intra-S-phase checkpoint and the Fanconi anaemia
pathway, which promote ICL incision, translesion synthesis and
homologous recombination (reviewed in refs 1, 2). Previous studies
have implicated the39–59 superfamily 2helicaseHELQin ICL repair
in Drosophila melanogaster (MUS301 (ref. 3)) and Caenorhabditis
elegans (HELQ-1 (ref. 4)). Although in vitro analysis suggests that
HELQ preferentially unwinds synthetic replication fork substrates
with 39 single-stranded DNA overhangs and also disrupts protein–
DNA interactions while translocating along DNA5,6, little is known
regarding its functions in mammalian organisms. Here we report
thatHELQhelicase-deficientmice exhibit subfertility, germcell attri-
tion, ICL sensitivity and tumour predisposition, with Helq hetero-
zygous mice exhibiting a similar, albeit less severe, phenotype than
the null, indicative of haploinsufficiency. We establish that HELQ
interacts directly with the RAD51 paralogue complex BCDX2 and
functions in parallel to the Fanconi anaemia pathway to promote
efficient homologous recombination at damaged replication forks.
Thus, our results reveal a critical role for HELQ in replication-
coupled DNA repair, germ cell maintenance and tumour suppres-
sion in mammals.
To examine the effect ofHELQdeficiency in vertebrates, we generated
aHelqDC-deficientmouse strain that is truncated at the carboxy terminus
of HELQ (Fig. 1a, b and ExtendedData Fig. 1a, b) and results in loss of
detectableHELQprotein (Fig. 1d andExtendedData Fig. 1c). Although
HelqDC/DC mice are viable (Fig. 1c), are born in normal Mendelian
ratios and lack growth or developmental abnormalities (Extended
Data Fig. 1d, e), breeding experiments with HelqDC/DC mutant pairs
revealed a fertility defect. Eight heterozygous and 8 homozygous pairs
were mated continuously for 5–6months, resulting in 320 offspring
in the case of heterozygotes (an average of 6.1 litters and 40 pups each)
but only 38 pups in the case of homozygotes (1.4 litters and 4.7 pups
per pair). Mating of mutants to control animals revealed that females
contribute more to this phenotype than males (Fig. 1e).
Consistent with a fertility defect,HelqDC/DC testes were smaller than
those of wild-type males (0.58% of body weight for wild type versus
0.38% formutants (Fig. 1f)).Histological analysis of testes revealedmany
normal tubules but also regions of atrophy in the mutants (Fig. 1g and
ExtendedDataFig. 1g–l).Dysgenesis/atrophywas evenmorepronounced
in HelqDC/DC ovaries (Fig. 1g and Extended Data Fig. 1f). A possible
stem cell origin was investigated as no particular subset of spermato-
cytes appeared affected (Extended Data Fig. 1g–l). Indeed, HelqDC/DC
adults had significantly fewer c-KIT (also known as KIT)1 spermato-
gonia than controls (Extended Data Fig. 2a, b). As atrophy was not
linked to ageing (Extended Data Fig. 2c), a developmental origin was
examined; tubules from 5-day-old wild-type mice contained sixfold
more spermatogonia than mutants (Fig. 1h), indicating that atrophic
tubules in mutant adults may primarily arise from reduced spermato-
gonial stem cell pools during development.
The effect of HELQ deficiency during organismal ageing revealed
that tumour-free survival was significantly reduced in Helq mutants
(Fig. 1i and ExtendedData Fig. 2d), with twice asmanyHelqDC/DCmice
developing two or more primary tumours in comparison to controls
(Fig. 1j). Ovarian tumours (resembling granulosa and other sex cord
stromal tumours; Extended Data Fig. 3b–f) and pituitary adenomas
(Extended Data Fig. 3g–j) were the most prominent tumour types in
femalemice, with incidences of 40% in the case of ovarian tumours and
30% in the case of pituitary tumours (Fig. 1k). Unexpectedly,Helq1/DC
heterozygous females also presented with ovarian pathology similar to
that of younger mutant females (Extended Data Fig. 2d). Pathology
included cystic (4 out of 7 mice) and dysgenic/atrophic (5 out of 7)
ovaries with few or no maturing follicles (7 out of 7) and luteinized
stroma (2 out of 7). Helq1/DC heterozygous females also frequently
displayed pituitary (5 out of 7 mice), Harderian gland (3 out of 7) and
gastrointestinal (3 out of 7) adenomas, polyps andhyperplasias. Although
these phenotypes are less severe than observed in theHelqDC/DC homo-
zygous mice, the data reveal that loss of a single allele of Helq confers
haploinsufficiency in mice.
The phenotype ofHelqDC/DCmice is similar to that observed inmouse
models of Fanconi anaemia7. Haematopoietic stem and progenitor cell
(HSPC) defects and sensitivity to ICLs are also hallmarks of Fanconi
anaemia andwere therefore examined inHelqmutants.Althoughbone
marrow HSPCs from HelqDC/DC mice exhibit hypersensitivity to the
ICL agent mitomycin C (MMC; Extended Data Fig. 4a), HelqDC/DC
HSPCs were not compromised in numbers (Extended Data Fig. 4b, c),
proliferative capacity (Extended Data Fig. 4d, e) or engraftment
(Extended Data Fig. 4f–i). HELQ-deficient cells exhibited hypersensi-
tivity to replication blocking agents such as MMC and camptothecin
(CPT; Fig. 2a, b), but not to ionizing radiation or ultraviolet radiation
(Fig. 2c, d).HelqDC/DC cells also exhibited significantlymore chromatid
breaks and radial chromosomes than control cells upon treatmentwith
mitomycinC (MMC; Fig. 2e, j). Silencing ofHELQ by short interfering
RNA(siRNA) inhuman cells resulted in similar phenotypes (Extended
Data Fig. 4j).
To examine the phenotypic relationship between HELQ and the
Fanconi anaemia pathway we generated HelqDC/DC Fancd22/2 double-
mutant mice (the Fancd2 strain is described in ref. 8). Double mutants
were born inMendelian ratios (ExtendedData Fig. 4k) and growth and
appearancewerenormal. Surprisingly, testes fromdoublemutantswere
significantly smaller than single mutants and all tubules were atrophic,
containing only Sertoli cells (Fig. 2f, g). Similarly, double-mutant cells
exhibited greater sensitivity to MMC and CPT than either single-
mutant (Fig. 2h, i) and spontaneous andMMC-induced chromosomal
aberrations were significantly increased over the Helq single mutant
1DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms EN6 3LD, UK. 2Center for Biological Sequence Analysis, Technical University of Denmark,
Lyngby 2800, Denmark. 3Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland. 4Department of Radiation Oncology, Dana Farber Cancer
Institute, Boston, Massachusetts 02215, USA. 5Protein Analysis and Proteomics Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms EN6 3LD, UK. 6Experimental
Histopathology Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3LY, UK. 7Translational Cancer Therapeutics Laboratory, London Research Institute,
Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3LY, UK. 8UCL Cancer Institute, Huntley Street, London WC1E 6DD, UK. {Present address: Mass Spectrometry, Medical Research Council
Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK.
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(Fig. 2j). These results suggest that HELQ and FANCD2 act in parallel
ICL repair pathways.
To gain insight into the function of HELQ during DNA repair, we
performed proteomic analysis of proteins co-precipitated with Flag-
taggedHELQ.Mass spectrometry revealed several checkpoint andDNA
repair proteins, including the replication checkpoint kinase ATR, the
single-stranded DNA binding protein RPA70 (also known as RPA1),
the four components of the BCDX2 complex required for homologous
recombination, and the FANCD2–FANCI heterodimer that functions
in the Fanconi anaemia pathway (Fig. 3a, b andExtendedData Fig. 5a).
Interaction partners identified by mass spectrometry were confirmed
via immunoprecipitation/western blot (Fig. 3c). Reciprocal immuno-
precipitation of RAD51C confirmed its association with Flag–HELQ
(Fig. 3d), and endogenous HELQ was detected in RAD51C immuno-
precipitates from293Tcells andvice versa (Fig. 3e). RecombinantBCDX2
proteins purified from either insect cells or bacteria also bound to puri-
fied Flag–HELQ but not to ALC1–Flag or Flag controls (Fig. 3f). Intri-
guingly, XRCC3, a component of the RAD51C–XRCC3 (CX3) RAD51
paralogue complex, was not detected by either mass spectrometry or
western blotting of Flag–HELQ immunoprecipitates (Fig. 3c). Further-
more, HELQ was not found in reciprocal immunoprecipitates with
endogenous XRCC3 (Extended Data Fig. 5c). These data indicate that
HELQ interacts directly with the BCDX2 complex but not with the
CX3 complex.
As ATR, RPA70, the BCDX2 complex and FANCD2–FANCI all
respond to stalled replication forks, we examined the localization of
green fluorescent protein-tagged HELQ (HELQ–GFP) expressed in
NIH 3T3 cells9. Subcellular fractionation revealed that HELQ–GFP
is enriched on chromatin in response to replication fork stalling with
either MMC or aphidicolin, and this is compromised by ATR inhibi-
tion (Fig. 3g and Extended Data Fig. 5e–g).
To determine the possible underlying cause of the defect in HELQ-
deficient cells we examined replication dynamics, indices of checkpoint
activation, Fanconi anaemia pathwayactivation, double-strandedbreak
(DSB) formation, and the integrity of homologous recombination.
Replication fork extension rates in HelqDC/DC cells were significantly
lower than in wild-type cells (Extended Data Fig. 6d, e) and this was
exacerbated by treatmentwithCPT (ExtendedData Fig. 6d). Replication
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fork tract asymmetry was also evident in mutants relative to controls
indicative of increased fork stalling/collapse (Extended Data Fig. 6f, g).
Checkpoint activation as measured by phosphorylation of ATM,
CHK1 and CHK2 (also known as CHEK1 and CHEK2, respectively)
andcH2AX in response toDNAdamagewas unaffectedby loss ofHELQ
in eithermouse or human cells (ExtendedData Fig. 7a–d). Furthermore,
HELQ-deficient cells exhibited constitutive FANCD2monoubiquitin-
ation, indicating that HELQ is dispensable for this modification
(Fig. 4a).AssessmentofRAD51recruitment todamaged replication forks
revealed that RAD51 is enriched on chromatin in response to MMC
treatment inHELQ-deficientmouseandhumancells (Fig.4bandExtended
Data Fig. 7e, 8a) and RAD51, RPA (also known as RPA1) and cH2AX
accumulate in repair foci (Fig. 4c andExtendedDataFig. 7e–g).However,
RAD51 and cH2AX persisted on chromatin and remained present in
repair foci at later time points in HELQ-deficient mouse and human
cells (Fig. 4b, c and Extended Data Fig. 7e, f), suggesting that the defect
in the absence ofHELQoccurs at a step downstreamofRAD51 recruit-
ment to damaged replication forks. Pulsed field gel electrophoresis
revealed that DSBs form inHelq and Fancd2 single and doublemutant
cells after MMC treatment, but that these lesions persist at later time
points, indicating thatDSBs induced at ICLs arenot efficiently repaired
(Fig. 4d). siRNA-induced depletion of HELQ resulted in a two- to
threefold decrease in homologous recombination efficiency, implic-
ating HELQ in promoting homologous recombination (Fig. 4e and
Extended Data Fig. 8b). Furthermore, clonogenic survival of HELQ-
deficient mouse and human cells were significantly compromised in
response to poly-ADP ribose polymerase (PARP) inhibition,which is a
hallmark of homologous recombination-deficient cells10 (Fig. 4f and
Extended Data Fig. 8c). It is notable that the HELQ interacting protein
and BCDX2 complex factor, RAD51D, is also required for PARP
inhibitor resistance11.
In summary, our results uncover a critical role for HELQ in germ
cell maintenance and tumour suppression in mammals, which we
attribute to a role in replication-coupled DNA repair. The interaction
betweenHELQand theRAD51paralogueBCDX2complexmayprovide
molecular insight into the HELQ phenotype and its role in tumori-
genesis, as the BCDX2 complex functions to promote replication-
coupled homologous recombination, RAD51C has been implicated
in a Fanconi anaemia-like disorder12, and mutations in RAD51B and
RAD51Dare associatedwithhereditaryovariancancer inhumans11,13–18.
These findings suggest HELQ as a strong candidate for screening in
human cancers and also explain why mutations in D. melanogaster
homologues ofHELQ,RAD51, and the twoRAD51paralogues (MUS301
(also known as SPN-C), SPN-A, SPN-B and SPN-D, respectively)
confer a very similar phenotype19. Finally, our findings help to explain
the prevalence of non-synonymous variants in HELQ, which are sig-
nificantly associated with upper aerodigestive tract cancers, particu-
larly amongst smokers20; and variants in HELQ associated with early
menopause21, which may reflect the germ cell defects and ovarian
dysgenesis observed in HELQ-deficient mice.
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METHODS SUMMARY
HELQ-deficient mice were generated from a commercially available embryonic
stem cell clone (clone ID: RRF112, BayGenomics, University of California, Davis).
All strains were maintained on a mixed B6/129 background. Testes for histology
were fixed in Bouin’s solution and periodic acid-Schiff/haematoxylin stained; all
other tissues were fixed in neutral buffered formalin and stained with haematox-
ylin and eosin. Bone marrow cells were collected and analysed by FACS, colony
formation and transplantation as described previously8,22,23. HELQ–Flag, Flag, and
ALC1–Flag cell lines were generated using theHEK293Flp-In system according to
the manufacturer’s protocol (Invitrogen). HELQ–GFP-expressing NIH3T3 cells
were generated according to the bacterial artificial chromosome recombineering
method described previously9. Pulse field gel electrophoresis was carried out sim-
ilar to themethod described in ref. 24. Isolation ofHELQ–Flag immunocomplexes
entailed lysis of cells in the presence of benzonase to prevent non-specific DNA-
bridging of proteins. Flag immunoprecipitates for mass spectrometry analysis
were eluted by boiling in SDS–PAGE sample buffer and processed using standard
methods. The Biological General Repository for Interaction Data sets (BioGRID,
http://thebiogrid.org/), the Molecular INTeraction database (MINT, http://mint.
bio.uniroma2.it/mint) and Search Tool for the Retrieval of Interacting Genes/
Proteins database (STRING, http://string-db.org/) were used to compile the inter-
action network. For assays of in vitro binding to purifiedHis-tagged BCDX2, Flag-
tagged proteins were purified by washing immune-complexed beads four times
with buffer containing 1MNaCl. Purified Flag proteins were then incubated with
recombinant BCDX2 complex, washed and eluted for analysis. Chromatin fractiona-
tionwas carried out usingmodified versions of previously establishedmethods25,26.
For siRNA transfections ofU2OScells, cellswere subjected to two rounds of reverse
transfections using siGENOME siRNA andDharmafect1 (Thermofisher) accord-
ing to the manufacturer’s protocol. Histology/immunohistochemistry, primary
cell line derivation and immortalization, immunofluorescence, assays for clonogenic
survival, metaphase aberrations, micronuclei and DNA combing were carried out
using standard procedures.
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METHODS
Mouse strains, maintenance, localization of genetrap, genotyping. All mice
were housed and maintained according to the Home Office guidance outlined in
the Animals Scientific Procedures Act. All strains weremaintained on amixed B6/
129 background.
A commercially available embryonic stem cell clone (clone ID: RRF112, Bay
Genomics, University of California, Davis) harbouring the trapped allele of Helq
was obtained. The position of the b-geo gene trap cassette from the pGT0LxF
vector was determined via splinkerette PCR27 using a modified version of the
method described in ref. 28. In brief, 3mg genomic DNA fromHelq gene-trapped
embryonic stem cells was digested overnight at 37 uCwith BfaI. Splinkerette primers
were annealed in SuRE Buffer M (Roche) by heating to 95 uC, followed by cooling
by 1 uC increments for 15 s each. A total of 40 pmol of the annealed splinkerette
adaptor was ligated to 600ng of BfaI-digested genomic DNA, followed by passage
over a PCR purification column (Qiagen). The splinkerette-adapted genomicDNA
was re-digested with BfaI for 1 h (eliminating potential background due to splin-
kerette ligation to partially digested genomic DNA fragments) and re-purified.
Primary andnestedPCRswere performedusing genetrap- and splinkerette-specific
primers, with 0.4% of the primary PCR used in the nested round. Nested PCR
products were gel purified and sequenced using standard methods.
The HelqDC mouse strain was generated using standard transgenic technology.
For more background and discussion pertaining to this and other aspects of the
manuscript, see elsewhere in theMethods and ExtendedData. FANCD2-deficient
mice were described previously8. Mice were identified using standard ear snip
methods, and snips were used for genomic DNA preparation using the HotSHOT
method29 for use in genotype PCR. Helq wild-type, heterozygous and mutant mice
were genotyped in a single reaction using the following primers: pGT0LxF_F2-CA
GGGTTTTCCCAGTCACGAC (genetrap-specific primer), mHELQint11_F8-GT
CCTTGTGCCCAAAGTACAG (wild-type-specific primer), mHELQint11_R5-CC
TAGTGTGGCTTATCTCCTTCTTC (common primer). Fancd2mice were geno-
typed according to the previously described method8.
Breedings to establish Mendelian ratios and fertility consisted of continuously
mated, individually housed pairs. The Helq Fancd2 double-mutant strain was
established from mating of double heterozygous Helq1/DCFancd21/2mice. Weights
of Helqmice were measured weekly starting at 10 days post-partum. The tumour
watch cohort was established using littermate controls wherever possible andmice
were regularlymonitored for signs of deterioration using a scoring system that will
be described in a separate publication. Mice were euthanized before terminal end
points were reached.
Statistics. For survival study, sample size was estimated using standard power
calculation methods in order to measure a difference of 3–4months in survival
between mutant and control groups. For Helq and Helq Fancd2 matings, devia-
tions from expected Mendelian ratios were tested by Chi-squared analysis
(P. 0.25 for both strains). For fertility analysis, the number of litters and pups
were tested using Kruskal–Wallace analysis of variance. The Gaussian approxi-
mation of P values indicated that medians varied significantly between the groups
(P5 0.0019 for litters, P5 0.0014 for pups). Dunn’s multiple comparison post-
test was used to compare specific sample pairs. Results of P value calculations for
both litters and pups were the same, and are the values indicated on the graph
(P, 0.001 for control versus mutant pairs, P5 not significant for control versus
male or femalemutant pairs). For wild-type versusHelqmutant testes weights, the
Mann–Whitney test was used to analyse whether the weights differed between the
two groups. Gaussian approximation was used for calculation of the indicated P
value (P, 0.0001). Forwild-type andHelqmutant testes weights versus age, linear
regression was used to generate slopes of best-fit lines which were tested for
deviation of slope from zero. R2 and P values indicated on the graph demonstrate
that although there is a correlation between reduced testes weight and age in wild-
type mice (P5 0.0091), there is no correlation between testes weight and age for
Helq mutants (P5 0.78). For spermatogonia numbers in wild-type versus Helq
mutant neonatal testes, the Mann–Whitney test was used to analyse whether
spermatogonia differed between the two groups. Gaussian approximation was
used for calculation of the indicated P value (P, 0.0001). For MMC-induced
metaphase aberrations in wild-type versus Helq mutant cell lines, the Mann–
Whitney test was used to analyse whether radial chromosomes per metaphase
differed between the two groups (P, 0.0001). For wild-type versus Helq and
Fancd2 single- and double-mutant testes weights, the Kruskal–Wallace analysis
of variance test was used. Gaussian approximation of the P value indicated that
medians varied significantly between the groups (P, 0.0001). Dunn’s multiple
comparison post-test was used to compare specific sample pairs. Results of P value
calculations are indicated on the graph (P, 0.001 for bothwild-type versus Fancd2
single mutant and wild type versus Helq Fancd2 double mutant). For MMC-
inducedmetaphase aberrations inwild-type versusHelq and Fancd2 singlemutants
and Helq Fancd2 double mutants, the Kruskal–Wallace analysis of variance test
was used. Gaussian approximation of the P value indicated medians varied signi-
ficantly between the groups (P, 0.0001). Dunn’s multiple comparison post-test
was used to compare specific samplepairs. Results ofP value calculations forMMC-
damaged samples are indicated on the graph (P, 0.001 for wild-type versus single
and double mutants, P, 0.01 for Helq mutants versus double mutants, and
P5 not significant forHelq versus Fancd2 singlemutants and for Fancd2mutants
versus doublemutants). ForHELQ–GFPchromatin recruitment uponATR inhib-
itor treatment, Student’s t-test was performed to determine whether the observed
differences were statistically significant. For DNA combing of replication tracts
from wild-type versusHelqmutant cells at atmospheric O2, and tracts from wild-
type,Helq andFancd2 single, andHelq Fancd2doublemutants at physiologicalO2,
the Kruskal–Wallace analysis of variance test was used. Gaussian approximation
of the P values indicated that medians varied significantly between the groups
(P, 0.0001 for both experiments). Dunn’s multiple comparison post-test was
used to compare specific sample pairs. Results of P value calculations are indicated
on the graphs (P, 0.01 for wild type versus Helq mutants and for undamaged
versus CPT damagedHelqmutant cells; P, 0.001 for wild type versus single and
double mutants). For wild type versus Helq mutant tumour watch, the Kaplan–
Meier epithelial and stromal tumour-free survival curvewas analysedwithMantel–
Cox log-rank test for P value calculation (P5 0.009).
Histology, immunohistochemistry sample preparation and reagents. For all
histology, samples were paraffin embedded and sectioned at 4mm. Testes for
histology were fixed in Bouin’s solution, Periodic acid-Schiff stained and haema-
toxylin counter-stained; all other tissues, including post-mortem tissues for ana-
lysis of tumour watch cohort, were fixed in 10% neutral buffered formalin (NBF)
and stained with haematoxylin and eosin.
Immunohistochemistry was carried out using standardmethods. In brief, testes
for immunohistochemistry were NBF fixed and sections from adult mice were
processed for c-KIT staining by microwaving in 0.01M citrate buffer, pH6, to
unmask antigens. After incubation with c-KIT primary antibodies (Dako A4502,
1:600), samples were incubated with biotinylated secondary antibody (Vector)
followedby incubationwithAvidinBiotinComplex (Vector); slideswere developed
in 3, 39-diaminobenzidine (DAB) substrate (Vector) and counterstained in haema-
toxylin. Neonatal testis sectionswere similarly processed and labelledwith antibodies
against WT1 (Santa Cruz sc-192, 1:450).
Cell line derivation. Ear fibroblasts for primary and SV40 immortalized cultures
were generated as follows: mice were euthanized and ear tissue was collected using
sterile scissors, ear fragments were rinsed twice in 70% ethanol followed by two
rinses in PBS supplemented with 100mgml21 kanamycin. Tissue was transferred
into 0.3 ml of protease solution (4mgml21 each of collagenase D and dispase in
DMEM; filter sterilized), and incubated at 37 uC for 45min. In total, 1.5mlDMEM
containing 10% FBS, 13 glutamine and 53 antibiotic–antimycotic solution were
added to protease solution containing ear fragments, and samples were incubated
at 37 uC overnight. Cells were dissociated by pipetting, passed through a 40-mm
mesh cell strainer, and plated in DMEM as above except using 13 antibiotic–
antimycotic solution. Cells were passaged upon reaching confluence to five dishes,
and upon reaching confluence, cells were frozen at passage 1 or used immediately
for immortalization or experiments.
Fibroblasts were immortalized via transfection with a vector expressing SV40
large T antigen. Constitutively expressed HELQ–Flag, Flag, and ALC1–Flag cell
lines were generated using the 293 Flp-In system according to the manufacturer’s
protocol (Invitrogen). NIH3T3 cells stably expressing GFP-tagged mouse HELQ
(consisting of a bacterial artificial chromosome (BAC) containing the entire Helq
promoter and genomic locus) were generated according to the BAC recombineer-
ing method described previously9. These and all other cell lines used in this study
(293T,HeLa, NIH3T3 andU2OS) were grown inDMEM supplemented with 10%
FBS and L-glutamine. Cells were grown in 5% CO2 incubators at atmospheric O2
concentrations (,21%) with noted exceptions where samples were cultured at
physiological O2 concentrations (,5%).
For HELQ–GFP transient transfections in HeLa cells (Extended Data Fig. 3d),
human HELQ was cloned into the pcDNA6.2/C-EmGFP-DEST vector using
Gateway technology (Invitrogen). The vector was transfected into HeLa cells with
Lipofectamine 2000 using the manufacturer’s protocol (Invitrogen). Live or para-
formaldehyde (PFA)-fixed cells (fixed cells were counterstained with DAPI (49,6-
diamidino-2-phenylindole)) were visualized 48–96 h after transfection under epi-
fluorescence using a Zeiss Axio ImagerM1microscope with anORCA-ER camera
(Hamamatsu), and imageswere acquiredusing theVolocity software (Improvision,
Perkin Elmer).
Clonogenic survival, metaphase spreads, growth and micronuclei analyses.
For all experiments, fibroblast lines established from littermates or siblings were
used wherever possible. Experiments involving primary cells were conducted in
physiological O2 using cell lines of similar passage number.
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For clonogenic survival assays, SV40 immortalized mouse ear fibroblasts and
siRNA-treated U2OS cells were plated in triplicate on 10-cm dishes at clonal den-
sity, allowed to adhere for 8–16 h, and damage treatments administered (CPT
medium was changed after 24 h). After 8–10 days of growth, plates were rinsed,
fixed/stained in 20% ethanol/4% crystal violet (w/v), rinsed in distilled water and
colonies tabulated. All results were normalized to untreated to adjust for plating
efficiency and determine percentage survival. Survival experiments were carried
out on at least two independent sets of mutant and control mouse cell lines, and in
most cases cell lines were tested in at least two independent experiments. Similar
results were obtained across all experiments and sets of cell lines.
For analysis of metaphase aberrations, SV40 immortalized cells were damaged
as indicated and treated with colcemid (23 1027 M) for 30min, collected, swelled
in hypotonic solution (0.075M KCl) for 7min at 37 uC, fixed and washed in ice-
coldmethanol-acetic acid (3:1), dropped on humid slides and briefly steamed over
a 65 uC bath. Slides were dried, stained with Giemsa (Sigma) for 10min, rinsed
with distilled water, and coverslips were mounted (Permount, Fisher). For each
sample$40 spreads were scored.
Growth kinetics of primary cellswere determinedusing amodified 3T3protocol
to calculate cumulative populationdoublings. In brief, primary cellswere collected,
countedand150,000cells reseeded in triplicate 10-cmdishes every thirdday.Cumu-
lative population doublings were calculated using the formula: log10(n/n0)3 3.32,
in which n5number of cells collected after growth and n05number of cells
seeded. Similar growth kinetics were obtained for three different mutant and con-
trol mouse embryonic fibroblasts and embryonic fibroblast cell line pairs.
Micronuclei were examined by seeding SV40 immortalized embryonic fibro-
blasts in 6-well dishes containing glass coverslips. The following day, cells were
fixed in 4% PFA and stained with DAPI. For each sample$100 cells were scored.
Bonemarrow protocols, antibodies/reagents, analysis. Bone marrow cells were
collected from 3–4-month-old control andHelqDC/DC mice and analysed for hae-
matopoietic stem and progenitor cells (HSPCs) as described previously8,22. For
LSK (lineage2 Sca-11 c-Kit1) staining, cells were stained in Hank’s balanced salt
solution containing 2%FBS and 10mMHEPES buffer (Gibco) using biotinylated-
anti-lineage antibody cocktail (anti-Mac1a, Gr-1, Ter119, CD3e, CD4 andCD8a),
phycoerythrin (PE)-Cy-7-anti-Sca-1 antibody (clone E13-161.7), and APC-anti-
c-Kit antibody (clone 2B8), followed by staining with PE-streptavidin secondary
antibody (all primary and secondary antibodies fromBDBiosciences). The samples
were acquired using a BD FACSAria high-speed sorter.
For c.f.u.-c assays, bonemarrowcellswere seeded in 12-well plates at a density of
73 104 cells perwell inmouseMethoCultmediumM3434 (StemCell Technologies)
and haematopoietic colonies (c.f.u.-c) were counted at 7–10 days after culture.
c.f.u.-c assays were used to determine the survival of bone marrow in presence of
MMC. To determine the ex vivo clonal growth of murine HSPCs, a cobblestone
area-forming cell (CAFC) assay was performed by a limiting dilution analysis of
bone marrow in micro-cultures using the bone marrow stromal cell line FBMD-1
(refs 8, 23). This assay quantifies a spectrum of haematopoietic cells that is well-
validated to compare with other functional assays. Specifically, day-7 and day-14
CAFCcorrespond toearly progenitor cells and to c.f.u.-spleen-day-12 cells,whereas
the more primitive haematopoietic stem cells with long-term repopulating ability
correspond to day-28 CAFC23.
Bone marrow transplantation was performed as described previously8. In brief,
bone marrow cells (53 105) from control or HelqDC/DC mice (CD45.21) were
mixed with 2.53 105 bonemarrow supporting cells fromCD45.11 congenicmice
and transplanted into lethally irradiatedCD45.11congenic recipientmice.Thedonor
cell engraftment efficiency in the recipient mice, after 17weeks post-transplant,
was determined by staining peripheral blood leukocytes with FITC-labelled anti-
CD45.2 (clone 104) antibody. The percentage of donor-derived T cells, B cells and
myeloid cells was determined by co-staining with PE-labelled anti-CD3e (clone
145-2C11), anti-B220 (clone RA3-6B2) and anti-Mac-1/Gr-1 antibodies (clones
M1/70 and RB6-8C5), respectively, and analysed on a FACScan instrument
(Becton Dickinson). All antibodies were from BD Biosciences.
Mass spectrometry and proteomics. HELQ–Flag and Flag control cells were
collected and lysed in benzonase lysis buffer (20mM Tris-Cl, pH7.5, 75 mM
NaCl, 10% glycerol, 2mM MgCl2, 0.5% NP40, 30Uml
21 benzonase, protease
inhibitors). NaCl concentration was adjusted to 150mM, EDTA to 3mM and
lysates were cleared by centrifugation. Supernatants were pre-cleared with Protein
G agarose beads for 30min at 4 uC. Pre-cleared lysates were incubated with anti-
Flag affinity agarose resin (Sigma) for 4 h at 4 uC. Beads were washed five times
with wash buffer (20mM Tris-Cl, pH7.5, 150mM NaCl, 3mM EDTA, 0.5%
NP40) and once with PBS. Bound proteins were eluted by boiling in SDS–PAGE
samplebuffer and eluateswere resolved onNuPAGEBis-Tris gels (Invitrogen) and
stainedwithSyproRuby (Invitrogen).Gel sliceswere excised and processed formass
spectrometry using the Janus automated liquid handling system (PerkinElmer).
Peptides were analysed by nanoscale capillary liquid chromatography–electrospray
ionization/multi-stage mass spectrometry (LC–ESI MS/MS), data were processed
using Mascot Distiller (Matrix Science) and exported to Scaffold for viewing
(Proteome Software).
The Biological General Repository for Interaction Data sets (BioGRID, http://
thebiogrid.org/), the Molecular INTeraction database (MINT, http://mint.bio.
uniroma2.it/mint), and Search Tool for the Retrieval of Interacting Genes/Proteins
database (STRING, http://string-db.org/) were used to compile the protein inter-
action network.
Cell lysates, in vitro binding assay and fractionation for western blot analyses.
All cell lines used in this study were short tandem repeat-profiled and tested for
mycoplasma infection before use. All lysis buffers were supplemented with prote-
ase inhibitor cocktail (Roche) and phosphatase inhibitors (Sigma).
For validation of mass spectrometry data, HELQ–Flag- and Flag-expressing
cells were used. (This was due to our inability to validate these interactions using
endogenousHELQ, stemming from the fact that it is expressed at very low levels in
most human cell lines, and no antibodies were found to reliably immunoprecipi-
tate the human version. Validation using endogenous mouse HELQ was similarly
hindered by a lack of reagents available for detection of the mouse RAD51 para-
logues.) Cells were lysed in the presence of benzonase and 2mg of total protein
were immunoprecipitatedwith anti-Flag affinity resin as above. Beadswerewashed,
bound proteins eluted with 13NuPAGE LDS sample buffer and analysed by
western blot. Similar methods were employed using lysates prepared from 293T
cells to examine endogenous HELQ or RAD51C coimmunoprecipitates.
For in vitro binding assays, HELQ–Flag, ALC1–Flag and Flag cells were lysed in
the presence of benzonase and pre-cleared lysate was used for Flag immunopre-
cipitate as described above. Flag-immunocomplexed beads were then washed four
times with a modified wash buffer containing 1 M NaCl to remove bound co-
precipitates, and oncewith in vitro binding buffer (20mMTris-Cl, pH7.5, 280mM
NaCl, 3mMEDTA, 0.5%NP40).Washed beadswere incubatedwith recombinant
RAD51 paralogue BCDX2 complex (gift of S.West’s laboratory) in binding buffer
for 4 h at 4 uCandwashed four timeswith the samebuffer. Eluateswere analysedby
western blot.
GFP-tagged HELQ was stably expressed in NIH3T3 cells using a BAC recom-
bineering method to C-terminally Flag/GFP-tag the BAC-containing full-length
genomic Helq, which included the endogenous promoter. This allowed HELQ–
GFP to be expressed at physiological levels.
For chromatin fractionation of embryonic fibroblasts and siRNA-treatedU2OS
cells, cells were treatedwith or without 3mM aphidicolin for 6 h orwith or with-
out 1mM MMC for 24 h, collected and fractionated using a modified version of
the method described in ref. 26: pellets were re-suspended in CSK buffer (10mM
PIPES, pH6.8, 100mMNaCl, 300mM sucrose, 3mMMgCl2, 1mMEGTA, pH7,
0.5% Triton X-100), incubated for 10min on ice (a small fraction of this was
removed and SDS–PAGE sample buffer was added to obtain WCEs), pelleted at
low speed and supernatants reserved as soluble fraction. Pellets were washed in
CSK buffer, and re-pelleted. Pellets were re-suspended in benzonase CSK buffer
(10mM PIPES, pH7.5, 100mM NaCl, 300mM sucrose, 3mM MgCl2, 0.5%
Triton X-100, 0.1Uml21 benzonase), lysates were incubated for 30min at 37 uC,
pelleted and supernatants reserved for chromatin fraction. Pelletswere re-suspended
in high-salt CSK (recipe as above except NaCl was added to 500mM), lysates were
incubated for 10min on ice, cleared at high speed and supernatants pooled with
benzonase CSK lysates to yield chromatin extracts25. In total, 25mg of soluble and
10mg of chromatin proteins were analysed by western blotting.
Western blot, immunoprecipitated antibodies/reagents and siRNA oligonu-
cleotides.PrecastNuPAGEBis-Tris orTris-acetate gels and electrophoresis system
were by Invitrogen.Westernblotting transferswere carriedout inBioRad transblot
chambers and all blots were blocked and probed in 5% milk-phosphate buffer
saline tritonX100 (PBST)with the exceptionof p-CHK1blots,whichwere processed
in 3%BSA-Tris buffered saline tritonX100 (TBST).Mouse and rabbit horseradish
peroxidase-conjugated secondary antibodies were from ThermoFisher, and sig-
nals were visualized with ECL western blotting detection reagent (Amersham) or
SuperSignal West Femto reagent (Thermoscientific).
Antibodies used for western blot analysis: Flag (Sigma F1804, 1:2,000), HELQ
(Santa Cruz 81095, 1:200), His (Clontech 631212, 1:2,000), PARP1 (Trevigen
4338-ML-50, 1:1,000), CHK1 (Sigma C9358, 1:500), S345-P-CHK1 (Cell Signalling
2348, 1:500), CHK2/p-CHK2 (Upstate 05-649, 1:400), ATM (SigmaA1106, 1:2,000),
S1981-p-ATM (Cell signalling 4526, 1:1,000), histone H3 (Abcam 10799, 1:2,000),
a-tubulin (Sigma T6199, 1:2,000), RAD51 (Santa Cruz 8349, 1:200), FANCD2
(Epitomics 2986-1, 1:1,000), cH2AX (Cell Signalling 2577, 1:1,000), RPA32 (Abcam
12F3.3, 1:1,000), BRCA2 (SantaCruz8326, 1:200), TFIIHp89 (SantaCruz293, 1:200).
All RAD51 paralogue antibodies were a kind gift from S. West’s laboratory, as
described in ref. 30: RAD51B (IH3 mouse monoclonal antibody, 1:500), RAD51C
(2H11 mouse monoclonal antibody, 1:500), RAD51D (5B3 mouse monoclonal
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antibody, 1:400), XRCC2 (7B7mousemonoclonal antibody, 1:400), XRCC3 (10F1
mouse monoclonal antibody, 1:400).
Antibodies used for immunoprecipitation: RAD51C (R68 rabbit antibody),
XRCC3 (10F1 mouse monoclonal antibody), mouse IgG (Abcam 18413) and
rabbit IgG (Abcam46540)were usedwhere appropriate as negative control immu-
noprecipitates.
siRNA oligonucleotides: RAD51 (ref. 31) 59-AAGGGAAUUAGUGAAGCCA
AA-39, BRCA2 (ref. 32) 59-AACAACAAUUACGAACCAAAC-39. siRNA oligo-
nucleotides used in DR–GFP and in HELQ_1 (this study): 59-GAAGGUCCAA
UAUAAUU-39, HELQ_3 (this study): 59-AAUGUGAGGUGAUUAAGAA-39,
HELQ_M33: 59-CAAAGGAAGATTTCCTCCAACTAAA-39,HELQ-01: 59-GUUU
GAAGAUUGCAACGAA-39, HELQ-03: 59-AAUGUGAGGUGAUUAAGAA-39,
HELQ-04: 59-GGUAGAAGAGUUACUAAGA-39,HELQ-17: 59-GUUUGAAGA
UUGCAACGAA-39, XRCC2: 59-CAGGGTACTACGCAAGCCT-39, XRCC3: 59-
CAGAATTATTGCTGCAATT-39, RAD51C: 59-AAGAGAATGTCTCACAAAT-39,
RAD51D: 59-CTGGGTGGAAATAAGCTTA-39.
siRNA transfection andATR inhibition.U2OScellswere subjected to two rounds
of reverse transfectionsusing siGENOMEsiRNAandDharmafect1 (Thermofisher)
according to the manufacturer’s protocol. Thirty-six hours after the second trans-
fection, cellswere treated for 14 hwith 3mMaphidicolin. ForATR inhibition, 3mM
ATR inhibitor was added to cultures 30min before aphidicolin treatment.
Immunofluorescence.Cells were first washed in PBS and then fixed with 2%PFA
at room temperature (18 uC) for 15min, and then washed three times in PBS. The
fixed cells were further permeabilized with 3%BSA in PBS plus 0.1%TritonX-100
for 30min at room temperature. Primary antibodies (RAD51; 1:500, RPA; 1:1,000,
cH2AX) were added and incubated at 37 uC for 1 h. After washing with PBS plus
0.1%TritonX-100, secondary antibodies (provided by Jackson ImmunoResearch)
were applied and incubated for 1 h in the dark.The stainedcoverslipsweremounted
with prolong Gold Antifade reagent (Invitrogen). Imaging was carried out using
Axio Imager (Zeiss) or Axioplan 2 Imaging (Zeiss) microscope and analysed by
Axiovision software (Zeiss).
Homologous recombination reporter assays.DSB repair efficiency by homolog-
ous recombinationwasmeasured inDR–GFPU2OS cells as described previously34.
In brief, 48 h after the first round of siRNA transfection (40nM) using Lipofec-
tamine RNAiMAX (Invitrogen), cells were either mock-transfected (pcDNA3.1)
or transfectedwith 0.6mg of an I-SceI expression plasmid (pCBASce) togetherwith
siRNA (20nM) using 3.6ml of Lipofectamine 2000 (Invitrogen). The media was
replaced 3 h after I-SceI transfection and cells were analysed forGFP expression by
flow cytometry on a Cyan ADP (Dako) 72 h after I-SceI transfection. To confirm
siRNA efficiency, western blotting was carried out on 50mg of NP-40 lysates plus
sonication run on 4–15% Precast SDS–PAGE gels (Bio-Rad).
DNA combing. Replication tracts were labelled for 20min with 20mM iododeox-
yuridine (IdU) (in atmospheric O2 experiments, cells were treatedwith or without
2.5mM CPT for the final 15min of IdU labelling to test replication fork stalling/
restart), washed three times with PBS and labelled for 20min with 200mM
chlorodeoxyuridine (CldU). Cells were washed, collected on ice, counted and
embedded in agarose. Cells were digested in 2–3 changes of proteinase K buffer
for 24 h at 50 uC. Plugs were washed for 53 10 min in Tris-EDTA followed by
b-agarase digestion overnight at 42 uC. Genomic DNAwas combed onto silanized
coverslips (Genomic Vision) using a Molecular Combing System instrument
(Genomic Vision), dried and stained using previously described methods35.
Experiments were conducted on two separate sets of mutant and control cell lines
with similar results obtained for both experiments.
Pulsed field gel electrophoresis analysis. Immortalized embryonic fibroblasts
were treatedwith orwithoutMMCfor 1 h and then allowed to recover for 16–48 h.
Cells were collected and processed for pulsed field gel electrophoresis (PFGE)
analysis similar to previously described methods24. In brief, cell suspensions were
placed on ice, cell numbers counted and equivalent cell numbers or each genotype
were embedded in agarose plugs in duplicate. Cells were digested by incubating
plugs in proteinase K overnight at 50 uC, plugs were washed 43 1 h, sealed with
low-melting-point agarose into the well of a 1% agarose/0.53 Tris/borate/EDTA
(TBE) pulsed field gel, and run for 24 h on a Gene Navigator PFGE apparatus
(Amersham) using the following conditions: running temperature: 13 uC; running
angle: 120u (hex electrode); connection setup: interpolation (phase 1 of 2: N/S 30 s,
E/W 30 s, phase time 23 h; phase 2 of 2: N/S 5 s, E/W 5 s); power program: 180 V
15min, 170V 30min, 160 V 1 h, 150V 2 h, 140V 4 h, 130V 8 h, 120V 7 h. Gels
were post-stained with ethidium bromide and washed in 0.53TBE. PFGE was
carried out on two independent sets of mutant and control cell lines and results
were repeated two or more times for each set of cell lines. Similar results were
obtained across all experiments and sets of cell lines.
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Extended Data Figure 1 | Allele and subfertility of HELQ deficiency.
a, Schematic of theb-geo gene trap and its approximate locationwithin theHelq
genomic locus. b, Sequence and traces showing the exact location of the gene
trap insertion as determined by sequencing of splinkerette PCR products.
c, HELQwestern blot fromwild-type (1/1) andHelqmutant (DC/DC)mouse
cells, showing loss of HELQ and absence of a HELQ–bgal fusion protein
(which, if present, would be evident in the region of the blot marked with the
red bar). d, Table of observed and expected Mendelian ratios calculated from
heterozygous matings. Chi-squared analysis was used to test for deviation of
observed from expected. e, Averageweights ofHelqmice tracked between 2 and
12 weeks of age. Means of 5–13 mice for each group are shown, and for clarity,
s.d. is not plotted. Differences are not significant. f, Table of ovarian pathology
in 30-week-oldHelq control andmutant females (black text) and heterozygous
females within the tumour watch study (blue text, 17–21 months old).
g–l, Histological sections of testes from HelqDC/DC males showing various
degrees of atrophy, including: normal tubules (g),mild atrophy (h, i), pockets of
atrophy (arrows), pyknotic nuclei (asterisks); moderate atrophy (j, k), missing
spermatogenic layer (arrowheads) and severe atrophy (l), with only Sertoli cells
present.
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Extended Data Figure 2 | HELQ-deficient germ cell and tumour
phenotypes. a, Immunohistochemical analysis of adult testes labelled with the
stem cell marker c-KIT1 (brown) to highlight spermatogonia, and
counterstained with haematoxylin to visualize remaining cells in the tubule
(blue). Two representative images from wild-type (left) and mutant (right)
mice are shown,with red circles indicating c-KIT1 cells. Thenumberof c-KIT1
cells for each panel is indicated in the bottom right corner. Boxed regions in top
panels are magnified in bottom panels to demonstrate staining. S, Sertoli cells;
SG, c-KIT1 spermatogonia. b, Tabulation of average c-KIT1 cells per tubule
normalized to the number of Sertoli cells. c, Testis weights plotted bymouse age
in days. Linear regression used to generate slope of best-fit line; tested best-fit
line for deviation of slope from 0: R2 and P values are indicated, revealing no
correlation between age and testes weight forHelqmutants. d, Table of tumour
frequency and tumour spectrumofHelqmutant and controlmice showing data
for all mice, females, and males in the tumour watch cohort. 129/B6
background phenomena are coloured in grey text,Helqmutant-specific effects
are in black, and female-specific pathology is highlighted in pink.
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Extended Data Figure 3 | Tumour histology of HELQ deficiency. a, The
frequency of liver steatosis in all mice, and inflammation and activated
mammary tissue in femalemice. b–f, Ovary sections showing normal wild-type
ovary (b) and common ovarian pathology in mutant animals (c–f). Low-
magnification (c) and high-magnification (d) images of dysgenic ovary from a
Helq mutant exhibiting a sex cord stromal tumour containing tubular-like
structures. Low-magnification (e) and high-magnification (f) images of large
nodular granulosa cell tumour from a Helq mutant. Arrowheads indicate
mitotic figures (f). g–j, Pituitary sections showing low-magnification (g) and
high-magnification (h) images of normal wild-type pituitary. Low-
magnification (i) and high-magnification (j) images of pituitary tumour from a
Helq mutant mouse. Arrows indicate boundary where large, haemorrhagic
pituitary adenoma compresses overlying brain (h).
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Extended Data Figure 4 | Characterization of HelqDC/DC bone marrow and
generation of Helq Fancd2 double-mutant offspring. a, HelqDC/DC and
control bone marrow cells were isolated and exposed to MMC at the indicated
doses and clonogenic survival of haematopoietic progenitors was plotted as
percentage of surviving cells relative to untreated. Means6 s.e.m. for three
mice per genotype are shown. b–i, Bone marrow (BM) from mutant and
control mice was isolated and subjected to various haematopoietic stem and
progenitor cell analyses: tabulation of bone marrow LSK (lineage2 Sca-11
c-Kit1) cell populations (b, c); bone marrow c.f.u.-c (colony-forming units in
culture) assays (d); bone marrow day-28 cobblestone area-forming cells
(CAFCs; e); and total donor-derived leukocyte (f), myeloid (g) and lymphoid
(h, i) engraftment upon bonemarrow transplantation. Raw data (symbols) and
means (horizontal lines) from three mice are plotted (b, c, e); means6 s.e.m.
for three mice per genotype (d); and means6 s.e.m. for 6–10 recipients for
each genotype (f–i). j, siRNA-treated U2OS cells were plated for
clonogenic survival and treated with the indicated reagents. k, Observed and
expected Mendelian ratios calculated from Helq1/DC Fancd21/2 double
heterozygous matings. Chi-square analysis was used to test for deviation of
observed from expected.
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Extended Data Figure 5 | HELQ mass spectrometry, its relationship with
the RAD51 paralogues, ATR, and overexpression. a, HELQ purification
scheme and SDS–PAGEgel showing proteins co-purifiedwithHELQ–Flag and
control Flag immunoprecipitates. b, Cells treated with the indicated siRNAs
were collected and probed for HELQ and the RAD51 paralogues. c, XRCC3
immunoprecipitated fromHELQ–Flag and Flag control cell lysates and probed
for Flag, XRCC3 and RAD51C (positive XRCC3 interacting protein control).
IgG was used as a negative control. d, HeLa cells transiently expressing
recombinant HELQ–GFP (green panels) fixed and stained with DAPI (blue
panels) to identify nuclei. Two examples of spontaneous nuclear aggregation
patterns are shown: small focal aggregates (right) and large filamentous
aggregates (left). e, Chromatin fractions of HELQ–GFP cells treatedwith or
without 2mMAPH for 24 h. f, Cells treated as in e, with or without 3mMATR
inhibitor (ATRi). Quantification of HELQ in chromatin fractions normalized
to H3 (right). g, Cells treatedwith or without 100ngml21 MMC for 24 h and
fractionated as in e.
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Extended Data Figure 6 | Spontaneous defects, checkpoint indices, damage
foci and clonogenic survival ofHELQ-deficient cells. a, PrimaryHelqmutant
and control cell lines were grown in physiological O2 for the indicated number
of days and passaged regularly to generate a cumulative population doubling
(CPD) curve. Means6 s.d. of triplicate replicas are shown. b, c, Helq mutant
and control cells grown on coverslips were formaldehyde fixed and DAPI
stained to determine levels of spontaneous micronuclei formation: percentage
of 100 cells exhibiting 1 or more micronucleus (b); representative images
(c), micronuclei (arrows). d, e, DNA combing used to calculate replication fork
rates of primary cells grown under atmospheric (d) or physiological (e) O2.
Cells in dwere treatedwith or without 2.5mMCPT for 15min during labelling.
f, Examples of origin containing IdU (green)- and CldU (red)-labelled fibres.
g, Right versus left replication tract lengths to determine fork asymmetry
(defined as tracts falling outside the interquartile lines).
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Extended Data Figure 7 | Checkpoint and double-strand break repair
function. a, b, Immortalized HelqDC/DC and Helq1/1 cells treatedwith or
without 500 ngml21 MMC (a) or 50 nM CPT (b) for 20 h and probed for the
indicated checkpoint indices. c, Primary wild-type (WT), HELQ-deficient (HQ)
and FANCD2-deficient (D2) cells were left untreated (2), or exposed to 5Gy
irradiation and collected 30min later, or 3mMAPH for 16h andharvested 10min
later, and lysateswere probed for the indicated checkpoint indices.d, Phospho-Ser
345CHK1 levels inU2OScells subjected to1mMMMCfor 24h. e, Immortalized
mouse cells were treated with 1mMMMC for 24 h, allowed to recover for the
indicated times (in hours), and stained for cH2AX. f, Quantification of
percentage of positive cells from e. g, RPA32 and RAD51 foci formation in
U2OS cells6 1mMMMC for 24 h subjected to control and HELQ siRNA.
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ExtendedData Figure 8 | Homologous recombination dynamics and PARP
inhibitor sensitivity. a, U2OS cells treatedwith or without 100ngml21 MMC
for 24 h, allowed to recover for the indicated times (in hours), fractionated and
probed for RAD51. H4 and a-tubulin are shown as controls for chromatin
fractionation. b, DR–GFP reporter cells treated with the indicated siRNAs were
probed for BRCA2, HELQ and RAD51; transcription factor IIH (TFIIH) is
shown as a loading control. c, siRNA-treated U2OS cells were plated for
clonogenic survival and treated with the indicated reagents.
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